Albumin variants and conjugates

ABSTRACT

The present invention relates to conjugation-competent albumins and albumin-related polypeptides, and their conjugates with at least one moiety, and to polynucleotides encoding them.

REFERENCE TO SEQUENCE LISTING

This application contains a Sequence Listing in computer readable form.The computer readable form is incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates to conjugation-competent albumins andalbumin-related polypeptides, and their conjugates with at least one(e.g. several) moiety, and to polynucleotides encoding them.

BACKGROUND OF THE INVENTION

Serum albumins provide valuable scaffolds to which bioactive moleculesmay be fused, either through genetic fusions or chemical fusions toimprove the properties of the fused molecule(s) (Leger, R. et al.(2004), Bioorg Med Chem Lett 14(17): 4395-8; Thibaudeau, K., et al.(2005). Bioconjug Chem 16(4): 1000-8; Balan, V. et al. (2006), AntivirTher 11(1): 35-45; EP 0413622; WO 90/13653; EP 1681304; WO 1997/024445).Albumin has a long plasma half-life of about 19 days and because of thisproperty it has been suggested for use in drug delivery.

The human serum albumin (HSA) polypeptide chain has 35 cysteineresidues, which form 17 disulphide bonds and one unpaired (free)cysteine at position 34 of the mature protein (SEQ ID NO. 2).Cysteine-34 has been used for conjugation of molecules to albumin (Legeret al. (2004) Bioorg Med Chem Lett 14(17): 4395-8; Thibaudeau et al.(2005), Bioconjug Chem 16(4): 1000-8), and provides a precise, welldefined site for conjugation. However, conjugation at cysteine-34provides only one site for attachment of a single moiety and thus thereis no choice of conjugation site. Also, the provision of a singleconjugation site means that only one moiety can be conjugated to eachalbumin molecule. WO 2009/126920 and WO 2010/059315 propose thesubstitution for cysteine of one or more (e.g. several) selectedsurface-exposed threonine or serine residues in albumin. However, theactual production of such variants is not disclosed. WO 2010/092135discloses albumin variants comprising three or more (several)conjugation-competent cysteine residues: cysteine-34 and at least twofurther cysteine residues; or variants in which another amino acid issubstituted for the cysteine-34, and there are at least three furtherfree cysteines.

Pharmaceutical agents, or their precursors, are generally prepared ashomogeneous species, to allow for quality control. In HSA, the freecysteine at position 34 is located in a hydrophobic crevice with a depthof 9.5 Å (Cornell C N, Chang R, Kaplan L J. 1981. Arch. Biochem.Biophys. 209(1):1-6.), and is not thought to be involved inhomodimerization of HSA. However, surface-exposed cysteine residues inpolypeptides may form stable inter-molecular disulphide bridges, asoccur naturally for example between the heavy and light chains ofimmunoglobulin. It is desirable to provide albumin variants havingintroduced cysteine residues which have a low propensity to form dimersor oligomers.

WO 2000/69902 discloses conjugation of pharmaceutically beneficialcompounds to HSA at cysteine-34, and it was found that the conjugatesmaintained the long plasma half-life of albumin. The resulting plasmahalf-life of the conjugate was generally considerably longer than theplasma half-life of the beneficial therapeutic compound alone. Further,albumin has been genetically fused to therapeutically beneficialpeptides (WO 2001/79271A and WO 2003/59934) with the typical result thatthe fusion has the activity of the therapeutically beneficial peptideand a considerably longer plasma half-life than the plasma half-life ofthe therapeutically beneficial peptide alone.

Albumin binds in vivo to its receptor, the neonatal Fc receptor (FcRn)“Brambell” and this interaction is known to be important for, the plasmahalf-life of albumin. FcRn is a membrane bound protein, expressed inmany cell and tissue types. FcRn has been found to salvage albumin fromintracellular degradation (Roopenian D. C. and Akilesh, S. (2007), Nat.Rev. Immunol 7, 715-725.). FcRn is a bifunctional molecule thatcontributes to maintaining a high level of IgGs and albumin in plasma inmammals such as humans. Data indicate that IgG and albumin bindnon-cooperatively to distinct sites on FcRn (Andersen et al. (2006),Eur. J. Immunol 36, 3044-3051; Chaudhury et al. (2006), Biochemistry 45,4983-4990). Andersen et al. (2010), Journal of Biological Chemistry285(7): 4826-36, describes the affinity of human and mouse FcRn for eachof mouse and human albumin (all possible combinations). No binding ofalbumin from either species was observed at physiological pH to eitherreceptor. At acidic pH, a 100-fold difference in binding affinity wasobserved.

The major FcRn receptor binding site in albumin is localized withinDomain III (DIII, 381-585), (Andersen et al. (2010), ClinicalBiochemistry 43, 367-372). A number of key amino acid residues have beenshown to be important in binding, notably histidines H464, H510 and H536and lysine K500 of human albumin (Andersen et al. (2010), Nat. Commun.3:610. DOI:10.1038/ncomms1607). Generally, the higher the affinity of analbumin for FcRn, the longer is its plasma half-life. WO 2011/124718discloses a class of variant albumins having modulated binding affinityto FcRn; the variants comprise domain III of an albumin with one or more(e.g. several) other domains of albumin and optionally include one ormore (e.g. several) point mutations. WO 2012/059486 discloses variantsof albumin in which a C-terminal portion of Domain III is swapped with acorresponding portion of an albumin of a different animal species. WO2013/075066, WO 2011/103076, WO 2012/112188, WO 2011/051489 and WO2014/072481 disclose point mutations within Domain III, or combinationsof such point mutations, which alter the binding affinity of albumin toFcRn.

Various amino acid residues of albumin located in Domain I or Domain IIhave also recently been found to affect its interaction with FcRn. WO2013/135896 discloses albumin variants having one or more (e.g. several)alterations in Domain I and one or more (e.g. several) alterations inDomain III. WO 2015/036579 discloses albumin variants having one or more(e.g. several) alterations in Domain II.

The listing or discussion of an apparently prior-published document inthis specification should not necessarily be taken as an acknowledgementthat the document is part of the state of the art or is common generalknowledge.

It is desirable to provide albumin variants having one or more (e.g.several) introduced cysteine residues in which an introduced freecysteine residue does not itself have a major impact on FcRn binding ofalbumin, or be positioned such that conjugation of a partner molecule tothe free cysteine will sterically hinder FcRn binding. Suchconsiderations could reduce the risk of unpredictable effects whenintroducing combinations of more than one free cysteine in a singlealbumin variant. Such variant polypeptides may be further modified toinclude alterations known to affect the binding affinity of albumin forFcRn, so as to allow the plasma half-life of the polypeptide, orconjugates thereof, to be tailored for specific applications.

SUMMARY OF THE INVENTION

Based on an analysis of the three-dimensional structure of a human serumalbumin (HSA) bound to FcRn, the inventors have designed variantpolypeptides (muteins) of albumin which have one or more (e.g. several)conjugation-competent cysteine residues. The term ‘thio-albumin’ is usedherein to describe an albumin variant which comprises one or more (e.g.several) unpaired cysteine residues, particularly an albumin variant inwhich one or more (e.g. several) of the unpaired cysteine residues doesnot occur in a naturally occurring variant of an albumin. Thus athio-albumin is a ‘conjugation-competent albumin’. A thio-albumin may bereferred to as a ‘cysteine variant of an albumin’. More particularly,the invention relates to a conjugation-competent polypeptide comprisingan amino acid sequence which is at least 60% identical to human albumin,particularly residues 1 to 585 of the mature human albumin polypeptidesequence of SEQ ID NO. 2, or a fragment thereof; wherein at least oneposition equivalent to a position selected from K93, E294, A226, E230,1271, E358, L24, F49, V54, D56, L66, A92, Q94, E97, H128, F156, E227,D237, K240, D259, K262, N267, Q268, L275, E277, L284, E311, K317, A322,E333, D340, E354, K359, A362, E382, and L398 of SEQ ID NO. 2 comprises aconjugation-competent cysteine residue; and wherein theconjugation-competent polypeptide preferably has a tendency to exist asa monomer in solution which is at least 70% of the tendency of thepolypeptide of SEQ ID NO. 2 to exist as a monomer in solution.

More preferably, the polypeptide has a tendency to exist as a monomer insolution which is at least 75% of the tendency of the polypeptide of SEQID NO. 2 to exist as a monomer in solution and at least one positionequivalent to a position selected from K93, E294, A226, E230, I271,E358, L24, F49, V54, D56, A92, Q94, E97, H128, F156, E227, D237, K240,D259, K262, N267, Q268, L275, L284, K317, A322, E333, D340, E354, K359,A362, E382, and L398 comprises a conjugation-competent cysteine residue.

The invention also relates to a conjugation-competent polypeptidecomprising an amino acid sequence as defined above, and at least one(e.g. several) further modification compared to SEQ ID NO. 2, such as afurther modification which causes the polypeptide to have at least one(e.g. several) further conjugation-competent cysteine, or alters thebinding affinity of the polypeptide for FcRn, or alters the plasmahalf-life of the polypeptide. The present invention also relates toisolated polynucleotides encoding the variants; nucleic acid constructs,vectors, and host cells comprising the polynucleotides; and methods ofproducing the variants.

The invention also relates to conjugates or associates comprising thevariant albumin or fragment thereof according to the invention and abeneficial therapeutic moiety or to a fusion polypeptide comprising avariant albumin or fragment thereof of the invention and a fusionpartner polypeptide.

The invention further relates to compositions comprising the variantalbumin, fragment thereof, fusion polypeptide comprising variant albuminor fragment thereof or conjugates comprising the variant albumin orfragment thereof, according to the invention or associates comprisingthe variant albumin or fragment thereof, according to the invention. Thecompositions are preferably pharmaceutical compositions.

The invention further relates to a pharmaceutical composition comprisinga variant albumin, fragment thereof, fusion polypeptide comprisingvariant albumin or fragment thereof or conjugates comprising the variantalbumin or fragment thereof, or associates comprising the variantalbumin or fragment thereof.

The invention also relates to the use of the variants, fragments, fusionpolypeptides, conjugates, associates, nanoparticles and microparticles.

The invention also relates to a method for preparing a variant albumin,fragment thereof, fusion polypeptide comprising variant albumin orfragment thereof or conjugates comprising the variant albumin orfragment thereof, or associates comprising the variant albumin orfragment thereof.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1. Multiple alignment of amino acid sequences of (i) full lengthmature HSA (Hu_1_2_3), (ii) an albumin variant comprising domain I anddomain III of HSA (Hu_1_3), (iii) an albumin variant comprising domainII and domain III of HSA (Hu_2_3), (iv) full-length Macaca mulattaalbumin (Mac_mul), (v) full-length Rattus norvegicus albumin (Rat) and(vi) full-length Mus musculus albumin (Mouse). Positions 500, 550 and573 (relative to full length HSA) are indicated by arrows.

FIG. 2. Multiple alignment of amino acid sequence of mature albumin fromhuman, sheep, mouse, rabbit and goat and immature albumins fromchimpanzee (“Chimp”), macaque, hamster, guinea pig, rat, cow, horse,donkey, dog, chicken, and pig. The Start and End amino acids of domains1, 2 and 3 (as defined by Dockal et al (The Journal of Biological.Chemistry, 1999, Vol. 274(41): 29303-29310)) are indicated with respectto mature human albumin.

FIG. 3. Venn diagram showing the classes of and relationship betweentwenty amino acids.

FIG. 4. A: Reaction scheme for biotinylation of a protein comprising afree thiol group with maleimide-PEG2-biotin. B: Schematic illustratingpotential retro-Michael and succinimide hydrolysis reactions ofconjugates formed in scheme A.

In A, the maleimide forms an adduct with the thiol group, thus forming asuccinimide moiety with a thio-ether bond.

B illustrates adduct formation. The adduct may revert back to maleimideand free thiol via a retro-Michael pathway. Alternatively, thesuccinimide moiety may undergo stabilizing ring opening to succinicacid, by hydrolysis at pH 9. The thio-ether bond of the conjugate isretained and the succinic acid moiety is unreactive to other thiolcompounds which may be present. Free maleimide, when subjected tohydrolysis, also becomes thiol unreactive.

FIG. 5. MS spectra of purified variants (A: C34A+I271C variant; B:C34A+K93C variant) conjugated with maleimide-PEG2-biotin. A: Theconjugate peak is 66924.1. The shorter peak is unconjugated protein. Therelative peak heights indicate a conjugated proportion of 72%.+MS,7.7-9.2 min, Baseline subtracted (0.50), Deconvoluted (MaxEnt), Smoothed(0.00,1,GA). B: The conjugate peak is 66908.3, and there is no freeproportion, indicating 100% conjugation. +MS, 7.6-9.4 min, Baselinesubtracted (0.50), Deconvoluted (MaxEnt), Smoothed (0.00,1,GA).

FIG. 6. MS spectra of purified albumins (A: wild type; B: C34A+E294Cvariant) conjugated with maleimide-PEG2-biotin and subjected tocontrolled hydrolysis. In A, 53% of the albumin is present as athiol-stable conjugate with a peak of 66978.4; and 47% is present as afree albumin following retro-Michael deconjugation. +MS, 7.0-9.6 min,Baseline subtracted (0.50), Deconvoluted (MaxEnt), Smoothed (0.00,1,GA).In B, 100% of the C34A+E294C variant is present as a thiol-stableconjugate with a peak of 66925.7. +MS, 7.6-9.5 min, Baseline subtracted(0.50), Deconvoluted (MaxEnt), Smoothed (0.00,1,GA).

FIG. 7. MS spectra of purified albumin variants (A: K93C+E294C; B:K93C+E294C; C: C34A+K93C+E294C) conjugated with maleimide-PEG2-biotinand subjected to controlled hydrolysis (B and C). In A, a single peak of67967.7 for K93C+E294C indicates 100% conjugation to each of the threefree thiols. +MS, 1.6-2.6 min, Baseline subtracted (0.40), Deconvoluted(MaxEnt). Smoothed (0.00,1,GA). In B, 20% of the triple conjugate ofK93C+E294C is thiol stable after hydrolysis. The main peak, at 67476.2,is indicative of two thiol stable conjugate bonds, and the loss of onemaleimide-PEG2-biotin through retro-Michael deconjugation. +MS, 1.8-2.9min, Baseline subtracted (0.40), Deconvoluted (MaxEnt), Smoothed(0.00,1,GA). In C, the double conjugate of C34A+K93C+E294C is the majorspecies, at a peak of 67443.1, and the other species is the singleconjugate at a peak of 66894.6. +MS, 1.7-2.8 min, Baseline subtracted(0.40), Deconvoluted (MaxEnt), Smoothed (0.00,1,GA).

FIG. 8. MS spectra of purified albumin variant K93C+E294C+K573P (whichincludes native Cys34). A: indicates 100% conjugation to each of thethree free thiols. +MS, 7.3-9.7 min, Baseline subtracted (0.50),Deconvoluted (MaxEnt), Smoothed (0.00,1,GA). In B, 23% of the tripleconjugate of K93C+E294C+K573P (which includes native Cys34) is thiolstable after hydrolysis. The main peak, at 67447.3, is indicative of twothiol stable conjugate bonds, and the loss of one maleimide-PEG2-biotinthrough retro-Michael deconjugation. +MS, 7.4-9.5 min, Baselinesubtracted (0.50), Deconvoluted (MaxEnt), Smoothed (0.00,1,GA).

FIG. 9. A: Schematic illustrating Alexa Fluor®488-PEG4-Lys(monobromomaleimide)-NH2 dye. The MS spectra of purifiedalbumin variants (B: K573P; C: K93C+E294C+K573P) conjugated with AlexaFluor® 488-PEG4-Lys(monobromomaleimide)-NH2 dye are shown. In B, asingle peak of 67468.5 for K573P indicates 100% conjugation to thesingle free thiol at Cys34. +MS, 7.6-9.7 min, Baseline subtracted(0.50), Deconvoluted (MaxEnt), Smoothed (0.00,1,GA). In C, the tripleconjugate of K93C+E294C+K573P (which includes native Cys34) is the majorspecies, at a peak of 69535.8. The shorter peak is double conjugate. Therelative peak heights indicate 58% triple conjugate and 42% doubleconjugate respectively. +MS, 7.6-9.3 min, Baseline subtracted (0.50),Deconvoluted (MaxEnt), Smoothed (0.00,1,GA).

FIG. 10. A: Schematic illustrating5-carboxyfluorescein-PEG4-Lys(monobromomaleimide)-NH2 dye. The MSspectra of purified albumin variants (B: K573P; C:C34A+K93C+E294C+K573P) conjugated with5-carboxyfluorescein-PEG4-Lys(monobromomaleimide)-NH2 dye are shown. InB, a single peak of 67310.6 for K573P indicates 100% conjugation to thesingle free thiol at Cys34. +MS, 7.2-9.3 min, Baseline subtracted(0.50), Deconvoluted (MaxEnt), Smoothed (0.00,1,GA). In C, the doubleconjugate of C34A+K93C+E294C+K573P is the major species, at a peak of68129.7. The shorter peak is single conjugated protein. The relativepeak heights indicate 91% double conjugate and 9% single conjugatedprotein respectively. +MS, 7.3-9.3 min, Baseline subtracted (0.50),Deconvoluted (MaxEnt), Smoothed (0.00,1,GA).

FIG. 11. A: Schematic illustrating monobromomaleimide-paclitaxel. The MSspectra of purified albumin variants (B: K573P; C: K93C+E294C+K573P)conjugated with monobromomaleimide-paclitaxel are shown. In B, a peak of67412.2 for K573P indicates conjugation to the single free thiol atCys34. The shorter peak is unconjugated protein. The relative peakheights indicate 77% single conjugate and 23% unconjugated proteinrespectively +MS, 7.1-8.9 min, Baseline subtracted (0.50), Deconvoluted(MaxEnt), Smoothed (0.00,1,GA). In C, the double conjugate ofK93C+E294C+K573P is the major species which is at a peak of 68364.2. Theshorter peak is triple conjugated protein. The relative peak heightsindicate 60% double conjugated and 30% triple conjugate proteinrespectively. +MS, 7.2-9.0 min, Baseline subtracted (0.50), Deconvoluted(MaxEnt), Smoothed (0.00,1,GA).

FIG. 12. A: Schematic illustrating monobromomaleimide-PEG2-exenatidepeptide. The MS spectra of purified albumin variants (B: K573P; C:C34A+K93C+E294C+K573P) conjugated with monobromomaleimide-PEG2-exenatidepeptide are shown. In B, a peak of 71018.7 for K573P indicatesconjugation to the single free thiol at Cys34. The main peak, at 66409.2is unconjugated protein. The relative peak heights indicate single 33%conjugate and 67% unconjugated protein respectively. +MS, 7.2-8.8 min,Baseline subtracted (0.50), Deconvoluted (MaxEnt), Smoothed (0.00,1,GA).In C, the double conjugate of C34A+K93C+E294C+K573P is 75557.3. The mainpeak, at 70941.7 is single conjugate. The shortest peak at 66322.4 isunconjugated protein. The relative peak heights indicate 33% doubleconjugate, 45% single conjugate and 22% unconjugated proteinrespectively. +MS, 7.2-9.2 min, Baseline subtracted (0.50), Deconvoluted(MaxEnt), Smoothed (0.00,1,GA).

FIG. 13. A: Schematic illustrating maleimide-propyl-FLAG peptide. The MSspectra of purified albumin variants (B: K573P; C: K93C+E294C+K573P)conjugated with maleimide-propyl-FLAG peptide are shown. In B, a peak of67573.4 for K573P indicates conjugation to the single free thiol atCys34. The main peak is unconjugated protein. The relative peak heightsindicate 29% single conjugate and 71% unconjugated protein respectively.+MS, 7.3-8.7 min, Baseline subtracted (0.50), Deconvoluted (MaxEnt),Smoothed (0.00,1,GA). In C, the triple conjugate of K93C+E294C+K573P(which includes native Cys34) is 69850.5. The main peak, at 68685.5 isdouble conjugate. The peak at 67520.3 is single conjugate. The shortestpeak, at 66350.2 is unconjugated protein. The relative peak heightsindicate 29% triple conjugate, 50% double conjugate, 20% singleconjugate and 2% unconjugated protein respectively. +MS, 7.2-8.8 min,Baseline subtracted (0.50), Deconvoluted (MaxEnt), Smoothed (0.00,1,GA).

DEFINITIONS

Variant: The term “variant” means a polypeptide derived from a parentalbumin by one or more (e.g. several) alteration(s), i.e. asubstitution, insertion, and/or deletion, at one or more (e.g. several)positions. A substitution means a replacement of an amino acid occupyinga position with a different amino acid; a deletion means removal of anamino acid occupying a position; and an insertion means adding 1 or more(e.g. several), such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, preferably 1-3amino acids immediately adjacent an amino acid occupying a position. Inrelation to insertion, ‘immediately adjacent’ may be to the N-side(‘upstream’) or C-side (‘downstream’) of the amino acid occupying aposition (‘the named amino acid’). Therefore, for an amino acidnamed/numbered ‘X’, the insertion may be at position ‘X+1’(‘downstream’) or at position ‘X-1’ (‘upstream’).

Mutant: The term “mutant” means a polynucleotide encoding a variant.

Wild-Type Albumin: The term “wild-type” (WT) albumin means albuminhaving the same amino acid sequence as naturally found in an animal orin a human being.

Parent Albumin: The term “parent” or “parent albumin” means an albuminto which an alteration is made by the hand of man to produce the albuminvariants of the invention. The parent may be a naturally occurring(wild-type) polypeptide or an allele thereof, or even a variant thereof.

Albumin: Albumins are proteins and constitute the most abundant proteinin plasma in mammals and albumins from a long number of mammals havebeen characterized by biochemical methods and/or by sequenceinformation. Several albumins, e.g. HSA, have also been characterizedcrystallographically and the structure determined (HSA: He X M, Carter DC (July 1992), “Atomic structure and chemistry of human serum albumin”,Nature 358 (6383): 209-15; horse albumin: Ho, J. X. et al. (2001). X-rayand primary structure of horse serum albumin (Equus caballus) at 0.27-nmresolution. Eur J Biochem. 215(1):205-12). The invention relates to allalbumins and their structures.

The term “albumin” means a protein having the same and/or very similarthree dimensional (tertiary) structure as HSA or HSA domains and havingsimilar properties to HSA or to the relevant domains. Similar threedimensional structures are for example the structures of the albuminsfrom the species mentioned herein. Some of the major properties ofalbumin are i) its ability to regulate plasma volume (oncotic activity),ii) a long plasma half-life of around 19 days ±5 days, iii) binding toFcRn, iv) ligand-binding, e.g. binding of endogenous molecules such asacidic, lipophilic compounds including bilirubin, fatty acids, hemin andthyroxine (see also Table 1 of Kragh-Hansen et al., 2002, Biol. Pharm.Bull. 25, 695, hereby incorporated by reference), v) binding of smallorganic compounds with acidic or electronegative features e.g. drugssuch as warfarin, diazepam, ibuprofen and paclitaxel (see also Table 1of Kragh-Hansen et al., 2002, Biol. Pharm. Bull. 25, 695, herebyincorporated by reference), vi) binding to gp60, also known as albondin.Not all of these properties need to be fulfilled in order tocharacterize a protein or fragment as an albumin. If a fragment, forexample, does not comprise a domain responsible for binding of certainligands or organic compounds the variant of such a fragment will not beexpected to have these properties either.

Albumins have generally a long plasma half-life of approximately 20 daysor longer, e.g. HSA has a plasma half-life of 19 days. It is known thatthe long plasma half-life of HSA is mediated via interaction with itsreceptor FcRn, however, an understanding or knowledge of the exactmechanism behind the long half-life of HSA is not essential for theinvention.

As examples of albumin proteins as starting parent “backbones” formaking albumin variants according to the invention can be mentioned HSA(e.g. AAA98797 or P02768-1, SEQ ID NO. 2 (mature), SEQ ID NO. 3(immature)), primate serum albumin, (such as chimpanzee serum albumin(e.g. predicted sequence XP_517233.2 SEQ ID NO. 4), gorilla serumalbumin or macaque serum albumin (e.g. NP_001182578, SEQ ID NO. 5),rodent serum albumin (such as hamster serum albumin (e.g. A6YF56, SEQ IDNO. 6), guinea pig serum albumin (e.g. Q6WDN9-1, SEQ ID NO. 7), mouseserum albumin (e.g. AAH49971 or P07724-1 Version 3, SEQ ID NO. 8) andrat serum albumin (e.g. AAH85359 or P02770-1 Version 2, SEQ ID NO. 9),bovine serum albumin (e.g. cow serum albumin P02769-1, SEQ ID NO. 10),equine serum albumin such as horse serum albumin (e.g. P35747-1, SEQ IDNO. 11) or donkey serum albumin (e.g. Q5XLE4-1, SEQ ID NO. 12), rabbitserum albumin (e.g. P49065-1 Version 2, SEQ ID NO. 13), goat serumalbumin (e.g. ACF10391, SEQ ID NO. 14), sheep serum albumin (e.g.P14639-1, SEQ ID NO. 15), dog serum albumin (e.g. P49822-1, SEQ ID NO.16), chicken serum albumin (e.g. P19121-1 Version 2, SEQ ID NO. 17) andpig serum albumin (e.g. P08835-1 Version 2, SEQ ID NO. 18) or apolypeptide having at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96,97, 98, 99, 99.2, 99.4, 99.6, or at least 99.8% amino acid identity tosuch an albumin. Other examples of albumin, which are also included inthe scope of this application, include ovalbumin (e.g. P01012.pro:chicken ovalbumin; 073860.pro: turkey ovalbumin). A mature albuminsequence can be identified from an immature albumin sequence usingtechniques known to the skilled person, for example alignment with HSA(for which the mature and immature regions are known). For example,immature HSA is 609 amino acids long in which amino acids 1 to 19 are asignal sequence (also known as a leader sequence or pre sequence), aminoacids 20 to 24 are a pro sequence and amino acids 25 to 609 are themature protein. The alignment in FIG. 2 allows the skilled person topredict mature sequences for several animal albumins (see “D1 Start”).

HSA as disclosed in SEQ ID NO. 2, or any naturally occurring allelethereof, is the preferred parent albumin according to the invention. HSAis a protein consisting of 585 amino acid residues and has a molecularweight of 67 kDa. In its natural form it is not glycosylated. Theskilled person will appreciate that natural alleles may exist havingessentially the same properties as HSA but having one or more (e.g.several) amino acid changes compared to SEQ ID NO. 2, and the inventorsalso contemplate the use of such natural alleles as parent albuminsaccording to the invention.

The parent albumin, a fragment thereof, or conjugation-competent albuminvariant, or albumin part of a fusion polypeptide or conjugate comprisingalbumin or a fragment thereof according to the invention preferably hasa sequence identity to the sequence of HSA shown in SEQ ID NO. 2 of atleast 60%, preferably at least 70%, preferably at least 80%, preferablyat least 85%, preferably at least 86%, preferably at least 87%,preferably at least 88%, preferably at least 89%, preferably at least90%, preferably at least 91%, preferably at least 92%, preferably atleast 93%, preferably at least 94%, preferably at least 95%, morepreferred at least 96%, more preferred at least 97%, more preferred atleast 98% and most preferred at least 99%, at least 99.2%, at least99.4%, at least 99.6% or at least 99.8% or 100%. It is preferred thatthe parent albumin maintains at least one of the major properties ofalbumin or a similar tertiary structure as an albumin, such as HSA. Thesequence identity may be over the full-length of SEQ ID NO. 2 or over amolecule consisting or comprising of a fragment such as one or more(e.g. several) domains of SEQ ID NO. 2, such as a molecule consisting ofor comprising Domain III (e.g. SEQ ID NO. 19), a molecule consisting ofor comprising Domain II and Domain III (e.g. SEQ ID NO. 20), a moleculeconsisting of or comprising Domain I and Domain III (e.g. SEQ ID NO.21), a molecule consisting of or comprising two copies of Domain III(e.g. SEQ ID NO. 22), a molecule consisting of or comprising threecopies of Domain III (e.g. SEQ ID NO. 23) or a molecule consisting of orcomprising Domain I and two copies of Domain III (e.g. SEQ ID NO. 24).

The parent albumin, a fragment thereof, or conjugation-competent albuminvariant, or albumin part of a fusion polypeptide or conjugate comprisingalbumin or a fragment thereof according to the invention, when folded,may have several, for example at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,11, 12, 13, 14, 15, 16 and suitably all 17, of the native disulphidebonds of the polypeptide of SEQ ID NO. 2.

The parent preferably comprises or consists of the amino acid sequenceof SEQ ID NO. 3 (immature sequence of HSA) or SEQ ID NO. 2 (maturesequence of HSA).

In another embodiment, the parent is an allelic variant of the maturepolypeptide of SEQ ID NO. 2.

The parent albumin may be encoded by a polynucleotide that hybridizesunder very low stringency conditions, low stringency conditions, mediumstringency conditions, medium-high stringency conditions, highstringency conditions, or very high stringency conditions with (i) themature polypeptide coding sequence of SEQ ID NO. 2, or (ii) thefull-length complementary strand of (i) (J. Sambrook, E. F. Fritsch, andT. Maniatis, 1989, Molecular Cloning, A Laboratory Manual, 2d edition,Cold Spring Harbor, N.Y.).

The polynucleotide of SEQ ID NO. 1 or a subsequence thereof, as well asthe amino acid sequence of SEQ ID NO. 2 or SEQ ID NO. 3 or a fragmentthereof, may be used to design nucleic acid probes to identify and cloneDNA encoding a parent from strains of different genera or speciesaccording to methods well known in the art. In particular, such probescan be used for hybridization with the genomic or cDNA of the genus orspecies of interest, following standard Southern blotting procedures, inorder to identify and isolate the corresponding gene therein. Suchprobes can be considerably shorter than the entire sequence, but shouldbe at least 14, e.g. at least 25, at least 35, or at least 70nucleotides in length. Preferably, the nucleic acid probe is at least100 nucleotides in length, e.g. at least 200 nucleotides, at least 300nucleotides, at least 400 nucleotides, at least 500 nucleotides, atleast 600 nucleotides, at least 700 nucleotides, at least 800nucleotides, or at least 900 nucleotides in length. Both DNA and RNAprobes can be used. The probes are typically labelled for detecting thecorresponding gene (for example, with ³²P, ³H, ³⁵S, biotin, or avidin).Such probes are encompassed by the invention.

A genomic DNA or cDNA library prepared from such other organisms may bescreened for DNA that hybridizes with the probes described above andencodes a parent. Genomic or other DNA from such other organisms may beseparated by agarose or polyacrylamide gel electrophoresis, or otherseparation techniques. DNA from the libraries or the separated DNA maybe transferred to and immobilized on nitrocellulose or other suitablecarrier material. In order to identify a clone or DNA that is homologouswith SEQ ID NO. 1 or a subsequence thereof, the carrier material is usedin a Southern blot.

For purposes of the invention, hybridization indicates that thepolynucleotide hybridizes to a labelled nucleotide probe correspondingto the polynucleotide shown in SEQ ID NO. 1, its complementary strand,or a subsequence thereof, under low to very high stringency conditions.Molecules to which the probe hybridizes can be detected using, forexample, X-ray film or any other detection means known in the art.

The nucleic acid probe may comprise or consist of the mature polypeptidecoding sequence of SEQ ID NO. 1, i.e. nucleotides 1 to 1785 of SEQ IDNO. 1. The nucleic acid probe may comprise or consist of apolynucleotide of SEQ ID NO. 25 (nucleotide sequence encoding HSA, thenucleotide sequence has been engineered to introduce restriction enzymesites) or a fragment thereof.

For long probes of at least 100 nucleotides in length, very low to veryhigh stringency conditions are defined as pre-hybridization andhybridization at 42° C. in 5×SSPE, 0.3% SDS, 200 micrograms/mL shearedand denatured salmon sperm DNA, and either 25% formamide for very lowand low stringencies, 35% formamide for medium and medium-highstringencies, or 50% formamide for high and very high stringencies,following standard Southern blotting procedures for 12 to 24 hoursoptimally. The carrier material is finally washed three times each for15 minutes using 2×SSC, 0.2% SDS at 45° C. (very low stringency), 50° C.(low stringency), 55° C. (medium stringency), 60° C. (medium-highstringency), 65° C. (high stringency), or 70° C. (very high stringency).

For short probes that are about 15 nucleotides to about 70 nucleotidesin length, stringency conditions are defined as pre-hybridization andhybridization at about 5° C. to about 10° C. below the calculated T_(m)using the calculation according to Bolton and McCarthy (1962, Proc.Natl. Acad. Sci. USA 48: 1390) in 0.9 M NaCl, 0.09 M Tris-HCl pH 7.6, 6mM EDTA, 0.5% NP-40, 1×Denhardt's solution, 1 mM sodium pyrophosphate, 1mM sodium monobasic phosphate, 0.1 mM ATP, and 0.2 mg of yeast RNA permL following standard Southern blotting procedures for 12 to 24 hoursoptimally. The carrier material is finally washed once in 6×SCC plus0.1% SDS for 15 minutes and twice each for 15 minutes using 6×SSC at 5°C. to 10° C. below the calculated T_(m).

The parent or conjugation-competent albumin may be encoded by apolynucleotide with a sequence identity to the mature polypeptide codingsequence of SEQ ID NO. 1 of at least 60%, e.g. at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%,which encodes a polypeptide which is able to function as an albumin. Inan embodiment, the parent is encoded by a polynucleotide comprising orconsisting of SEQ ID NO 1.

Three Dimensional (3D) Models

The present disclosure makes reference to the crystal structure of HSAfrom the RCSB Protein Databank (PDB, which can be viewed athttp://www.rcsb.org/pdb/) with the entry with PDB identity 1AO6 or 1ao6(Sugio, S., A. Kashima, et al. (1999), Protein Eng 12(6): 439-46).Compared to the mature HSA sequence (SEQ ID NO. 2), the 1AO6 structurestarts at residue S5 (with the first 4 amino acids absent from thestructure) and finishes at A582 of SEQ ID NO. 2 (with the last 3 aminoacids absent from the structure). The amino acid positions used hereinto describe positions to alter to generate conjugation-competentcysteines are referring to the positions in SEQ ID NO. 2, not 1ao6.Further structures of albumin are available to the skilled person, forexample the atomic coordinates for the tertiary structure of humanalbumin are available at the GenBank DNA database which can be viewed atwww.ncbi.nlm.nih.gov. Structures may be viewed using suitable softwaresuch as RasM.1 Chime (Sayle, TIBS 20, 374, 1995). Available albumincoordinates include:

1AO6, 1BM0 (Sugio et al. (1999), Protein Eng 12(6): 439-46), which wasamong the top 17 requested proteins.

1UOR, He & Carter (1992), Nature 358(6383): 209-15.

1 bj5 and 1bke, Curry et al. (1998), Nat Struct Biol 5(9): 827-35.

1e7a, 1e7b, 1e7c, Bhattacharya et al. (2000), J Biol Chem 275(49):38731-8.

1e7e, 1e7f, 1e7g, 1e7h and 1e7i, Bhattacharya et al. (2000), J Mol Biol303(5): 721-32.

1GNJ, Petitpas et al. (2001), J Mol Biol 314(5): 955-60.

1HA2 and 1H9Z Petitpas et al. (2001), J Biol Chem 276(25): 22804-9.

4K71, Schmidt et al. (2013), Structure 21:1966-1978

4N0F and 4N0U, Oganesyan et al. (2014), J Biol Chem 289(11):7812-24.

Albumin moiety: The albumin part of a fusion polypeptide, conjugate,associate, nanoparticle or composition comprising the albumin variant orfragment thereof according to the invention, may be referred to as an‘albumin moiety’ or ‘albumin component’. A polypeptide according to theinvention may comprise or consist of an albumin moiety.

Isolated variant: The term “isolated variant” means a variant in a formor environment which does not occur in nature. Non-limiting examples ofisolated variants include (1) any non-naturally occurring variant; (2)any variant that is at least partially removed from one or more (e.g.several) or all of the naturally occurring constituents with which it isassociated in nature; (3) any variant modified by the hand of manrelative to the polypeptide from which it is derived (e.g. thepolypeptide from which it is derived as found in nature); or (4) anyvariant modified by increasing the amount of the variant relative toother components with which it is naturally associated (e.g. multiplecopies of a gene encoding the substance; use of a stronger promoter thanthe promoter naturally associated with the gene encoding the substance).An isolated variant may be present in a fermentation broth sample.Isolated variants may be recombinant or synthetic.

Substantially pure variant: The term “substantially pure variant” meansa preparation that contains at most 10%, at most 8%, at most 6%, at most5%, at most 4%, at most 3%, at most 2%, at most 1%, and at most 0.5% byweight of other polypeptide material with which it is natively orrecombinantly associated. Preferably, the variant is at least 92% pure,e.g. at least 94% pure, at least 95% pure, at least 96% pure, at least97% pure, at least-98% pure, at least 99%, at least 99.5% pure, and 100%pure by weight of the total polypeptide material present in thepreparation. Purity may be determined by SDS-PAGE or GP-HPLC. Thevariants of the invention are preferably in a substantially pure form.This can be accomplished, for example, by preparing the variant bywell-known recombinant methods and by purification methods.

Mature polypeptide: The term “mature polypeptide” means a polypeptide inits final form following translation and any post-translationalmodifications, such as N-terminal processing, C-terminal truncation,glycosylation, phosphorylation, etc. The mature polypeptide may be aminoacids 1 to 585 of SEQ ID NO. 2, e.g. with the inclusion of alterationsaccording to the invention and/or any post-translational modifications.

Mature polypeptide coding sequence: The term “mature polypeptide codingsequence” means a polynucleotide that encodes a mature albuminpolypeptide. The mature polypeptide coding sequence may be nucleotides 1to 1758 of SEQ ID NO. 1 e.g. with the alterations required to encode avariant according to the invention.

Sequence Identity: The relatedness between two amino acid sequences orbetween two nucleotide sequences is described by the parameter “sequenceidentity”.

For purposes of the present invention, the sequence identity between twoamino acid sequences is determined using the Needleman-Wunsch algorithm(Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implementedin the Needle program of the EMBOSS package (EMBOSS: The EuropeanMolecular Biology Open Software Suite, Rice et al., 2000, Trends Genet.16: 276-277), preferably version 3.0.0 or later, more preferably version5.0.0 or later. The parameters used are gap open penalty of 10, gapextension penalty of 0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62)substitution matrix. The output of Needle labelled “longest identity”(obtained using the −nobrief option) is used as the percent identity andis calculated as follows:

(Identical Residues×100)/(Length of Alignment−Total Number of Gaps inAlignment)

For purposes of the present invention, the sequence identity between twodeoxyribonucleotide sequences is determined using the Needleman-Wunschalgorithm (Needleman and Wunsch, 1970, supra) as implemented in theNeedle program of the EMBOSS package (EMBOSS: The European MolecularBiology Open Software Suite, Rice et al., 2000, supra), preferablyversion 3.0.0 or later, more preferably version 5.0.0 or later. Theparameters used are gap open penalty of 10, gap extension penalty of0.5, and the EDNAFULL (EMBOSS version of NCBI NUC4.4) substitutionmatrix. The output of Needle labelled “longest identity” (obtained usingthe −nobrief option) is used as the percent identity and is calculatedas follows: (Identical Deoxyribonucleotides×100)/(Length ofAlignment−Total Number of Gaps in Alignment)

Fragment: The term “fragment” as used herein includes any fragment offull-length albumin or a variant thereof, so long as at least one (e.g.several) basic property, for example binding activity (type of andspecific activity e.g. binding to bilirubin), osmolarity (oncoticpressure, colloid osmotic pressure), behaviour in a certain pH-range(pH-stability) has not significantly been changed. “Significantly” inthis context means that one skilled in the art would say that theproperties of the variant may still be different but would not beunobvious over the ones of the original protein. A fragment may consistof one uninterrupted sequence derived from HSA or it may comprise two ormore (e.g. several) sequences derived from HSA. The fragments accordingto the invention have a size of more than approximately 20 amino acidresidues, preferably more than 30 amino acid residues, more preferredmore than 40 amino acid residues, more preferred more than 50 amino acidresidues, more preferred more than 75 amino acid residues, morepreferred more than 100 amino acid residues, more preferred more than200 amino acid residues, more preferred more than 300 amino acidresidues, even more preferred more than 400 amino acid residues and mostpreferred more than 500 amino acid residues. A fragment may comprise orconsist of at least 50, 60, 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99%of an albumin or of a domain of an albumin. Preferred albumin domains ofthe invention are domains having at least 70, 75, 80, 85, 90, 95, 96,97, 98, 99, 99.5% or 100% identity to HSA domain I consisting of aminoacid residues 1 to 194±1 to 15 amino acids of SEQ ID NO. 2; at least 70,75, 80, 85, 90, 95, 96, 97, 98, 99, 99.5% or 100% identity to HSA domainII consisting of amino acid residues 192 to 387±1 to 15 amino acids ofSEQ ID NO. 2 and at least 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, 99.5%or 100% identity to HSA domain III consisting of amino acid residues 381to 585±1 to 15 amino acids of SEQ ID NO. 2.

Domains I, II and III may be defined with reference to HSA (SEQ ID NO.2). For example, HSA Domain I may consist of or comprise amino acids 1to 194 (±1 to 15 amino acids) of SEQ ID NO. 2, HSA Domain II may consistof or comprise amino acids 192 (±1 to 15 amino acids) to 387 (±1 to 15amino acids) of SEQ ID NO. 2 and Domain III may consist of or compriseamino acid residues 381 (±1 to 15 amino acids) to 585 (±1 to 15 aminoacids) of SEQ ID NO. 2. “±1 to 15 amino acids” means that the residuenumber may deviate by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or15 amino acids to the C-terminus and/or to the N-terminus of the statedamino acid position. Examples of domains I, II and III are described byDockal et al. (The Journal of Biological Chemistry, 1999, Vol. 274(41):29303-29310) and Kjeldsen et al. (Protein Expression and Purification,1998, Vol 13: 163-169) and are tabulated below.

TABLE 1 Amino acid residues of HSA domains I, II and III with referenceto SEQ ID NO. 2 Dockal et al Kjeldsen et al Domain I 1 to 197 1 to 192Domain II 189 to 385 193 to 382 Domain III 381 to 585 383 to 585

A fragment may comprise or consist of one or more (e.g. several) domainsof albumin described herein such as DI+DII, DI+DIII, DII+DIII,DIII+DIII, DI+DIII DIII, DIII+DIII+DIII, or fragments of such domains orcombinations of domains.

The skilled person can identify domains I, II and III in non-humanalbumins by amino acid sequence alignment with HSA, for example usingthe Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol.Biol. 48: 443-453) as implemented in the Needle program of the EMBOSSpackage (EMBOSS: The European Molecular Biology Open Software Suite,Rice et al., 2000, Trends Genet. 16: 276-277), preferably version 3.0.0or later, more preferably version 5.0.0 or later. The optionalparameters used are gap open penalty of 10, gap extension penalty of0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix.Other suitable software includes MUSCLE ((Multiple sequence comparisonby log-expectation, Robert C. Edgar, Version 3.6,http://www.drive5.com/muscle; Edgar (2004) Nucleic Acids Research 32(5),1792-97 and Edgar (2004) BMC Bioinformatics, 5(1):113) which may be usedwith the default settings as described in the User Guide (Version 3.6,September 2005). Versions of MUSCLE later than 3.6 may also be used forany aspect of the invention). Examples of suitable alignments areprovided in FIGS. 1 and 2.

It is preferred that domains have at least 70, 75, 80, 85, 90, 95, 96,97, 98, 99, 99.5% identity or 100% identity to Domain I, II or III ofHSA (SEQ ID NO. 2).

Additionally, single or multiple heterologous fusions comprising any ofthe above; or single or multiple heterologous fusions to albumin, or avariant or fragment of any of these may be used. Such fusions includealbumin N-terminal fusions, albumin C-terminal fusions and co-N-terminaland C-terminal albumin fusions as exemplified by WO 01/79271(incorporated herein by reference).

Equivalent amino acid positions: Throughout this specification aminoacid positions are defined in relation to full-length mature HSA (i.e.without leader sequence, SEQ ID NO. 2). However, the skilled personunderstands that the invention also relates to variants of non-humanalbumins (e.g. those disclosed herein) and/or fragments of a human ornon-human albumin. For clarity, for albumins other than HSA (SEQ ID NO.2), equivalent residues are favoured for mutation. Equivalent positionscan be identified in fragments of HSA, in animal albumins and infragments, fusions and other derivatives or variants thereof bycomparing amino acid sequences using pairwise (e.g. ClustalW) ormultiple (e.g. MUSCLE) alignments. For example, FIG. 1 shows thatpositions equivalent to 500, 550 and 573 in full length HSA are easilyidentified in fragments of HSA and in albumins of other species.Positions 500, 550 and 573 are indicated by arrows. Further details areprovided in Table 2 below.

TABLE 2 Example of identification of equivalent positions in HSA, animalalbumins and albumin fragments Organism Albumin (accession Total lengthPosition equivalent to number of Full length Fragment of mature HSA(native amino acid): protein) or fragment details protein 500 (K) 550(D) 573 (K) Homo Full length — 585 500 (K) 550 (D) 573 (K) sapiens(AAA98797) Homo Fragment DI, DIII 399 314 (K) 364 (D) 387 (K) sapiensHomo Fragment DI, DIII 403 318 (K) 368 (D) 391 (K) sapiens Macaca Fulllength — 584 500 (K) 550 (N) 573 (P) mulatta (NP_001182578) Rattus Fulllength — 584 500 (K) 550 (D) 573 (P) norvegicus (AAH85359) Mus Fulllength — 584 500 (K) 550 (D) 573 (P) musculus (AAH49971)

FIG. 1 was generated by MUSCLE using the default parameters includingoutput in ClustalW 1.81 format. The raw output data was shaded usingBoxShade 3.21 (which can be accessed athttp://www.ch.embnet.org/software/BOX_form.html) using Output Format:RTF_new; Font Size: 10; Consensus Line: no consensus line; Fraction ofsequences (that must agree for shading): 0.5; Input sequence format:ALN. Therefore, throughout this specification amino acid positionsdefined in HSA also apply to equivalent positions in fragments,derivatives or variants and fusions of HSA, albumins from other speciesand fragments and fusions thereof. Such equivalent positions may have(i) a different residue number in its native protein and/or (ii) adifferent native amino acid in its native protein. Likewise, FIG. 2shows that equivalent positions can be identified in fragments (e.g.domains) of an albumin with reference to SEQ ID NO. 2 (HSA).

Conservative substitution: As used herein, the term “conservative” aminoacid substitutions refers to substitutions made within the same group,and which typically do not substantially affect protein function. By“conservative substitutions” is intended combinations such as Gly, Ala.;Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe, Tyr.Such variants may be made by techniques well known in the art, such asby site-directed mutagenesis as disclosed in U.S. Pat. No. 4,302,386issued 24 Nov. 1981 to Stevens, incorporated herein by reference.

In one embodiment, the Venn diagram of FIG. 3 may be used to determineconservative amino acid substitutions: Using FIG. 3, a conservationmutation score (ranging from 0 to 5) may be calculated. A score of 0 isthe highest conservation, which, for cysteine, is only assigned forsubstitution of a cysteine residue with another cysteine residue. Forchanges from any other amino acid to a cysteine (or for a cysteine toany other amino acid), the score may be 1, 2, 3, 4, 5. A score of 1 is amore conservative substitution than a score of 2, 3, 4 or 5. A score of5 is assigned to the lowest conservation between a substituted aminoacid and the cysteine. The score of 0 to 5 is calculated from FIG. 3 asthe number of boundaries (i.e. lines) crossed to go from cysteine to theappropriate amino acid. Thus the score for cysteine is 0 as noboundaries are crossed. Likewise, the score of aspartic acid (D) is 3,since 3 boundaries are crossed. The conservation mutation score (withrespect to FIG. 3) for the 20 different amino acids are defined as(using one-letter codes for the amino acids): A=1, C=0, D=3, E=4, F=4,G=2, H=5, 1=4, K=4, L=4, M=3, N=2, P=3, Q=3, R=5, S=1, T-1, V-3, W-3,Y=3.

Alternatively, or in addition, “conservative” amino acid substitutionsrefers to substitutions made within the same group such as within thegroup of basic amino acids (such as arginine, lysine, histidine), acidicamino acids (such as glutamic acid and aspartic acid), polar amino acids(such as glutamine and asparagine), hydrophobic amino acids (such asleucine, isoleucine, valine), aromatic amino acids (such asphenylalanine, tryptophan, tyrosine) and small amino acids (such asglycine, alanine, serine, threonine, methionine).

For example, a conservative substitution of alanine-2 in SEQ ID NO. 2can include glycine or serine. Non-conservative substitutions encompasssubstitutions of amino acids in one group by amino acids in anothergroup. For example, a non-conservative substitution could include thesubstitution of a polar amino acid for a hydrophobic amino acid.

Conventions for Designation of Variants

For purposes of the present invention, the mature polypeptide disclosedin SEQ ID NO.

2 is used to determine the corresponding amino acid residue in anotheralbumin. The amino acid sequence of another albumin is aligned with themature polypeptide disclosed in SEQ ID NO. 2, and based on thealignment, the amino acid position number corresponding to any aminoacid residue in the mature polypeptide disclosed in SEQ ID NO. 2 isdetermined using the Needleman-Wunsch algorithm (Needleman and Wunsch,1970, J. Mol. Biol. 48: 443-453) as implemented in the Needle program ofthe EMBOSS package (EMBOSS: The European Molecular Biology Open SoftwareSuite, Rice et al., 2000, Trends Genet. 16: 276-277), preferably version3.0.0 or later, more preferably version 5.0.0 or later. The parametersused are gap open penalty of 10, gap extension penalty of 0.5, and theEBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix.

Identification of the corresponding amino acid residue in anotheralbumin can be determined or confirmed by an alignment of multiplepolypeptide sequences using several computer programs including, but notlimited to, MUSCLE (multiple sequence comparison by log-expectation;version 3.5 or later; Edgar, 2004, Nucleic Acids Research 32:1792-1797), MAFFT (version 6.857 or later; Katoh and Kuma, 2002, NucleicAcids Research 30: 3059-3066; Katoh et al., 2005, Nucleic Acids Research33: 511-518; Katoh and Toh, 2007, Bioinformatics 23: 372-374; Katoh etal., 2009, Methods in Molecular Biology 537: 39-64; Katoh and Toh, 2010,Bioinformatics 26: 1899-1900), and EMBOSS EMMA employing ClustalW (1.83or later; Thompson et al., 1994, Nucleic Acids Research 22: 4673-4680),using their respective default parameters.

When the other polypeptide (or protein) has diverged from the maturepolypeptide of SEQ ID NO. 2 such that traditional sequence-basedcomparison fails to detect their relationship (Lindahl and Elofsson,2000, J. Mol. Biol. 295: 613-615), other pairwise sequence comparisonalgorithms can be used. Greater sensitivity in sequence-based searchingcan be attained using search programs that utilize probabilisticrepresentations of polypeptide families (profiles) to search databases.For example, the PSI-BLAST program generates profiles through aniterative database search process and is capable of detecting remotehomologs (Altschul et al., 1997, Nucleic Acids Res. 25: 3389-3402). Evengreater sensitivity can be achieved if the family or superfamily for thepolypeptide has one or more (e.g. several) representatives in theprotein structure databases. Programs such as GenTHREADER (Jones, 1999,J. Mol. Biol. 287: 797-815; McGuffin and Jones, 2003, Bioinformatics 19:874-881) utilize information from a variety of sources (PSI-BLAST,secondary structure prediction, structural alignment profiles, andsolvation potentials) as input to a neural network that predicts thestructural fold for a query sequence. Similarly, the method of Gough etal., 2000, J. Mol. Biol. 313: 903-919, can be used to align a sequenceof unknown structure with the superfamily models present in the SCOPdatabase. These alignments can in turn be used to generate homologymodels for the polypeptide, and such models can be assessed for accuracyusing a variety of tools developed for that purpose.

For proteins of known structure, several tools and resources areavailable for retrieving and generating structural alignments. Forexample the SCOP superfamilies of proteins have been structurallyaligned, and those alignments are accessible and downloadable. Two ormore (e.g. several) protein structures can be aligned using a variety ofalgorithms such as the distance alignment matrix (Holm and Sander, 1998,Proteins 33: 88-96) or combinatorial extension (Shindyalov and Bourne,1998, Protein Engineering 11: 739-747), and implementation of thesealgorithms can additionally be utilized to query structure databaseswith a structure of interest in order to discover possible structuralhomologs (e.g. Holm and Park, 2000, Bioinformatics 16: 566-567).

In describing the albumin variants of the present invention, thenomenclature described below is adapted for ease of reference. Theaccepted IUPAC single letter or three letter amino acid abbreviation isemployed. The term ‘point mutation’ and/or ‘alteration’ includesdeletions, insertions and substitutions.

Substitutions. For an amino acid substitution, the followingnomenclature is used: Original amino acid, position, substituted aminoacid. Accordingly, the substitution of threonine at position 226 withalanine is designated as “Thr326Ala” or “T326A”. Multiple mutations (oralterations) are separated by addition marks (“+”), e.g.“Gly205Arg+Ser411Phe” or “G205R S411F”, representing substitutions atpositions 205 and 411 of glycine (G) with arginine (R) and serine (S)with phenylalanine (F), respectively. The Figures also use (“/”), e.g.“E492T/N503D” this should be viewed as interchangeable with (“+”).

Deletions. For an amino acid deletion, the following nomenclature isused: Original amino acid, position*. Accordingly, the deletion ofglycine at position 195 is designated as “Gly195*” or “G195*”. Multipledeletions are separated by addition marks (“+”), e.g. “Gly195*+Ser411*”or “G195*+S411*”.

Insertions. As disclosed above, an insertion may be to the N-side(‘upstream’, ‘X-1’) or C-side (‘downstream’, ‘X+1’) of the amino acidoccupying a position (‘the named (or original) amino acid’, ‘X’).

For an amino acid insertion to the C-side (‘downstream’, ‘X+1’) of theoriginal amino acid (‘X’), the following nomenclature is used: Originalamino acid, position, original amino acid, inserted amino acid.Accordingly the insertion of lysine after glycine at position 195 isdesignated “Gly195GlyLys” or “G195GK”. An insertion of multiple aminoacids is designated [Original amino acid, position, original amino acid,inserted amino acid #1, inserted amino acid #2; etc.]. For example, theinsertion of lysine and alanine after glycine at position 195 isindicated as “Gly195GlyLysAla” or “G195GKA”.

In such cases the inserted amino acid residue(s) are numbered by theaddition of lower case letters to the position number of the amino acidresidue preceding the inserted amino acid residue(s). In the aboveexample, the sequence would thus be:

Parent: Variant: 195 195 195a 195b G G - K - A

For an amino acid insertion to the N-side (‘upstream’, ‘X-1’) of theoriginal amino acid (X), the following nomenclature is used: Originalamino acid, position, inserted amino acid, original amino acid.Accordingly the insertion of lysine (K) before glycine (G) at position195 is designated “Gly195LysGly” or “G195KG”. An insertion of multipleamino acids is designated [Original amino acid, position, inserted aminoacid #1, inserted amino acid #2; etc., original amino acid]. Forexample, the insertion of lysine (K) and alanine (A) before glycine atposition 195 is indicated as “Gly195LysAlaGly” or “G195KAG”. In suchcases the inserted amino acid residue(s) are numbered by the addition oflower case letters with ‘prime’ to the position number of the amino acidresidue following the inserted amino acid residue(s). In the aboveexample, the sequence would thus be:

Parent: Variant: 195 195a′ 195b′ 195 G K - A - G

Multiple alterations. Variants comprising multiple alterations areseparated by addition marks (“+”), e.g. “Arg170Tyr+Gly195Glu” or“R170Y+G195E” representing a substitution of arginine and glycine atpositions 170 and 195 tyrosine and glutamic acid, respectively.

Different alterations. Where different alterations can be introduced ata position, the different alterations are separated by a comma, e.g.“Arg170Tyr,Glu” represents a substitution of arginine at position 170with tyrosine or glutamic acid. Thus, “Tyr167Gly,Ala+Arg170Gly,Ala”designates the following variants: “Tyr167Gly+Arg170Gly”,“Tyr167Gly+Arg170Ala”, “Tyr167Ala+Arg170Gly”, and “Tyr167Ala+Arg170Ala”.

Conjugation competence: A conjugation-competent cysteine is a cysteineresidue which is capable of forming an intermolecular bond with aconjugation partner, particularly a conjugation partner that is not analbumin. A conjugation-competent polypeptide, i.e. thio-albumin, iscapable of forming an intermolecular bond with a conjugation partner byvirtue of the conjugation-competent cysteine residue. The thio-albuminmay or may not have a high level of conjugation competence, for exampleat least 50, 60, 70, 80, 90, 95, 96, 97, 98, 99 or 100% relative to theconjugation competence of an albumin consisting of SEQ ID NO. 2 havingonly one conjugation competent cysteine at Cys-34. Conjugationcompetence may be determined relative to any conjugatable molecule(conjugation partner) of interest, for example a bioactive molecule or afluorescent dye. Determination may be through mass spectrometry (MS)analysis or quantification of the activity of the bioactive compoundsuch as its fluorescence. Conjugation competence of albumin and biotinor HRP may be determined by assaying the mass of the resultant conjugateand/or the enzyme activity of the conjugated compound. Determination byfluorescent labelling and cellular uptake is described by McGraw et al.,(1987), The Journal of Cell Biology, 105, 207-214; and Presley et al.,(1993), The Journal of Cell Biology, 122, 1231-1241. An advantage of athio-albumin having a high conjugation competence is that it may allowefficient conjugation of molecules to the thio-albumin. Conjugationcompetence may be measured with respect to time. Favoured thio-albuminsmay be (a) those which achieve maximal conjugation quickly or (b)slowly. The conjugation competence of a specific cysteine may bedetermined by methods known to those skilled in the art—for example, theprotein may be digested post-conjugation and peptide mapping performedto determine the degree of conjugation at the specific cysteine.

A bioactive agent or bioactive compound is one which has the ability tointeract with a living organism, system or cell. It may, for example, bea biological or chemical agent or compound.

Ligand binding: The ligand binding properties of albumin include bindingto anionic and neutral ligands such as long-chain fatty acids, bilirubinand other miscellaneous ligands. The long-chain fatty acids, oleic(C18:1), palmitic (C16:0), linoleic (C18:2), stearic (C18:0),arachidonic (C20:4) and palmitoleic (C16:1) are known to bind HSA.Ligand binding studies can be performed on HSA and thio-albumins usingan isothermal titration calorimetry method that had been suitablyqualified for this purpose. Samples can be pre-treated by defatting(Sogami, M. and J. F. Foster (1968). Biochemistry 7(6): 2172-82,incorporated herein by reference) followed by thiol blocking (Sogami,M., H. A. Petersen, et al. (1969). Biochemistry 8(1): 49-58,incorporated herein by reference) and subsequent gel permeationchromatography. The binding curves generated for thio-albumins and HSAwith octanoate, for example, may subsequently be compared, andfunctional similarity established. Conjugated- and/or non-conjugatedthio-albumin may have at least 5%, 10%, 15%, 20%, 30%, 40% or 50%, 60%,70%, at least 80%, 90%, 95%, 100%, 105% or more of HSA's receptorbinding activity, mole for mole, to biliru bin and/or a fatty acid.

FcRn and shFcRn: The term “FcRn” means the neonatal Fc receptor (FcRn),particularly the human neonatal Fc receptor. shFcRn is a solublerecombinant form of FcRn. shFcRn is a heterodimer of SEQ ID NO. 26(truncated heavy chain of the major histocompatibility complex classI-like Fc receptor (FCGRT)) and SEQ ID NO. 27 (beta-2-microglobulin).Together, SEQ ID NO. 26 and 27 form hFcRn.

The conjugated- and/or non-conjugated thio-albumin may or may not havean altered binding affinity to FcRn.

The thio-albumin or conjugate thereof may have a binding to FcRn that isstronger or weaker (and, preferably, is stronger) than that of theparent albumin or conjugate thereof.

The thio-albumin or conjugate thereof may have a KD to FcRn (e.g.shFcRn) that is lower than the corresponding KD for HSA or conjugatethereof to. Preferably, the KD for the thio-albumin or conjugate is lessthan 0.9X KD for HSA to FcRn, more preferred less than 0.5X KD for HSAto FcRn, more preferred less than 0.1X KD for HSA to FcRn, even morepreferred less than 0.05X KD for HSA to FcRn, even more preferred lessthan 0.02X KD for HSA to FcRn, even more preferred less than 0.01X KDfor HSA to FcRn and most preferred less than 0.001X KD for HSA to FcRn(where X means ‘multiplied by’).

For a conjugate comprising a thio-albumin, preferably the KD for theconjugate is less than 0.9X KD for the corresponding conjugatecomprising HSA to FcRn, more preferred less than 0.5X KD for thecorresponding conjugate to FcRn, more preferred less than 0.1X KD forthe corresponding conjugate to FcRn, even more preferred less than 0.05XKD for the corresponding conjugate to FcRn, even more preferred lessthan 0.02X KD for the corresponding conjugate to FcRn, even morepreferred less than 0.01X KD for the corresponding conjugate to FcRn andmost preferred less than 0.001X KD for the corresponding conjugate toFcRn (where X means ‘multiplied by’). ‘Corresponding conjugate’ means aconjugate comprising HSA (e.g. SEQ ID NO. 2) instead of the thio-albumin(i.e. albumin variant).

The thio-albumin or conjugate thereof may have a KD to FcRn that ishigher than the corresponding KD for HSA or conjugate thereof to FcRn.Preferably, the KD for the thio-albumin or conjugate is more than 2X KDfor HSA to FcRn, more preferred more than 5X KD for HSA to FcRn, morepreferred more than 10X KD for HSA to FcRn, even more preferred morethan 25X KD for HSA to FcRn, most preferred more than 50X KD for HSA toFcRn. The thio-albumin or conjugate may be a null binder to FcRn.

For a conjugate comprising a thio-albumin, preferrably the KD for theconjugate, Preferably, the KD for the corresponding conjugate comprisingHSA is more than 2X KD for the corresponding conjugate to FcRn, morepreferred more than 5X KD for the corresponding conjugate to FcRn, morepreferred more than 10X KD for the corresponding conjugate to FcRn, evenmore preferred more than 25X KD for the corresponding conjugate to FcRn,most preferred more than 50X KD for the corresponding conjugate to FcRn.Corresponding conjugate′ means a conjugate comprising HSA (e.g. SEQ IDNO. 2) instead of the thio-albumin (i.e. albumin variant).

When determining and/or comparing KD, one or more (e.g. several) (andpreferably all) of the following parameters may be used:

Instrument: Biacore 3000 instrument (GE Healthcare)

Flow cell: CM5 sensor chip

FcRn: human FcRn, preferably soluble human FcRn, optionally coupled to atag such as Glutathione S Transferase (GST) or Histidine (His), mostpreferably His such as 6 histidine residues at the C-terminus of thebeta-2-microglobulin.

Quantity of FcRn: 1200-2500 RU

Coupling chemistry: amine coupling chemistry (e.g. as described in theprotocol provided by the manufacturer of the instrument).

Coupling method: The coupling may be performed by injecting 20 μg/mL ofthe protein in 10 mM sodium acetate pH 5.0 (GE Healthcare). Phosphatebuffer (67 mM phosphate buffer, 0.15 M NaCl, 0.005% Tween 20) at pH 5.5may be used as running buffer and dilution buffer. Regeneration of thesurfaces may be done using injections of HBS-EP buffer (0.01 M HEPES,0.15 M NaCl, 3 mM EDTA, 0.005% surfactant P20) at pH 7.4 (Biacore AB).

Quantity of injection of test molecule (e.g. HSA or variant) 20-0.032 μM

Flow rate of injection: constant, e.g. 30 μL/mL

Temperature of injection: 25° C.

Data evaluation software: BIAevaluation 4.1 software (BIAcore AB).

Plasma half-life: Plasma half-life is ideally determined in vivo insuitable individuals. However, since it is time consuming and expensiveand inevitably there are ethical concerns connected with doingexperiments in animals or man, it is desirable to use an in vitro assayfor determining whether plasma half-life is extended or reduced. It isknown that the binding of albumin to its receptor (FcRn) is importantfor plasma half-life and the correlation between receptor binding andplasma half-life is that a higher affinity of albumin to its receptorleads to longer plasma half-life. Thus for the invention a higheraffinity of albumin to FcRn is considered indicative of an increasedplasma half-life and a lower affinity of albumin to its receptor isconsidered indicative of a reduced plasma half-life.

The binding of albumin to its receptor FcRn may be described using theterm affinity and the expressions “stronger” or “weaker”. Thus, itshould be understood that a molecule having a higher affinity to FcRnthan HSA is considered to bind more strongly to FcRn than HSA and amolecule having a lower affinity to FcRn than HSA is considered to bindmore weakly to FcRn than HSA. The term ‘binding coefficient’ can be usedinstead of the term ‘binding affinity’.

The terms “longer plasma half-life” or “shorter plasma half-life” andsimilar expressions are understood to be in relationship to thecorresponding parent or reference or corresponding albumin molecule.Thus, a longer plasma half-life with respect to a variant albumin of theinvention means that the variant has longer plasma half-life than thatof the corresponding albumin having the same sequences except for thealteration(s) described herein.

Reference: a reference is an albumin, fusion, conjugate, composition,associate, nanoparticle or microparticle to which an albumin variant,fusion, conjugate, composition, associate, nanoparticle or microparticleis compared. The reference may comprise or consist of full lengthalbumin (such as HSA or a natural allele thereof) or a fragment thereof.A reference may also be referred to as a ‘corresponding’ albumin,fusion, conjugate, composition, associate or nanoparticle to which analbumin variant, fusion, conjugate, composition, associate ornanoparticle is compared. A reference may comprise or consist of HSA(SEQ ID NO. 2) or a fragment, fusion, conjugate, associate, nanoparticleor microparticle thereof. Preferably, the reference is identical to thepolypeptide, fusion polypeptide, conjugate, composition, associate,nanoparticle or microparticle according to the invention (“beingstudied”) with the exception of the albumin moiety. Preferably thealbumin moiety of the reference comprises or consists of an albumin(e.g. HSA, SEQ ID NO. 2) or a fragment thereof. The amino acid sequenceof the albumin moiety of the reference may be longer than, shorter thanor, preferably, the same (±1 to 15 amino acids) length as the aminosequence of the albumin moiety of the polypeptide, fusion polypeptide,conjugate, composition, associate, nanoparticle or microparticleaccording to the invention (“being studied”).

Allelic variant: The term “allelic variant” means any of two or more(several) alternative forms of a gene occupying the same chromosomallocus. Allelic variation arises naturally through mutation, and mayresult in polymorphism within populations. Gene mutations can be silent(no change in the encoded polypeptide) or may encode polypeptides havingaltered amino acid sequences. An allelic variant of a polypeptide is apolypeptide encoded by an allelic variant of a gene. Polymorphisms knownfor HSA (SEQ ID NO. 2) are discussed in Minchiotti et al. (2008). HumMutat 29(8): 1007-16 and at http://www.uniprot.org/uniprot/P02768.

Coding sequence: The term “coding sequence” means a polynucleotide,which directly specifies the amino acid sequence of its translatedpolypeptide product. The boundaries of the coding sequence are generallydetermined by an open reading frame, which usually begins with the ATGstart codon or alternative start codons such as GTG and TTG and endswith a stop codon such as TAA, TAG, and TGA. The coding sequence may bea DNA, cDNA, synthetic, or recombinant polynucleotide.

cDNA: The term “cDNA” means a DNA molecule that can be prepared byreverse transcription from a mature, spliced, mRNA molecule obtainedfrom a eukaryotic cell. cDNA lacks intron sequences that may be presentin the corresponding genomic DNA. The initial, primary RNA transcript isa precursor to mRNA that is processed through a series of steps,including splicing, before appearing as mature spliced mRNA.

Nucleic acid construct: The term “nucleic acid construct” means anucleic acid molecule, either single- or double-stranded, which isisolated from a naturally occurring gene or is modified to containsegments of nucleic acids in a manner that would not otherwise exist innature or which is synthetic. The term nucleic acid construct issynonymous with the term “expression cassette” when the nucleic acidconstruct contains the control sequences required for expression of acoding sequence of the invention.

Control sequences: The term “control sequences” means all nucleic acidsequences necessary for the expression of a polynucleotide encoding avariant of the invention. Each control sequence may be native (i.e. fromthe same gene) or foreign (i.e. from a different gene) to thepolynucleotide encoding the variant or native or foreign to each other.Such control sequences include, but are not limited to, a leader,polyadenylation sequence, propeptide sequence, promoter, signal peptidesequence, and transcription terminator. At a minimum, the controlsequences include a promoter, and transcriptional and translational stopsignals. The control sequences may be provided with linkers for thepurpose of introducing specific restriction sites facilitating ligationof the control sequences with the coding region of the polynucleotideencoding a variant.

Operably linked: The term “operably linked” means a configuration inwhich a control sequence is placed at an appropriate position relativeto the coding sequence of a polynucleotide such that the controlsequence directs the expression of the coding sequence.

Expression: The term “expression” includes any step involved in theproduction of the variant including, but not limited to, transcription,post-transcriptional modification, translation, post-translationalmodification, and secretion. The thio-albumin may or may not be capableof being expressed at a level of at least 10, 20, 30, 40, 50, 60, 70,80, 90 or 100% relative to the expression of an unmodified albumin (suchas SEQ ID NO. 2) from a suitable expression system, such as yeast (e.g.Saccharomyces, e.g. S. cerevisiae) or an Aspergillus. Relativeexpression levels can be determined, for example, by expression of theprotein followed by quantification by SDS-PAGE, GP-HPLC or WesternBlotting.

Expression vector: The term “expression vector” means a linear orcircular DNA molecule that comprises a polynucleotide encoding a variantand is operably linked to control sequences that provide for itsexpression.

Host cell: The term “host cell” means any cell type that is susceptibleto transformation, transfection, transduction, or the like with anucleic acid construct or expression vector comprising a polynucleotideof the present invention. The term “host cell” encompasses any progenyof a parent cell that is not identical to the parent cell due tomutations that occur during replication.

DETAILED DESCRIPTION OF THE INVENTION Conjugation-Competent PolypeptidesI

A first aspect of the invention provides a conjugation-competentpolypeptide comprising an amino acid sequence which is at least 60%identical to human albumin, particularly residues 1 to 585 of the maturehuman albumin polypeptide sequence of SEQ ID NO. 2, or a fragmentthereof;

wherein at least one (e.g. several) position equivalent to a positionselected from K93, E294, A226, E230, 1271, E358, L24, F49, V54, D56,L66, A92, Q94, E97, H128, F156, E227, D237, K240, D259, K262, N267,Q268, L275, E277, L284, E311, K317, A322, E333, D340, E354, K359, A362,E382, and L398 of SEQ ID NO. 2 comprises a conjugation-competentcysteine residue;

preferably wherein the conjugation-competent polypeptide has a tendencyto exist as a monomer in solution which is at least 70% of the tendencyof the parent polypeptide (such as the polypeptide of SEQ ID NO. 2) toexist as a monomer in solution, more preferably at least 75, 80, 85, 90,95, 96, 97, 98, at least 99 or 100% of the tendency of the polypeptideof SEQ ID NO. 2 to exist as a monomer in solution. Preferably the parentpolypeptide does not contain the conjugation-competent Cys residue orresidues described herein. Preferably the parent polypeptide does notcontain the additional mutation or mutations described herein. That is,preferably the parent polypeptide is identical to theconjugation-competent polypeptide with the exception of the introducedcysteine residue or residues and, if present, the introduced othermutation or mutations.

Suitably, the at least one (e.g. several) position is selected from K93,E294, A226, E230, I271, and E358, particularly from K93, E294, A226,E230, and I271.

Preferably the conjugation-competent polypeptide has at least 70, 75,80, 85, 90, 95, 96, 97, 98, 99, 99.2, 99.4, 99.6, 99.8% sequenceidentity to SEQ ID NO. 2. For example, in addition to the introduced Cysresidue or Cys residues, the conjugation-competent polypeptide may haveat least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 (e.g. several) other mutationsrelative to SEQ ID NO. 2. Alternatively, in addition to the introducedCys residue or Cys residues, the conjugation-competent polypeptide mayhave zero other mutations relative to SEQ ID NO. 2.

Preferably, the conjugation-competent polypeptide has a tendency toexist as a monomer in solution which is at least 75% of the tendency ofthe polypeptide of SEQ ID NO. 2 to exist as a monomer in solution and atleast one position equivalent to a position selected from K93, E294,A226, E230, 1271, E358, L24, F49, V54, D56, A92, Q94, E97, H128, F156,E227, D237, K240, D259, K262, N267, Q268, L275, L284, K317, A322, E333,D340, E354, K359, A362, E382, and L398 comprises a conjugation-competentcysteine residue.

Preferably the polypeptide is a recombinant polypeptide. Preferably thepolypeptide is an isolated and/or purified polypeptide. Preferably thepolypeptide is synthetic and/or does not naturally occur in nature.

A conjugation-competent cysteine at the position defined above may ormay not be created in an albumin by insertion, for example by adding acysteine with or without one or more (e.g. several) additional residuesand without removal of an amino acid residue from the albumin sequence;or by substituting one or more (e.g. several) adjacent amino acids witha larger number of residues containing at least one (e.g. several)cysteine, thus extending the overall length of the polypeptide. Forexample, a cysteine residue may be introduced immediately adjacent analbumin residue identified herein. The cysteine residue may beintroduced as a single cysteine residue or within a polypeptide. Thepolypeptide may be from 2 to 50 amino acids long, preferably from 2, 10,20, 30, or 40 to 10, 20, 30, 40 or 50 amino acids long.

Suitably, the polypeptide comprises one or more (e.g. several) of:

-   -   a) substitution of an amino acid, other than cysteine, with a        cysteine at a position corresponding to a position equivalent to        any of residues K93, E294, A226, E230, I271, E358, L24, F49,        V54, D56, L66, A92, Q94, E97, H128, F156, E227, D237, K240,        D259, K262, N267, Q268, L275, E277, L284, E311, K317, A322,        E333, D340, E354, K359, A362, E382, and L398, particularly from        K93, E294, A226, E230, and 1271, of SEQ ID NO. 2; and/or    -   b) insertion of a cysteine at a position adjacent the N- or        C-side of an amino acid corresponding to a position equivalent        to any of residues K93, E294, A226, E230, 1271, E358, L24, F49,        V54, D56, L66, A92, Q94, E97, H128, F156, E227, D237, K240,        D259, K262, N267, Q268, L275, E277, L284, E311, K317, A322,        E333, D340, E354, K359, A362, E382, and L398, particularly from        K93, E294, A226, E230, and 1271, of SEQ ID NO. 2.

Substitutions are preferred, and the following disclosure of selectedpositions should be understood to specifically encompass substitutions,without limitation.

Suitably 2, 3, 4, 5 or more (e.g. several) positions equivalent topositions selected from K93, E294, A226, E230, 1271, E358, L24, F49,V54, D56, L66, A92, Q94, E97, H128, F156, E227, D237, K240, D259, K262,N267, Q268, L275, E277, L284, E311, K317, A322, E333, D340, E354, K359,A362, E382, and L398, particularly from K93, E294, A226, E230, and 1271,of SEQ ID NO. 2 comprise a conjugation-competent cysteine residue.Suitably the 2, 3, 4, 5 or more (e.g. several) positions are selectedfrom K93, E294, A226, E230, 1271, and E358, particularly from K93, E294,A226, E230 and 1271.

For a polypeptide comprising a Cys at a position equivalent to positionE294 of SEQ ID NO. 1, preferably the polypeptide also comprises a Cys ata position equivalent to one or more of K93, A226, E230, 1271, E358,L24, F49, V54, D56, L66, A92, Q94, E97, H128, F156, E227, D237, K240,D259, K262, N267, Q268, L275, E277, L284, E311, K317, A322, E333, D340,E354, K359, A362, or E382.

The inventors have found that variants of HSA in which cysteine has beensubstituted at a position selected from K93, E294, A226, E230, 1271,E358, L24, F49, V54, D56, L66, A92, Q94, E97, H128, F156, E227, D237,K240, D259, K262, N267, Q268, L275, E277, L284, E311, K317, A322, E333,D340, E354, K359, A362, and E382 have the beneficial property of atendency to exist as a monomer in solution which is at least 70% of thetendency of the HSA polypeptide of SEQ ID NO. 2 to exist as a monomer insolution. A cysteine introduced at one of the selected positionstherefore has a low tendency to cause the variant to form dimers orhigher order oligomers in solution. This beneficial effect is also notedin variants in which there are cysteines at more than one selectedposition. Without wishing to be bound by theory, the inventors ascribethe monomer tendencies of the polypeptides of the invention to theflexibility of the polypeptide chain in the region of, and surfaceexposure at, the site of cysteine substitution. This reflects anexercise of inventive skill, based on years of experience in proteinstructural biology, in the choices applied by the inventors in selectingpositions within HSA for substitution with cysteine.

The tendency of albumin or variants thereof to exist as a monomer,rather than a dimer or higher order oligomer, can be determined based onmeasurement of monomer, dimer and higher order oligomer quantities insolutions of the albumin or variant under similar conditions.

Suitable techniques for performing such measurements include GelPermeation High Pressure Liquid Chromatography, as described in theExamples. Results are typically expressed as “percentage monomer”, whichis calculated as:

amount of monomeric albumin by mass×100/(amount of monomeric albumin bymass+amount of dimeric albumin by mass+amount of higher order oligomerby mass).

Alternatively, the tendency to form non-monomers in solution, that isdimers and/or higher order oligomers, may be expressed. The “percentagenon-monomer” is 100% minus percentage monomer.

Samples may be tested shortly after purification (for example, within 24hours after purification) following production in shake flasks or 10 Lbioreactors, or following storage at 2-8° C., e.g. 5° C., for timeperiods of up to or including 1 week, 1 month, 2 months, 3 months or 6months. Samples are typically tested, and optionally stored, in asolution of one or more (e.g. several) salts and at a pH of about7.0±0.5. The solution may comprise a buffer comprising 50 mM ammoniumacetate, 10 mM sodium octanoate, pH 7.0, preferably at a polypeptideconcentration of from about 0.2 to about 2.5 mg/mL. The solution maycomprise a buffer comprising 25 mM sodium phosphate, 215 mM sodiumchloride, pH 6.5, preferably at a polypeptide concentration of fromabout 5 to about 50 mg/mL.

The percentage monomer for a given albumin may differ depending on thealbumin purity and concentration. Albumin produced in shake flaskculture is typically purified using a single AlbuPure® (Prometic LifeSciences Inc. or Albumedix Ltd (formerly Novozymes Biopharma UK Ltd))chromatography step, and typically is obtained at a concentration ofabout 0.2 to 2.0 mg/mL, more preferably 1±0.5 mg/mL and a protein purityof >95% by SDS reducing PAGE. AlbuPure® is a high-performance affinitycapture adsorbent designed for albumin fusion protein purification,which comprises a synthetic triazine ligand coupled to a base matrix.Under these conditions, percentage monomer of HSA was found to be about87%, rising to about 89% upon storage at 6 months at 2-8° C. e.g. 5° C.Albumin produced in 10 L bioreactor culture is typically purified by aAlbuPure® chromatography step followed by an ion exchangechromatography, is ultrafiltered, and then formulated at 50 mg/mL, andhas a protein purity of >99% by SDS reducing PAGE. Under theseconditions, percentage monomer of HSA was found to be about 94%, and wasstable at two months of storage at 2-8° C. and at 6 months storage at2-8° C. A variant having at least 70% of the tendency of HSA to exist asa monomer in solution may therefore be found to be at least 60% monomer,preferably at least 69% monomer (less than 40% non-monomer, preferablyless than 31% non-monomer) when tested after typical shake flaskproduction and purification as described above, for samples testedshortly after purification or stored for up to two or up to six months.For a variant having at least 80% of the tendency of HSA to exist as amonomer in solution, the percentage monomer should be at least 70%preferably at least 79% monomer, and the percentage non-monomer lessthan 30%, preferably less than 21%. A variant having at least 70% of thetendency of HSA to exist as a monomer in solution may be found to be atleast 65% monomer, preferably at least 69% monomer, when tested aftertypical 10 L bioreactor production and purification as described above,for samples tested shortly after purification or stored for up to twomonths. For a variant having at least 80% of the tendency of HSA toexist as a monomer in solution, the percentage monomer should be atleast 75% preferably at least 79%. The tendency is preferably measuredat day 0, e.g. the day that the variant is produced, however it may alsobe measured later e.g. at day 1, 2, 3, 4, 5, 6, 7 or after 2, 3, 4, 5,6, 7 weeks or after 1 or 2 months storage e.g. at 2-8° C. e.g. 5° C.Suitably, the percentage monomer should be stable upon storage for up toseven weeks or two months, meaning that it does not reduce by more than10, more than 9, 8, 7, 6, 5, 4, 3, 2 or 1 percentage points betweentesting shortly after purification and testing after two months ofstorage e.g. at 2-8° C. e.g. 5° C. Preferably the percentage monomershould not reduce by more than 5 percentage points between testingshortly after purification and testing after 7 weeks of storage at 2-8°C. e.g. 5° C.

The variant may or may not have a tendency to exist as a monomer insolution which is at least 75%, at least 80%, at least 85%, at least90%, at least 95%, at least 96%, at least 97%, at least 98%, at least99%, or at least 100% of the tendency of the polypeptide of SEQ ID NO. 2to exist as a monomer in solution. This tendency may be tested shortlyafter purification or after storage for up to six months e.g. at 2-8° C.e.g. 5° C.

The tendency of the polypeptide to exist as monomer in solution may bemeasured following storage for at least 7 weeks at a temperature from 2to 8° C. such as 5° C., at least 8 weeks at a temperature from 2 to 8°C. such as 5° C., at least 3 months at a temperature from 2 to 8° C.such as 5° C., at least 4 months at a temperature from 2 to 8° C. suchas 5° C., at least 6 months storage at a temperature from 2 to 8° C.such as 5° C., or at least 3 months storage at a tempature of about 40°C. Most preferably the tendency of the polypeptide to exist as monomerin solution is measured following storage for at least 3 months at atemperature from 2 to 8° C. such as 5° C.

The tendency of the polypeptide to exist as a monomer in solution may bemeasured at a polypeptide concentration of from 0.2 to 50 mg/mL, forexample at about 5 mg/mL.

The tendency of the polypeptide to exist as a monomer in solution may bemeasured at a pH from about 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8,6.9, 7.0, 7.1, 7.2, 7.3, or 7.4 to about 6.1, 6.2, 6.3, 6.4, 6.6, 6.7,6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4 or 7.5, preferably about pH 7.

The tendency of the polypeptide to exist as a monomer in solution may bemeasured in a buffer comprising 50 mM ammonium acetate, 10 mM sodiumoctanoate, pH 7.0, preferably at a polypeptide concentration of fromabout 0.5 to about 5 mg/mL.

The tendency of the polypeptide to exist as a monomer in solution may bemeasured in a buffer comprising 25 mM sodium phosphate, 215 mM sodiumchloride, pH 6.5, preferably at a polypeptide concentration of fromabout 5 to about 50 mg/mL.

The conjugation-competent polypeptide may, prior to storage, be purifiedfor example using a triazine (such as AlbuPure®) chromatography matrixor DE-FF chromatography matrix, more preferably by triazine (such asAlbuPure®) chromatography matrix followed by DE-FF chromatographymatrix. Suitable methods are disclosed in Example 10

The polypeptide sample storage may be static. The polypeptide samplestorage may be vertical.

Where a variant comprises more than one conjugation-competent cysteineas provided above, the tendency to exist as a monomer may be reducedcompared to the variant which differs only by virtue of having one fewersuch cysteines. For example, a variant albumin having the substitutionsE294C+K93C has a lower tendency to exist as a monomer than a variantalbumin having either substitution alone. Suitably, the variantcomprises a conjugation-competent cysteine residue at two positionsselected from K93, E294, A226, E230, 1271, E358, L24, F49, V54, D56,L66, A92, Q94, E97, H128, F156, E227, D237, K240, D259, K262, N267,Q268, L275, E277, L284, E311, K317, A322, E333, D340, E354, K359, A362,E382, and L398, particularly from K93, E294, A226, E230, and I271, ofSEQ ID NO. 2, wherein the variant has a tendency to exist as a monomerin solution which is at least 75% of the tendency of a variant whichdiffers only by virtue of comprising a conjugation-competent cysteineresidue at only one of the two positions.

Suitably, the variant comprises a conjugation-competent cysteine residueat two positions selected from K93, E294, A226, E230, 1271, E358,particularly from K93, E294, A226, E230, and 1271, of SEQ ID NO. 2,wherein the variant has a tendency to exist as a monomer in solutionwhich is at least 75% of the tendency of a variant which differs only byvirtue of comprising a conjugation-competent cysteine residue at onlyone of the two positions. Higher monomer tendencies are preferred, suchas at least 80%, at least 85%, at least 90%, at least 95%, at least 96%,at least 97%, at least 98%, at least 99%, or at least 100%. For example,HSA comprising the substitution E294C+K93C has a tendency to exist as amonomer in solution which is at least 90% of the tendency of HSAcomprising the substitution K93C, or at least 85% of the tendency of HSAcomprising the substitution E294C, to exist as a monomer in solution.These results are illustrated in the Examples, with material purifiedfrom 10 L bioreactor preparations, and tested shortly afterpurification, or after storage for seven weeks or two months at 2-8° C.e.g. 5° C. The same samples were also stable following storage for 6months. Albumin variants having more than one conjugation-competentcysteine can be prepared by introducing a further conjugation-competentcysteine residue into a variant which already has at least one (e.g.several) conjugation-competent cysteine residue. Variants comprising afurther conjugation-competent cysteine residue which have at least 75%of the tendency of the reference albumin lacking the furtherconjugation-competent cysteine residue to exist as a monomer in solutionmay be preferred.

Suitable variants may comprise a conjugation-competent cysteine residueat one or two or more (e.g. several) positions selected from K93, E294,A226, E230, 1271 and E358 of SEQ ID NO. 2. Suitable combinations ofpositions are (i) K93+E294, A226, E230, 1271, or E358; (ii) E294+K93,A226, E230, 1271, or E358; (iii) A226+K93, E294, E230, 1271, or E358;(iv) E230+K93, E294, A226, 1271, or E358; (v) 1271+K93, E294, A226,E230, or E358; (vi) K93+E294+A226, E230, 1271, or E358 of SEQ ID NO. 2.Suitable variants may comprise a conjugation-competent cysteine residueat one or two or more (e.g. several) positions selected from L24, F49,V54, D56, L66, A92, K93, Q94, E97, H128, F156, A226, E227, D237, E230,K240, D259, K262, N267, Q268, 1271, L275, E277, L284, E294, E311, K317,A322, E333, D340, E354, E358, K359, A362, E382, L398 of SEQ ID NO. 2.Suitable combinations of positions are: (1) L24+F49, V54, D56, L66, A92,K93, Q94, E97, H128, F156, E227, E230, D237, K240, D259, K262, N267,Q268, 1271, L275, E277, L284, E294, E311, K317, A322, E333, D340, E354,E358, K359, A362, E382, or L398; (2) F49+L24, V54, D56, L66, A92, K93,Q94, E97, H128, F156, A226, E227, E230, D237, K240, D259, K262, N267,Q268, 1271, L275, E277, L284, E294, E311, K317, A322, E333, D340, E354,E358, K359, A362, E382, or L398; (3) V54+L24, F49, D56, L66, A92, K93,Q94, E97, H128, F156, A226, E227, E230, D237, K240, D259, K262, N267,Q268, 1271, L275, E277, L284, E294, E311, K317, A322, E333, D340, E354,E358, K359, A362, E382, or L398; (4) D56+L24, F49, V54, L66, A92, K93,Q94, E97, H128, F156, A226, E227, E230, D237, K240, D259, K262, N267,Q268, 1271, L275, E277, L284, E294, E311, K317, A322, E333, D340, E354,E358, K359, A362, E382, or L398; (5) L66+L24, F49, V54, D56, A92, K93,Q94, E97, H128, F156, A226, E227, E230, D237, K240, D259, K262, N267,Q268, 1271, L275, E277, L284, E294, E311, K317, A322, E333, D340, E354,E358, K359, A362, E382, or L398; (6) A92+L24, F49, V54, D56, L66, K93,Q94, E97, H128, F156, A226, E227, E230, D237, K240, D259, K262, N267,Q268, 1271, L275, E277, L284, E294, E311, K317, A322, E333, D340, E354,E358, K359, A362, E382, or L398; (7) Q94+L24, F49, V54, D56, L66, A92,K93, E97, H128, F156, A226, E227, E230, D237, K240, D259, K262, N267,Q268, 1271, L275, E277, L284, E294, E311, K317, A322, E333, D340, E354,E358, K359, A362, E382, or L398; (8) E97+L24, F49, V54, D56, L66, A92,K93, Q94, H128, F156, A226, E227, E230, D237, K240, D259, K262, N267,Q268, 1271, L275, E277, L284, E294, E311, K317, A322, E333, D340, E354,E358, K359, A362, E382, or L398; (9) H128+L24, F49, V54, D56, L66, A92,K93, Q94, E97, F156, A226, E227, E230, D237, K240, D259, K262, N267,Q268, 1271, L275, E277, L284, E294, E311, K317, A322, E333, D340, E354,E358, K359, A362, E382, or L398; (10) F156+L24, F49, V54, D56, L66, A92,K93, Q94, E97, H128, A226, E227, E230, D237, K240, D259, K262, N267,Q268, 1271, L275, E277, L284, E294, E311, K317, A322, E333, D340, E354,E358, K359, A362, E382, or L398; (11) E227+L24, F49, V54, D56, L66, A92,K93, Q94, E97, H128, F156, A226, E230, D237, K240, D259, K262, N267,Q268, 1271, L275, E277, L284, E294, E311, K317, A322, E333, D340, E354,E358, K359, A362, E382, or L398; (12) D237+L24, F49, V54, D56, L66, A92,K93, Q94, E97, H128, F156, A226, E230, E227, K240, D259, K262, N267,Q268, 1271, L275, E277, L284, E294, E311, K317, A322, E333, D340, E354,E358, K359, A362, E382, or L398; (13) K240+L24, F49, V54, D56, L66, A92,K93, Q94, E97, H128, F156, A226, E230, E227, D237, D259, K262, N267,Q268, 1271, L275, E277, L284, E294, E311, K317, A322, E333, D340, E354,E358, K359, A362, E382, or L398; (14) D259+L24, F49, V54, D56, L66, A92,K93, Q94; E97, H128, F156, A226, E230, E227, D237, K240, K262, N267,Q268, 1271, L275, E277, L284, E294, E311, K317, A322, E333, D340, E354,E358, K359, A362, E382, or L398; (15) K262+L24, F49, V54, D56, L66, A92,K93, Q94, E97, H128, F156, A226, E230, E227, D237, K240, D259, N267,Q268, 1271, L275, E277, L284, E294, E311, K317, A322, E333, D340, E354,E358, K359, A362, E382, or L398; (16) N267+L24, F49, V54, D56, L66, A92,K93, Q94, E97, H128, F156, A226, E230, E227, D237, K240, D259, K262,Q268, 1271, L275, E277, L284, E294, E311, K317, A322, E333, D340, E354,E358, K359, A362, E382, or L398; (17) 0268+L24, F49, V54, D56, L66, A92,K93, Q94, E97, H128, F156, A226, E227, E230, D237, K240, D259, K262,N267, 1271, L275, E277, L284, E294, E311, K317, A322, E333, D340, E354,E358, K359, A362, E382, or L398; (18) L275+L24, F49, V54, D56, L66, A92,K93, Q94, E97, H128, F156, A226, E227, E230, D237, K240, D259, K262,N267, Q268, 1271, E277, L284, E294, E311, K317, A322, E333, D340, E354,E358, K359, A362, E382, or L398; (19) E277+L24, F49, V54, D56, L66, A92,K93, Q94, E97, H128, F156, A226, E227, E230, D237, K240, D259, K262,N267, Q268, 1271, L275, L284, E294, E311, K317, A322, E333, D340, E354,E358, K359, A362, E382, or L398; (20) L284+L24, F49, V54, D56, L66, A92,K93, Q94, E97, H128, F156, A226, E227, E230, 0237, K240, D259, K262,N267, Q268, 1271, L275, E277, E294, E311, K317, A322, E333, D340, E354,E358, K359, A362, E382, or L398; (21) E311+L24, F49, V54, D56, L66, A92,K93, Q94, E97, H128, F156, A226, E227, E230, D237, K240, D259, K262,N267, Q268, 1271, L275, E277, L284, E294, K317, A322, E333, D340, E354,E358, K359, A362, E382, or L398; (22) K317+L24, F49, V54, D56, L66, A92,K93, Q94, E97, H128, F156, A226, E227, E230, D237, K240, D259, K262,N267, Q268, 1271, L275, E277, L284, E294, E311, A322, E333, D340, E354,E358, K359, A362, E382, or L398; (23) A322+L24, F49, V54, D56, L66, A92,K93, Q94, E97, H128, F156, A226, E227, E230, D237, K240, D259, K262,N267, Q268, 1271, L275, E277, L284, E294, E311, K317, E333, D340, E354,E358, K359, A362, E382, or L398; (24) E333+L24, F49, V54, D56, L66, A92,K93, Q94, E97, H128, F156, A226, E227, E230, D237, K240, D259, K262,N267, Q268, 1271, L275, E277, L284, E294, E311, K317, A322, D340, E354,E358, K359, A362, E382, or L398; (25) D340+L24, F49, V54, D56, L66, A92,K93, Q94, E97, H128, F156, E227, D237, E230, K240, D259, K262, N267,Q268, I271, L275, E277, L284, E294, E311, K317, A322, E333, E354, E358,K359, A362, E382, or L398; (26) E354+L24, F49, V54, D56, L66, A92, K93,Q94, E97, H128, F156, A226, E227, E230, D237, K240, D259, K262, N267,Q268, 1271, L275, E277, L284, E294, E311, K317, A322, E333, D340, E358,K35,9, A362, E382, or L398; (27) K359+L24, F49, V54, D56, L66, A92, K93,Q94, E97, H128, F156, A226, E227, E230, D237, K240, D259, K262, N267,Q268, 1271, L275, E277, L284, E294, E311, K317, A322, E333, D340, E354,E358, A362, E382, or L398; (28) A362+L24, F49, V54, D56, L66, A92, K93,Q94, E97, H128, F156, A226, E227, E230, D237, K240, D259, K262, N267,Q268, 1271, L275, E277, L284, E294, E311, K317, A322, E333, D340, E354,E358, K359, E382, or L398; (29) E382+L24, F49, V54, D56, L66, A92, K93,Q94, E97, H128, F156, A226, E227, E230, D237, K240, D259, K262, N267,Q268, 1271, L275, E277, L284, E294, E311, K317, A322, E333, D340, E354,E358, K359, A362, or L398; (30) L398+L24, F49, V54, D56, L66, A92, K93,Q94, E97, H128, F156, A226, E227, E230, D237, K240, D259, K262, N267,Q268, 1271, L275, E277, L284, E294, E311, K317, A322, E333, D340, E354,E358, K359, A362, or E382; (31) K93+L24, F49, V54, D56, L66, A92, Q94,E97, H128, F156, A226, E227, E230, D237, K240, D259, K262, N267, Q268,1271, L275, E277, L284, E294, E311, K317, A322, E333, D340, E354, E358,K359, A362, E382 or L398; (32) E294+L24, F49, V54, D56, L66, A92, K93,Q94, E97, H128, F156, A226, E227, E230, D237, K240, D259, K262, N267,Q268, 1271, L275, E277, L284, E311, K317, A322, E333, D340, E354, E358,K359, A362, E382 or L398; (33) A226+L24, F49, V54, D56, L66, A92, K93,Q94, E97, H128, F156, E227, E230, D237, K240, D259, K262, N267, Q268,1271, L275, E277, L284, E294, E311, K317, A322, E333, D340, E354, E358,K359, A362, E382 or L398; (34) E230+L24, F49, V54, D56, L66, A92, K93,Q94, E97, H128, F156, A226, E227, D237, K240, D259, K262, N267, Q268,1271, L275, E277, L284, E294, E311, K317, A322, E333, D340, E354, E358,K359, A362, E382 or L398; (35) 1271+L24, F49, V54, D56, L66, A92, K93,Q94, E97, H128, F156, A226, E227, E230, D237, K240, D259, K262, N267,Q268, L275, E277, L284, E294, E311, K317, A322, E333, D340, E354, E358,K359, A362, E382 or L398; and (36) E358+L24, F49, V54, D56, L66, A92,K93, Q94, E97, H128, F156, A226, E227, E230, D237, K240, D259, K262,N267, Q268, 1271, L275, E277, L284, E294, E311, K317, A322, E333, D340,E354, K359, A362, E382 or L398.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine provided at a position equivalent to K93 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to E294 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to A226 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to E230 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to 1271 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to E358 in SEQ ID NO. 2.

A particularly preferred polypeptide may have at least 90% identity toSEQ ID NO. 2, a cysteine at a position equivalent to K93 in SEQ ID NO. 2and a cysteine at a position equivalent to E294 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to L24 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to F49 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to V54 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to D56 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to L66 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to A92 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to Q94 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to E97 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to H128 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to F156 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to E227 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to D237 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to K240 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to D259 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to K262 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to N267 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to Q268 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to L275 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to E277 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to L284 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to E311 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to K317 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to A322 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to E333 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to D340 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to E354 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to K359 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to A362 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to E382 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2and a cysteine at a position equivalent to L398 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine provided at a position equivalent to K93 and a cysteine at aposition equivalent to C34 in SEQ ID NO. 2.

A particularly preferred polypeptide may have at least 90% identity toSEQ ID NO. 2 a cysteine at a position equivalent to E294 in SEQ ID NO. 2and a cysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to A226 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to E230 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to 1271 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to E358 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to K93 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2, a cysteine ata position equivalent to E294 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to L24 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to F49 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to V54 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to D56 in SEQ ID NO. 2 and acysteine at a position equivalent to 034 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to L66 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to A92 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to Q94 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to E97 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to H128 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to F156 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to E227 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to D237 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to K240 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to D259 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to K262 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to N267 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to Q268 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to L275 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to E277 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to L284 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO: 2,a cysteine at a position equivalent to E311 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to K317 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to A322 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to E333 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to D340 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to E354 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to K359 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to A362 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to E382 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to L398 in SEQ ID NO. 2 and acysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine provided at a position equivalent to K93 and no cysteine at aposition equivalent to 034 in SEQ ID NO. 2.

A particularly preferred polypeptide may have at least 90% identity toSEQ ID NO. 2 a cysteine at a position equivalent to E294 in SEQ ID NO. 2and no cysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to A226 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to E230 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to 1271 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to E358 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to K93 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2, a cysteine ata position equivalent to E294 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent, to L24 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to F49 SEQ ID NO. 2 and no cysteineat a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to V54 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to D56 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to L66 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to A92 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to Q94 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to E97 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to H128 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to F156 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to E227 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to D237 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to K240 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to D259 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to K262 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to N267 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to Q268 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to L275 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to E277 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to L284 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to E311 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to K317 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to A322 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to E333 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to D340 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to E354 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to K359 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to A362 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to E382 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

A preferred polypeptide may have at least 90% identity to SEQ ID NO. 2,a cysteine at a position equivalent to L398 in SEQ ID NO. 2 and nocysteine at a position equivalent to C34 in SEQ ID NO. 2.

The ‘no cysteine’ at a position equivalent to C34 in SEQ ID NO. 2 may beprovided, for example, by a substitution of C34 to an amino acid, suchas a natural amino acid, for example, A, D, E, F, G, H, I, K, L, M, N,P, Q, R, S, T, V, W, or Y. Such a substitution may be described as C34X.The substitution C34A is preferred. The ‘no cysteine’ at a positionequivalent to C34 in SEQ ID NO. 2 may be provided, for example, bydeletion of the cysteine at this position.

A thio-albumin may or may not include a polypeptide where one or more(e.g. several) naturally occurring free-thiol group(s), such ascysteine-34 in HSA (SEQ ID NO. 2), is modified to an amino acid which isnot cysteine. For example, cysteine may or may not be replaced by anamino acid which has a relatively high conservation score (e.g. 1, 2 or3 as calculated according to FIG. 3) such as alanine or serine. Athio-albumin may or may not include a polypeptide where one or more(e.g. several) naturally occurring free-thiol group(s), such ascysteine-34 in HSA (SEQ ID NO. 2) are present. Thus, theconjugation-competent polypeptide of any of the above embodiments maycomprise, at a position equivalent to position 34 of SEQ ID NO. 2, aconjugation-competent cysteine. Alternatively, there may not be aconjugation-competent cysteine at a position equivalent to position 34of SEQ ID NO. 2.

For a polypeptide comprising two or more (several) conjugation competentcysteine residues, when the polypeptide is folded, the conjugationcompetent cysteine residues may or may not be relatively evenlydistributed over the surface of the folded protein. The term ‘folded’includes folding of a polypeptide/protein into its naturalconfiguration, for example the most thermodynamically stable foldedconfiguration. An advantage of relatively even distribution is that itallows conjugation of two or more (several) moieties to the thio-albuminwith minimal steric hindrance or without steric hindrance between two ormore (several) of the conjugated moieties. This has the advantage ofminimising, and optionally eliminating, potential loss of activity dueto issues such as steric hindrance between adjacent moieties(conjugation partners) which may be conjugated to the thio-albumin. Suchmoieties, for example bioactive molecules, may be relatively bulky.

Preferably the two or more (several) conjugation-competent cysteines aredistributed over the surface of the thio-albumin molecule such that theyare spaced as far from each other as possible, for example geometricallypossible. Preferably the distance between two or more (several)conjugation-competent cysteines is at least 5, 10, 20, 30, 40, 50, 60,70, or 80 Angstroms. Preferably each conjugation competent cysteine isat least 5, 10, 20, 30, 40, 50, 60, 70, or 80 Angstroms distant from oneor several or all other conjugation-competent cysteines in the molecule.The distance between two conjugation-competent cysteines is preferably adistance which is at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 95%and most preferably 100% of the length of the longest axis of the foldedalbumin molecule, for example as shown in a model of an albumin. Forexample, the longest axis of SEQ ID NO. 2 as shown in protein structure1A06 is approximately 85 Angstroms. Therefore, it is preferred that thetwo or more (several) of the cysteine residues are at least 65, 70, 75or most preferably 80 Angstroms apart. Most preferably eachconjugation-competent cysteine residue is at a distance of at least 80,90, or 95% and most preferably 100% of the length of the longest axis ofthe folded albumin molecule.

Preferably the side chains of conjugation-competent cysteines aredirected away from each other and/or directed so that a moietyconjugated to the cysteine will be directed away from the centre of thealbumin structure. This provides the advantage of preventinginteractions between the conjugated moieties and/or the albumin moietyitself.

With reference to an amino acid sequence, candidate amino acid residuesmay be visually inspected using software such as Yasara (Krieger andVriend, 2014, Bioinformatics 30(20) 2981-2982; and described athttp://www.yasara.org/).

Suitably, the polypeptide comprises substitution of an amino acid, otherthan cysteine, with a cysteine at one or both positions corresponding toa position equivalent to residues K93 or E294 of SEQ ID NO. 2. The Cα-Cαdistance between C34 and K93 is 20.3 Å, between C34 and E294 is 39.9 Åand K93 and E294 45.9 Å in WT HSA (SEQ ID NO. 2).

Maleimide conjugation is a convenient means of conjugating a conjugationpartner to an albumin. Capability to form a conjugate withmaleimide-polyethylenglycol2-biotin is believed to be indicative ofcapability to form a conjugate with other conjugation partnerscontaining a maleimide group. Conversely, if a conjugation-competentpolypeptide has a low efficiency of conjugation withmaleimide-polyethylenglycol2-biotin, or fails to conjugate, this is notindicative that it is poorly capable or not capable of conjugating witha different chemical group. Maleimide conjugates form a thio-ether bond,which may or may not be capable of stabilisation upon controlledhydrolysis. Stable conjugate formation may be preferred, such that theconjugate does not release a reactive maleimide conjugation partnerduring storage or use. The latter could potentially form unwantedconjugates with thiol-reactive species encountered in vivo.

As shown in the Examples, native HSA having a single free thiol atcysteine 34 forms approximately 50% stable conjugate upon maleimideconjugation and controlled hydrolysis. In contrast, polypeptides of theinvention may form stable conjugates at higher efficiencies. Inparticular, albumins comprising a free thiol group at a positionselected from those equivalent to K93, E294, and E358 of SEQ ID NO. 2form stable maleimide conjugates at high efficiency, as shown in theExamples. Albumins comprising two or more (several) such thiols also mayalso form stable maleimide conjugates.

A conjugation-competent polypeptide of the invention may or may not becapable of forming a conjugate with maleimide-polyethylenglycol2-biotin(maleimide-PEG2-biotin) at a conjugation efficiency of at least 90%,preferably at least 95%, which conjugate may or may not be at least 90%,preferably at least 95% stable upon controlled hydrolysis. FIG. 4illustrates the conjugation of maleimide-PEG2-biotin to a free thiol ofa protein, and reactions which may occur to the formed conjugate.

A conjugation efficiency of a particular percentage indicates that thespecified percentage of free thiol groups in the albumin form an adductwith the maleimide moiety, under suitable reaction conditions. Themaleimide group reacts with thiols in the pH range 6.5-7.5 to form athio-ether linkage with very little cross-reactivity with amines at thispH. The use of 20 mM sodium phosphate, 150 mM sodium chloride, pH 7.2works well for this reaction. The concentration of protein shouldideally be in the range of 1-10 mg/mL. Lower concentrations of proteinmay result in the need to increase the molar excess of reagent to obtainan acceptable level of modification (Hermanson, Greg T. (2008),Bioconjugate Techniques. Second Edition, Academic Press, San Diego,Calif.). The formation of the adduct results in an increase in masswhich can be measured, for example by mass spectrometry, as in theExamples. Conveniently, the percentage conjugation efficiency is inrelation to all free thiols of the albumin. Where the albumin has morethan one such free thiol, a different percentage conjugation efficiencymay pertain to each free thiol, and may be expressed in relation eitherto each individual free thiol, or collectively to all free thiols. Thus,if an albumin has two free thiols, one having 50% conjugation efficiencyand the other having 100% conjugation efficiency, the overallconjugation efficiency for the albumin is the average of the twoconjugation efficiencies, in this case 75%.

A stability of a particular percentage upon controlled hydrolysisindicates that the specified percentage of thiol-maleimide adductundergoes ring-opening stabilisation, that is, the succinimide ringmoiety is hydrolysed to a succinic acid moiety, and the thio-ether bondof the conjugate is maintained, as illustrated in FIG. 4. The percentagestability may be expressed in relation either to each individual freethiol or the albumin, or collectively to all free thiols. Controlledhydrolysis may be performed at alkaline pH and above ambienttemperature. Suitably, adducts are incubated at pH 9.0 and 37° C. for atleast 18 hours, preferably 24 hours in a buffered salts solution, suchas phosphate buffered saline. The hydrolysis of the succinimide moietyto a succinic acid moiety by the addition of H₂O has the effect ofincreasing the mass of the conjugate, which can be measured, for exampleby mass spectrometry, as in the Examples. Where conjugation efficiencyis incomplete, this must be taken into account in determining thepercentage stability. For example, if 50% of an albumin having one freethiol forms a conjugate, and 40% of the albumin is conjugated followingcontrolled hydrolysis, this represents a stability of 80%. In thesecircumstances, 50% of the albumin is initially unconjugated, andtherefore has a mass indicative of free albumin. The mass does notchange upon controlled hydrolysis. Of the 50% of the albumin that isinitially conjugated, a portion, 40% of the total albumin, has anincreased mass of 18 Da due to the addition of H₂O. The other portion,10% of the total albumin, does not undergo hydrolysis and therefore itsmass does not change. Although this albumin is still conjugated, it maybe unstable during storage or use, because it can undergo de-conjugationvia the retro-Michael pathway, as illustrated in FIG. 4. In contrast,the stably hydrolysed conjugate can be expected to remain stable duringstorage or use (Fontaine, S. et al, Bioconjugate Chem. 2015, 26,145-152).

Suitably conjugation efficiencies for a polypeptide of the invention maybe at least 50%, at least 60%, at least 70%, at least 80%, at least 90%,at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, orsubstantially 100%. Suitably conjugation efficiencies for an individualfree thiol of a polypeptide of the invention may be at least 50%, atleast 60%, at least 70%, at least 80%, at least 90%, at least 95% atleast 96%, at least 97%, at least 98%, at least 99%, or substantially100%. Suitable stabilities of a polypeptide conjugate upon controlledhydrolysis may be at least 50%, at least 60%, at least 70%, at least80%, at least 90%, at least 95%, at least 96%, at least 97%, at least98%, at least 99%, or substantially 100%.

As shown in the Examples, native HSA having a single free thiol atcysteine 34 forms greater than about 90% conjugate. Albumins comprisinga free thiol group at a position selected from those equivalent to K93,E294, E358, L24, V54, H128, E227, K240, K262, Q268, E277, K317, A322,K359, and A362 of SEQ ID NO. 2 form maleimide conjugates greater thanabout 90% efficiency, those with a free thiol group at a positionselected from those equivalent to L24, V54, H128, E227, K240, K262,K359, and A362 form maleimide conjugates greater than about 95%efficiency.

Suitable stabilities of a particular thiol-ether conjugate bond of apolypeptide conjugate upon controlled hydrolysis may be at least 50%, atleast 60%, at least 70%, at least 80%, at least 90%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99%, or substantially100%.

The polypeptide may or may not further comprise a further linker towhich a conjugation partner, such as a bioactive compound,radiopharmaceutical or imaging agent, may be linked. For example alinker may comprise a primary amine such as a lysine.

It is preferred that the conjugation-competent polypeptide has anacceptable immunogenicity, particularly in humans. More preferably theconjugation-competent polypeptide has an immunogenicity that iscomparable to or lower than that of a parent albumin such as WT HSA (SEQID NO. 2). Therefore, preferably the alteration(s) to provide aconjugation competent cysteine residue(s) do not adversely affect theimmunogenicity of the polypeptide relative to the parent albumin such asWT HSA.

Preferably, the alteration(s) made to provide the conjugation competentcysteine residue(s) do not adversely affect the immunogenicity of thepolypeptide in human, e.g. relative to the immunogenicity of wild-typeHSA (SEQ ID NO. 2).

The immunogenicity of the polypeptide may be determined or predicted byscreening for T-cell epitopes and/or for B-cell epitopes. Screening maybe in silico, in vitro or ex vivo. For example, the immunogenicity ofthe polypeptide may be determined or predicted by an ex vivo T cellactivation assay. The T cell activation assay may comprise measuring Tcell responses using a proliferation assay, e.g. [3H]-thymidine uptake.Preferably, the polypeptide has less than 10% reactivity in the T cellproliferation assay, preferably less than 8, 6, 4, or 2% reactivity,most preferably 0%. ‘Reactivity’ means that a positive response wasobserved. Therefore 10% reactivity means that a positive response wasobserved in 10% of the donor samples.

The T cell activation assay may comprise measuring T cell responsesusing a cytokine secretion assay, e.g. IL-2 ELISpot. Preferably thepolypeptide has less than 10% reactivity in the cytokine secretionassay, preferably less than 8, 6, 4, or 2% reactivity, most preferably0%. ‘Reactivity’ means that a positive response was observed. Therefore10% reactivity means that a positive response was observed in 10% of thedonor samples.

More preferred, the conjugation-competent polypeptide has less than 10%reactivity in a T cell proliferation assay and in a cytokine secretionassay, e.g. an EpiScreen™ assay (Abzena, Cambridge, UK).

The T cell assays may comprise CD4+ T cells.

The T cell assays may use peripheral blood mononuclear cells from acohort of 50 healthy donors representing the European and North Americanpopulation (based on HLA allotypes).

Preferably, the polypeptide does not stimulate an adverse antibodyresponse in human, such as a specific antibody response.

For a conjugate comprising the conjugation-competent polypeptide,preferably the conjugate has an immunogenicity that is comparable to orlower than that of a corresponding conjugate comprising a parent albuminsuch as WT HSA (SEQ ID NO. 2) instead of the conjugation-competentpolypeptide. Consequently, the properties mentioned for theconjugation-competent polypeptide also apply to a conjugate comprisingthe conjugation-competent polypeptide, however the ‘control’ may be aparent albumin such as WT HSA or a corresponding conjugate comprising aparent albumin such as WT HSA.

Conjugation-Competent Polypeptides II

A second aspect of the invention provides a conjugation-competentpolypeptide comprising an amino acid sequence according to the firstaspect of the invention, and at least one (e.g. several) furthermodification compared to SEQ ID NO. 2, such as a further modificationwhich causes the polypeptide to have at least one (e.g. several) furtherconjugation-competent cysteine, or alters the binding affinity of thepolypeptide for FcRn, or alters the plasma half-life of the polypeptide.

The second aspect of the invention allows for the favouredconjugation-competent cysteines as defined in relation to the firstaspect of the invention to be combined with other modifications in analbumin background, and provides the option to further tailor thealbumin for specific applications.

Further Conjugation-Competent Cysteines

The at least one (e.g. several) further modification may or may notcause the polypeptide to have at least one (e.g. several) furtherconjugation-competent cysteine. The polypeptide may or may not comprisea total of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,19 or 20 conjugation competent cysteine residues. The polypeptide may ormay not comprise at least one (e.g. several) furtherconjugation-competent cysteine as defined in relation to the firstaspect of the invention.

The polypeptide may or may not comprise at least one (e.g. several)further conjugation-competent cysteine, other than at a positioncorresponding to least one position equivalent to a position selectedfrom K93, E294, A226, E230, 1271, E358, L24, F49, V54, D56, L66, A92,Q94, E97, H128, F156, E227, D237, K240, D259, K262, N267, Q268, L275,E277, L284, E311, K317, A322, E333, D340, E354, K359, A362, E382, andL398, particularly from K93, E294, A226, E230, and 1271, of SEQ ID NO.2. Suitable conjugation-competent cysteines are disclosed in WO2010/092135 (incorporated by reference, particularly FIGS. 5 and 6).Suitably, at least one (e.g. several) position equivalent to a positionselected from D1, A2, H3, S5, A55, S58, C75, T76, T79, E82, T83, E86,C91, D121, V122, C124, T125, D129, C169, C177, A229, T236, E266, D269,S270, 5273, S304, K313, D314, C316, N318, A320, C361, A364, C369, A371,N386, Q390, Q397, S435, T478, T496, A504, E505, T506, T508, D549, C558,D562, C567, A581, L585 and A578 of SEQ ID NO. 2 may comprise aconjugation-competent cysteine. Suitably, the polypeptide may compriseone or more (e.g. several) of: (a) substitution of an amino acid, otherthan cysteine, with a cysteine at a position corresponding to a positionequivalent to any of residues D1, A2, H3, S5, A55, S58, C75, T76, T79,E82, T83, E86, C91, D121, V122, C124, T125, D129, C169, C177, A229,T236, E266, D269, 8270, S273, S304, K313, D314, C316, N318, A320, C361,A364, 0369, A371, N386, Q390, Q397, S435, T478, T496, A504, E505, T506,T508, D549, C558, D562, C567, A581, L585 and A578 of SEQ ID NO. 2; (b)insertion of a cysteine at a position adjacent the N- or C-side of anamino acid corresponding to a position equivalent to any of residues D1,A2, H3, S5, A55, S58, C75, T76, T79, E82, T83, E86, C91, D121, V122,C124, T125, D129, C169, C177, A229, T236, E266, D269, S270, S273, S304,K313, D314, 0316, N318, A320, C361, A364, C369, A371, N386, Q390, Q397,S435, T478, T496, A504, E505, T506, T508, D549, C558, D562, C567, A581,L585 and A578 of SEQ ID NO. 2 so as to generate a conjugation competentcysteine at any of C369, C361, C91, C177, C567, C316, C75, C169, C124and C558; and (c) addition of a cysteine to the N-side of the N-terminalresidue of an albumin sequence or to the C-side of the C-terminalresidue of an albumin sequence. Exemplary combinations includeconjugation-competent cysteines located at: (a) A2+L585, (b)A2+A364+D562+L585C, (c) A2 and adjacent the C-side of the C-terminus ofthe albumin (d) T79+A364; (e) A364+D1; (f) T79+D562+A364; (g)D562+A364+D1; (h) T79+D562+A364+A504; (i) T79+D562+A364+L585; (j)T79+D562+A364+D1; (k) T79+D562+A364+L585+D1; (I) E86+D562+A364+A504+A2;(m) S270+A581; (n) 5270+D129; (o) S270+A581+E82; (p) S270+A581+D129; (q)S270+A581+E82+D129; (r) 5270+A581+E82+D129+Q397; (s) C369+C177; (t)A364+A581; (u) T79+A364+A581; (v) A364+A581+D129; (w) A364+0177; (x)D562+C369; (y) D129+C369; (z) A581+C369; or (aa) D562+D129+C369.

Further suitable cysteine residues may be introduced as disclosed in WO2009/126920 or WO 2010/059315 (incorporated herein by reference).Specifically, one or more (e.g. several) surface-exposed amino acidresidues may be substituted for a cysteine residue, corresponding to oneor more (e.g. several) positions corresponding S58, T76, T79, T83, T125,T236, S270, S273, 5304, S435, T478, T496, T506 and T508 of SEQ ID NO. 2.

As noted in relation to the first aspect of the invention, increasingthe number of conjugation-competent cysteine residues in an albuminvariant may reduce its tendency to exist as a monomer in solution. It ispreferred that the conjugation-competent polypeptide of the secondaspect of the invention has a tendency to exist as a monomer in solutionwhich is at least 70% of the tendency of the polypeptide of SEQ ID NO. 2to exist as a monomer in solution, and optionally at least 75%, at least80%, at least 90%, at least 91%, at least 92%, at least 93%, at least94%, at least 95%, at least 96%, at least 97%, at least 98%, at least99%, or at least 100%. This preference applies whether or not thepolypeptide comprises a further conjugation-competent cysteine asdefined in relation to the second aspect. Nevertheless, usefulconjugation-competent polypeptides may still be provided which have alower tendency to exist as a monomer in solution. Because theconjugation-competent cysteine residues defined in relation to the firstaspect of the invention themselves contribute relatively minimally tonon-monomer formation, combining one or more (e.g. several) of them withone or more (e.g. several) other conjugation-competent cysteine residuescan be expected to result in a variant having increased monomerpercentage compared to a variant having the same number ofconjugation-competent cysteine residues selected from the prior art.

Albumin Variants with Altered Binding to FcRn and/or Altered PlasmaHalf-Life

The at least one (e.g. several) further modification may or may notalter the binding affinity of the albumin variant to FcRn and/or alterthe plasma half-life. Preferably the albumin variant may have at least70, 75, 80, 85, 90, 95, 96, 97, 98, 99, 99.2, 99.4, 99.6, 99.8% sequenceidentity to SEQ ID NO. 2. For example, in addition to the introduced Cysresidue or Cys residues, the albumin variant may have at least 1, 2, 3,4, 5, 6, 7, 8, 9, 10 (e.g. several) other mutations relative to SEQ IDNO. 2. Alternatively, in addition to the introduced Cys residue or Cysresidues, the albumin variant may have zero other mutations relative toSEQ ID NO. 2.

The thio-albumin or conjugate may have a plasma half-life that is eitherlonger or shorter, preferably longer, than that of the parent albumin orconjugate thereof, or a binding to FcRn that is stronger or weaker,preferably stronger. Preferably the thio-albumin or conjugate has aplasma half-life that is longer than that of HSA or the correspondingconjugate thereof.

Alternatively, this may be expressed as the thio-albumin or conjugatehaving a KD to FcRn (e.g. shFcRn) that is lower than the correspondingKD for HSA or conjugate thereof to. Preferably, the KD for thethio-albumin or conjugate is less than 0.9X KD for HSA to FcRn, morepreferred less than 0.5X KD for HSA to FcRn, more preferred less than0.1X KD for HSA to FcRn, even more preferred less than 0.05X KD for HSAto FcRn, even more preferred less than 0.02X KD for HSA to FcRn, evenmore preferred less than 0.01X KD for HSA to FcRn and most preferredless than 0.001X KD for HSA to FcRn (where X means ‘multiplied by’).

For a conjugate comprising a thio-albumin, preferrably the KD for theconjugate is less than 0.9X KD for the corresponding conjugatecomprising HSA to FcRn, more preferred less than 0.5X KD for thecorresponding conjugate to FcRn, more preferred less than 0.1X KD forthe corresponding conjugate to FcRn, even more preferred less than 0.05XKD for the corresponding conjugate to FcRn, even more preferred lessthan 0.02X KD for the corresponding conjugate to FcRn, even morepreferred less than 0.01X KD for the corresponding conjugate to FcRn andmost preferred less than 0.001X KD for the corresponding conjugate toFcRn (where X means ‘multiplied by’). ‘Corresponding conjugate’ means aconjugate comprising HSA (e.g. SEQ ID NO. 2) instead of the thio-albuminalbumin variant).

Alternatively, the thio-albumin or conjugate may have a plasma half-lifethat is shorter than that of HSA or the conjugate thereof.

This may be expressed as the thio-albumin or conjugate having a KD toFcRn that is higher than the corresponding KD for HSA or conjugatethereof to FcRn. Preferably, the KD for the thio-albumin or conjugate ismore than 2X KD for HSA to FcRn, more preferred more than 5X KD for HSAto FcRn, more preferred more than 10X KD for HSA to FcRn, even morepreferred more than 25X KD for HSA to FcRn, most preferred more than 50XKD for HSA to FcRn. The thio-albumin or conjugate may be a null binderto FcRn.

For a conjugate comprising a thio-albumin, preferrably the KD for theconjugate, Preferably, the KD for the corresponding conjugate comprisingHSA is more than 2X KD for the corresponding conjugate to FcRn, morepreferred more than 5X KD for the corresponding conjugate to FcRn, morepreferred more than 10X KD for the corresponding conjugate to FcRn, evenmore preferred more than 25X KD for the corresponding conjugate to FcRn,most preferred more than 50X KD for the corresponding conjugate to FcRn.Corresponding conjugate′ means a conjugate comprising HSA (e.g. SEQ IDNO. 2) instead of the thio-albumin (i.e. albumin variant).

The half-life of the thio-albumin or conjugate or product made fromassociate, nanoparticle, microparticle or liposome may be tailored inorder to achieve a binding affinity or half-life which meets the needsof the user.

When determining and/or comparing KD, one or more (e.g. several) (andpreferably all) of the following parameters may be used:

Instrument: Biacore 3000 instrument (GE Healthcare)

Flow cell: CM5 sensor chip

FcRn: human FcRn, preferably soluble human FcRn, optionally coupled to atag such as

Glutathione S Transferase (GST) or Histidine (His), most preferably Hissuch as 6 histidine residues at the C-terminus of thebeta-2-microglobulin.

Quantity of FcRn: 1200-2500 RU

Coupling chemistry: amine coupling chemistry (e.g. as described in theprotocol provided by the manufacturer of the instrument).

Coupling method: The coupling may be performed by injecting 20 μg/mL ofthe protein in 10 mM sodium acetate pH 5.0 (GE Healthcare). Phosphatebuffer (67 mM phosphate buffer, 0.15 M NaCl, 0.005% Tween 20) at pH 5.5may be used as running buffer and dilution buffer. Regeneration of thesurfaces may be done using injections of HBS-EP buffer (0.01 M HEPES,0.15 M NaCl, 3 mM EDTA, 0.005% surfactant P20) at pH 7.4 (Biacore AB).

Quantity of injection of test molecule (e.g. HSA or variant) 20-0.032 μM

Flow rate of injection: constant, e.g. 30 μL/mL

Temperature of injection: 25° C.

Data evaluation software: BIAevaluation 4.1 software (BIAcore AB).

Domain III of albumin is primarily responsible for binding FcRn. Theconjugation-competent polypeptide may or may not comprise or consist ofalbumin domain III or a variant thereof and at least one (e.g. several)additional albumin domain or fragment thereof, such as a second albumindomain III or a variant thereof, as disclosed in WO 2011/124718(incorporated herein by reference). Suitably, the polypeptide comprisesor consists of at least one (e.g. several) albumin domain III or variantor fragment thereof, wherein at least one (e.g. several) albumin domainIII comprises one or more (e.g. several) substitutions in positionscorresponding to the positions in SEQ ID NO. 2 selected among: 573, 500,550, 417, 440, 464, 490, 492, 493, 494, 495, 496, 499, 501, 503, 504,505, 506, 510, 535, 536, 537, 538, 540, 541, 542, 574, 575, 577, 578,579, 580, 581, 582 and 584, as disclosed in WO 2011/051489 (incorporatedherein by reference). Suitable substitutions include one or more (e.g.several) substitutions in positions corresponding to the positions inSEQ ID NO. 2 selected among: K573Y, W, P, H, F, V, I, T, N, S, G, M, C,A, E, Q, R, L, D, K500E, G, D, A, 5, C, P, H, F, N, W, T, M, Y, V, Q, L,I, R, Q417A, H440A, H464Q, E492G, D494N,Q,A, E495Q,A, T496A,D494E+Q417H, D494N+T496A, E492G+V493P, P499A, E501A,Q, N503H,K, H510Q,H535Q, K536A, P537A, K538A, K541G,D, D550E,N, E492G+K573P,A, orE492G/N503H/K573P.

In an alternative embodiment, the polypeptide may comprise alterationsat two or more (several) positions selected from positions correspondingto positions (a) 492 and 580; (b) 492 and 574; (c) 492 and 550; (d) 550and 573; (e) 550 and 574; (f) 550 and 580 in SEQ ID NO. 2, as disclosedin WO 2014/072481 (incorporated herein by reference).

In an alternative embodiment, the conjugation-competent polypeptide maycomprise: (i) an N-terminal region comprising a first albumin which is ahuman albumin variant, in which the N-terminal of the first albumincomprises all amino acids of the human albumin variant except theC-terminal 2 to 30 amino acids; and (ii) a C-terminal region of a secondalbumin, which is selected from macaque albumin, mouse albumin, rabbitalbumin, sheep albumin, human albumin, goat albumin, chimpanzee albumin,hamster albumin, guinea pig albumin, rat albumin, cow albumin, horsealbumin, donkey albumin, dog albumin, chicken albumin, or pig albumin,or a variant thereof, in which the C-terminal of the second albumin oralbumin variant comprises the C-terminal 2 to 30 amino acids of thesecond albumin or albumin variant; wherein the polypeptide has (i) analtered plasma half-life compared with the human albumin variant and/or(ii) an altered binding affinity to FcRn compared with the human albuminvariant, as disclosed in WO 2012/059486 (incorporated herein byreference).

In an alternative embodiment, the polypeptide may comprise one or more(e.g. several) alterations in Domain I of the mature human albuminpolypeptide sequence of SEQ ID NO. 2; and one or more (e.g. several)alterations in Domain III of the mature human albumin polypeptidesequence of SEQ ID NO. 2, wherein the one or more (e.g. several)alterations cause the polypeptide to have an altered binding affinity toFcRn, as disclosed in WO 2013/135896 (incorporated herein by reference).Suitably, the alteration(s) in Domain I are selected from positionscorresponding to any of positions 78 to 120 of SEQ ID NO. 2, such as anyof positions 78 to 88 and/or from any of 105 to 120; and thealteration(s) in Domain III are selected from positions corresponding toany of positions 425, 505, 510, 512, 524, 527, 531, 534, 569, 573, 575of SEQ ID NO. 2. Suitably, the alteration at the position correspondingto positions 78 to 120 or 425, 505, 510, 512, 524, 527, 531, 534, 569,573, and/or 575 of SEQ ID NO. 2 is a substitution; and the alteration isoptionally a substitution selected from (i) 83N, K or S; (ii) 111D, G,H, R, Q or E; or (iii) 573P, Y, W, H, F, T, I or V.

In an alternative embodiment, the polypeptide may comprise one or more(e.g. several) alterations in Domain II of the mature human albuminpolypeptide sequence of SEQ ID NO. 2 selected from the group consistingof positions corresponding to positions 349, 342, 381, 345, 384, 198,206, 340, 341, 343, 344, 352, 382, 348, and/or 383 in SEQ ID NO. 2;wherein the one or more (e.g. several) alterations causes theconjugation-competent polypeptides to have (i) an altered plasmahalf-life and/or (ii) an altered binding affinity to FcRn, as disclosedin WO 2015/036579 (incorporated herein by reference). Suitably, thealteration at the position corresponding to position 349, 342, 381, 345,384, 198, 206, 340, 341, 343, 344, 352, 382, 348, and/or 383 is asubstitution; and the alteration is optionally a substitution selectedfrom (i) 349F, W, Y, H, P, K or Q, preferably F; (ii) 342Y, W, F, H, T,N, Q, A, C, I, L, P, V, preferably Y; (iii) 381G or A, preferably G; or(iv) 345E, H, I or Q.

In an alternative embodiment, the polypeptide may comprise a variantDomain III of an albumin, or fragment thereof, comprising a mutation,such as a substitution, corresponding to one or more (e.g. several)positions corresponding to V418, T420, V424, E505 and V547 of SEQ ID NO.2. These mutations are disclosed in WO 2013/075066 (incorporated hereinby reference). Substitutions may be at one, two or more (several, e.g.at two, three, four, or five) of the positions corresponding to V418,T420, V424, E505 and V547; for example, there may be one or more (e.g.several) substitutions selected from V418M, T420A, V4241, E505(R/K/G)and V547A. In a particular embodiment, the albumin comprises thesubstitutions V418M, T420A and E505R; or V418M, T420A, E505G and V547A.The albumin may comprise one or more (e.g. several) additionalsubstitutions at positions selected from N429, M446, A449, T467, andA552; such as selected from N429D, M446V, A449V, T467M, and A552T.

In an alternative embodiment, the variant may comprise a variant DomainIII of an albumin, or fragment thereof, comprising one to eighteen aminoacid substitutions to increase one or both of affinity for FcRn andserum half-life of the polypeptide, as disclosed in WO 2011/103076(incorporated herein by reference). Substitutions may be at any one ormore (e.g. several) of positions corresponding to positions 381, 383,391, 401, 402, 407, 411, 413, 414, 415, 416, 424, 426, 434, 442, 445,447, 450, 454, 455, 456, 457, 459, 463, 495, 506, 508, 509, 511, 512,515, 516, 517, 519, 521, 523, 524, 525, 526, 527, 531, 535, 538, 539,541, 557, 561, 566 or 569 of SEQ ID NO. 2. Suitable substitutions may beselected from V381N, V381Q, E383A, E383G, E3831, E383L, E383V, N391A,N391G, N391I, N391L, N391V, Y401D, Y401E, K402A, K402G, K4021, K402L,K402V, L407F, L407N, L407Q, L407W, L407Y, Y411Q, Y411N, K413C, K413S,K413T, K414S, K414T, V415C, V415S, V415T, Q416H, Q416P, V424A, V424G,V424I, V424L, V424N, V424Q, V426D, V426E, V426H, V426P, G434C, G4345,G434T, E442K, E442R, R445F, R445W, R445Y, P447S, P447T, E450D, E450E,S454C, S454M, 5454T, V455N, V455Q, V456N, V456Q, L457F, L457W, L457Y,Q459K, Q459R, L463N, L463Q, E495D, 1506F, T506W, 1506Y, T508K, T508R,T508S, F509C, F5091, F509L, F509M, F509V, F509W, F509Y, A511F, A511W,A511Y, D512F, D512W, D512Y, T515C, T515H, T515N, T515P, T515Q, T515S,L516F, L516S, L516T, L516W, L516Y, S5170, 5517F, S517M, 5517T, S517W,S517Y, K519A, K519G, K5191, K519L, K519V, R521F, R521W, R521Y, I523A,I523D, 1523E, I523F, I523G, I523K, I523L, I523N, 1523Q, I523R, I523V,1523W, I523Y, K524A, K524G, K5241, K524L, K524V, K525A, K525G, K5251,K525L, K525V, Q526C, Q526M, Q526S, Q526T, Q526Y, T527F, T527W, T527Y,E531A, E531G, E5311, E531L, E531V, H535D, H535E, H535P, K538F, K538W,K538Y, A539I, A539L, A539V, K541F, K541W, K541Y, K557A, K557G, K557I,K557L, K557V, A561F, A561W, A561Y, T566F, T566W, T566Y, A569H, andA569P; such as selected from L407N, L407Y, V415T, V4241, V424Q, V426E,V426H, P447S, V455N, V456N, L463N, E495D, T506Y, 1508R, F509M, F509W,A511F, D512Y, T515Q, L516T, L516W, S517W, R521W, I523D, 1523E, I523G,1523K, I523R, K524L, Q526M, T527Y, H535P and K557G.

The variant may comprise a variant Domain III of an albumin, or fragmentthereof, comprising amino acid substitutions at positions correspondingto the following positions of SEQ ID NO. 2: (a) residues 383 and 413;(b) residues 401 and 523; (c) residues 407 and 447; (d) residues 407 and447 and 539; (e) residues 407 and 509; (f) residues 407 and 526; (g)residues 411 and 535; (h) residues 414 and 456; (i) residues 415 and569; (j) residues 426 and 526; (k) residues 442 and 450 and 459; (I)residues 463 and 508; (m) residues 508 and 519 and 525; (n) residues 509and 527; (o) residues 523 and 538; (p) residues 526 and 557; (q)residues 541 and 561; (r) residues 463 and 523; (s) residues 508 and523; (t) residues 508 and 524; (u) residues 463, 508 and 523; (v)residues 463, 508 and 524; (w) residue 508, 523 and 524; (x) residue463, 508, 523 and 524; (y) residues 463 and 524; (z) residues 523 and524; and (aa) residues 463, 523, and 524, wherein the substitutionsincrease one or both of affinity for FcRn and serum half-life of thepolypeptide, as disclosed in WO 2012/112188 (incorporated herein byreference). Suitable substitutions may be selected from (a) L463C, F, G,H, I, N, S or Q; (b) T5080, E, I, K, R or S; (c) I523A, C, D, E, F, G,H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; (d) K524A, F, G, H, I, L, M,Q, T or V; (e) L463F or N; (f) T508R or S; (g) I523D, E, F, G, K or R;and (h) K524L.

The variant albumin may comprise one or more (e.g. several) alterationsin the mature human albumin polypeptide sequence of SEQ ID NO. 2selected from the group consisting of positions corresponding topositions V418, T420, V424, E505, V547, K573 in SEQ ID NO. 2; whereinthe one or more (several) alterations causes the conjugation-competentpolypeptides to have (i) an altered plasma half-life and/or (ii) analtered binding affinity to FcRn.

The variant albumin may comprise one or more (e.g. several) alterationsin the mature human albumin polypeptide sequence of SEQ ID NO. 2selected from the group consisting of positions corresponding topositions V381, preferably V381N or Q; E383, preferably E383A, G, I, L,or V; N391, preferably N391A, G, I, L or V; Y401 preferably Y401D or E;K402, preferably K402A, G, I, L, or V; L407, preferably L407F, N, Q, W,or Y; Y411, preferably Y411Q, or N; K413, preferably K413C, S, or T;K414, preferably K414S or T; V415C, preferably V415C, S, or T; Q416,preferably Q416H or P; V424, preferably V424A, G, I, L, N, or Q; V4260,preferably V426D, E, H, or P; G434, preferably G434C, S, or T; E442,preferably E442K or R; R445, preferably R445F, W or Y; P447, preferablyP447S or T; E450, preferably E450D or E; S454, preferably S454C, M or T;V455, preferably V455N or Q; V456, preferably V456N or Q; L457,preferably L457F, W or Y; Q459, preferably Q459K or R; L463, preferablyL463N or Q; E495, preferably E495D; T506, preferably T506F, W or Y;T508, preferably T508K, R, or S; F509, preferably F5090, I, L, M, V, Wor Y; A511, preferably A511F, W, or Y; D512, preferably D512F, W or Y;T515, preferably T515C, H, N, P, Q or S; L516, preferably L516F, S, T, Wor Y; S517, preferably S517C, F, M, T, W or Y; K519, preferably K519A,G, I, L, or V; R521, preferably R521F, W or Y; 1523, preferably I523A,D, E, F, G, K, L, N, Q, R, V, W or Y; K524, preferably K524A, G, I, L orV; K525, preferably K525A, G, I, L or V; Q526, preferably Q526C, M, S, Tor Y; T527, preferably T527F, W or Y; E531, preferably E531A, G, I, L orV; H535, preferably H535D, E or P; K538, preferably K538F, W or Y; A539,preferably A5391, L or V; K541, preferably, K541F, W or Y; K557,preferably K557A, G, I, L or V; A561, preferably A561F, W or Y; T566,preferably T566F, W or Y; A569, preferably A569H or P in SEQ ID NO. 2;wherein the one or more (e.g. several) alterations causes theconjugation-competent polypeptides to have (i) an altered plasmahalf-life and/or (ii) an altered binding affinity to FcRn.

The variant albumin may comprise one or more (e.g. several) alterationsin the mature human albumin polypeptide sequence of SEQ ID NO. 2selected from the group consisting of positions corresponding topositions V547, preferably V457A; K573, preferably K573P or Y; I523,preferably I523A or G, T527, preferably T527M, K500, preferably K500A;or E505, preferably E505Q in SEQ ID NO. 2; wherein the one or more (e.g.several) alterations causes the conjugation-competent polypeptides tohave (i) an altered plasma half-life and/or (ii) an altered bindingaffinity to FcRn.

The variant albumin may comprise one or more (e.g. several) alterationsin the mature human albumin polypeptide sequence of SEQ ID NO. 2selected from the group consisting of positions corresponding topositions 573, 523, 527 or 505 of SEQ ID NO. 2, preferably K573Y; I523G;I523A; T527M; E5050; or K573P, for example K573Y and 1523G; K573Y, I523Gand T527M; K573Y, E5050 and T527M; K573Y and T527M; K573P and I523G;K573P, 1523G and T527M; K573P, E505Q and T527M; K573P and T527M; V547A;V547A and K573P; V547A, E5050, K573P and T527M; or K500A and H510Q ofSEQ ID NO. 2.

Other Modifications

The second aspect of the invention encompasses other modifications. Forexample, the polypeptide may or may not comprise at least one (e.g.several) mutation that reduces glycosylation.

Fusion Polypeptide

A third aspect of the invention provides a fusion polypeptide comprisinga conjugation-competent polypeptide of either the first or the secondaspect of the invention.

Polypeptides of the invention may be fused with a non-albuminpolypeptide fusion partner. The fusion partner may in principle be anypolypeptide but generally it is preferred that the fusion partner is apolypeptide having bioactive, therapeutic, prophylactic (includingvaccine), diagnostic, imaging or other beneficial properties. Suchproperties may be referred to as ‘pharmaceutically beneficialproperties’. Fusion polypeptides comprising albumin or fragments thereofare known in the art. It has been found that such fusion polypeptidescomprising albumin or a fragment thereof and a fusion partnerpolypeptide have a longer plasma half-life compared to the unfusedfusion partner polypeptide alone.

One or more (e.g. several) bioactive, therapeutic, prophylactic(including vaccine), diagnostic, imaging or other beneficialpolypeptides may be fused to the N-terminus, the C-terminus of albumin,inserted into a loop in the albumin structure or any combinationthereof. It may or it may not comprise linker sequences separating thevarious components of the fusion polypeptide. By way of non-limitingexamples, a fusion may comprise N′-partner-albumin-C′,N′-albumin-partner-C′, N′-albumin-partner-albumin-C′,N′-partner-albumin-partner-C′ where ‘partner’ is the fusion partner.

Teachings relating to fusions of albumin or a fragment thereof are knownin the art and the skilled person will appreciate that such teachingscan also be applied to the invention. WO 2001/79271A (particularly page9 and/or Table 1), WO 2003/59934 (particularly Table 1), WO 03/060071(particularly Table 1) and WO 01/079480 (particularly Table 1) (eachincorporated herein by reference in their entirety) also containexamples of bioactive, therapeutic, prophylactic (including vaccine),diagnostic, imaging or other beneficial polypeptides that may be fusedto albumin or fragments thereof, and these examples apply also to theinvention.

An advantage of using a genetically or chemically fused albumin is thateither or all of the molecules which contribute to the fusion may haveimproved properties relative to the unfused molecule(s) (Balan et al.(2006), Antivir Ther 11(1): 35-45). Albumins and albumin particles arealso important for carrying and delivering drugs and prodrugs to theirsites of action (Kratz, F. (2008), Journal of Controlled Release, 132(3), p. 171-183). Fusion and particle technologies offer improved dosingregimens due to improved pharmacokinetic properties, such as half-lifeextension, and may improve bioavailability and protect the fusedconjugation partner, for example bioactive molecule, radiopharmaceuticalor imaging agent, from inactivation.

The polypeptide may also be fused to one or more (e.g. several)purification tags such as (Ala-Trp-Trp-Pro)_(n),avidin/streptavidin/Strep-tag, FLAG™ peptide (DYKDDDDK), His-tag.

Further preferences for the third aspect of the invention include thoseof the first and second aspects of the invention. The skilled personunderstands that any aspect of the invention may be combined withanother aspect or aspects of the invention and/or with one or more (e.g.several) of the preferences for the aspects of the invention and/orother disclosures made herein.

Polynucleotides

A. fourth aspect of the invention provides a polynucleotide whichencodes the polypeptide according to the first, second or third aspectsof the invention.

The polynucleotide may be an isolated polynucleotide. The polynucleotidemay be comprised in a vector (such as a plasmid) and/or in a host cell.

The polynucleotide may or may not be codon-optimised relative to thehost from which it is to be expressed. SEQ ID NO. 1 provides the usualcoding sequence of HSA (SEQ ID NO. 2). SEQ ID NO. 28 provides a codingsequence of HSA (SEQ ID NO. 1) which is codon-optimised for expressionfrom S. cerevisiae. SEQ ID NO. 1 or SEQ ID NO. 28 may be mutated inorder to provide a polynucleotide which encodes a polypeptide accordingto the invention. Preferably the polynucleotide is synthetic and/orrecombinant. Preferably the polynucleotide is an isolatedpolynucleotide. The polynucleotide may encode an HSA with or without aleader sequence. For example, the polynucleotide may encode an HSA withthe natural leader sequence of HSA (amino acids 1 to 24 of SEQ ID NO. 3)or an HSA with a fusion leader sequence (amino acids 1 to 24 of SEQ IDNO. 29).

The polypeptide may be provided as a nucleic acid construct comprising apolynucleotide encoding a polypeptide of the invention operably linkedto one or more (e.g. several) control sequences that direct theexpression of the coding sequence in a suitable host cell underconditions compatible with the control sequences.

A polynucleotide may be manipulated in a variety of ways to provide forexpression of a variant. Manipulation of the polynucleotide prior to itsinsertion into a vector may be desirable or necessary depending on theexpression vector. The techniques for modifying polynucleotidesutilizing recombinant DNA methods are well known in the art.

The control sequence may be a promoter sequence, which is recognized bya host cell for expression of the polynucleotide. The promoter sequencecontains transcriptional control sequences that mediate the expressionof the variant. The promoter may be any nucleic acid sequence that showstranscriptional activity in the host cell including mutant, truncated,and hybrid promoters, and may be obtained from genes encodingextracellular or intracellular polypeptides either homologous orheterologous to the host cell.

In a yeast host, useful promoters are obtained from the genes forSaccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiaeprotease A (PRA1), Saccharomyces cerevisiae protease B (PRB1),Saccharomyces cerevisiae translation elongation factor (TEF1),Saccharomyces cerevisiae translation elongation factor (TEF2),Saccharomyces cerevisiae galactokinase (GAL1), Saccharomyces cerevisiaealcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH1,ADH2/GAP), Saccharomyces cerevisiae triose phosphate isomerase (TPI),Saccharomyces cerevisiae metallothionein (CUP1), and Saccharomycescerevisiae 3-phosphoglycerate kinase. Other useful promoters for yeasthost cells are described by Romanos et al., 1992, Yeast 8: 423-488.

The skilled person knows useful promoters for use in rice and mammaliancells, such as CHO or HEK. In a rice host, useful promoters are obtainedfrom cauliflower mosaic virus 35S RNA gene (CaMV35S), maize alcoholdehydrogenase (Adh1) and alpha Amy3.

In a mammalian host cell, such as CHO or HEK, useful promoters areobtained from Cytomegalovirus (CMV) and CAG hybrid promoter (hybrid ofCMV early enhancer element and chicken beta-actin promoter), Simianvacuolating virus 40 (SV40).

The control sequence may also be a suitable transcription terminatorsequence, which is recognized by a host cell to terminate transcription.The terminator sequence is operably linked to the 3′-terminus of thepolynucleotide encoding the variant. Any terminator that is functionalin the host cell may be used.

Preferred terminators for yeast host cells are obtained from the genesfor Saccharomyces cerevisiae enolase, Saccharomyces cerevisiaecytochrome C (CYC1), Saccharomyces cerevisiae alcohol dehydrogenase(ADH1) and Saccharomyces cerevisiae glyceraldehyde-3-phosphatedehydrogenase. Other useful terminators for yeast host cells aredescribed by Romanos et al., 1992, supra. The skilled person knowsuseful terminators for use in rice and mammalian cells, such as CHO orHEK. For example, in a rice host, preferred terminators are obtainedfrom Agrobacterium tumefaciens nopaline synthase (Nos) and cauliflowermosaic virus 35S RNA gene (CaMV35S).

The control sequence may also be a suitable leader sequence, anontranslated region of an mRNA that is important for translation by thehost cell. The leader sequence is operably linked to the 5′-terminus ofthe polynucleotide encoding the variant. Any leader sequence that isfunctional in the host cell may be used.

Suitable leaders for yeast host cells are obtained from the genes forSaccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiae3-phosphoglycerate kinase, Saccharomyces cerevisiae alpha-factor, andSaccharomyces cerevisiae alcoholdehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAP).

The control sequence may also be a polyadenylation sequence, a sequenceoperably linked to the 3′-terminus of the variant-encoding sequence and,when transcribed, is recognized by the host cell as a signal to addpolyadenosine residues to transcribed mRNA. Any polyadenylation sequencethat is functional in the host cell may be used.

Useful polyadenylation sequences for yeast host cells are described byGuo and Sherman, 1995, Mol. Cellular Biol. 15: 5983-5990.

The control sequence may also be a signal peptide coding region thatencodes a signal peptide linked to the N-terminus of a variant anddirects the variant into the cell's secretory pathway. The 5′-end of thecoding sequence of the polynucleotide may inherently contain a signalpeptide coding region naturally linked in translation reading frame withthe segment of the coding region that encodes the variant.Alternatively, the 5′-end of the coding sequence may contain a signalpeptide coding region that is foreign to the coding sequence. Theforeign signal peptide coding region may be required where the codingsequence does not naturally contain a signal peptide coding region.Alternatively, the foreign signal peptide coding region may simplyreplace the natural signal peptide coding region in order to enhancesecretion of the variant. However, any signal peptide coding region thatdirects the expressed variant into the secretory pathway of a host cellmay be used.

Useful signal peptides for yeast host cells are obtained from the genesfor Saccharomyces cerevisiae alpha-factor and Saccharomyces cerevisiaeinvertase. Other useful signal peptide coding sequences are described byRomanos et al., 1992, supra. The skilled person knows useful signalpeptides for use In rice and mammalian cells, such as CHO or HEK.

Where both signal peptide and propeptide regions are present at theN-terminus of a variant, the propeptide region is positioned next to theN-terminus of the variant and the signal peptide region is positionednext to the N-terminus of the propeptide region.

Plasmids

A fifth aspect of the invention provides a plasmid comprising thepolynucleotide of the fourth aspect of the invention. The plasmid may bea 2 micron based plasmid such as those described in WO 2005/061719, WO2005/061718 and WO 2006/067511 (all incorporated herein by reference).The plasmid may exhibit enhanced chaperone activity, for example throughover expression of a chaperone, particularly PDI. Preferred helperproteins include PDI1, AHA1, ATP11, CCT2, CCT3, CCT4, CCT5, CCT6, CCT7,CCT8, CNS1, CPR3, CPR6, DER1, DER3, DOA4, ERO1, EUG1, ERV2, EPS1, FKB2,FMO1, HCH1, HRD3, HSP10, HSP12, HSP104, HSP26, HSP30, HSP42, HSP60,HSP78, HSP82, KAR2, JEM1, MDJ1, MDJ2, MPD1, MPD2, PDI1, PFD1, ABC1,APJ1, ATP11, ATP12, BTT1, CDC37, CPR7, HSC82, KAR2, LHS1, MGE1, MRS11,NOB1, ECM10, SCJ1, SSA1, SSA2, SSA3, SSA4, SSB1, SSB2, SSC1, SSE2, SIL1,SLS1, ORM1, ORM2, PER1, PTC2, PSE1, UBC7, UBI4 and HAC1 or a truncatedintronless HAC1 (Valkonen et al. 2003, Applied Environ. Micro., 69,2065). Such helper proteins are disclosed in WO 2005/061718, WO2006/067511 and WO 2006/136831 (all incorporated herein by reference).

Host Cells

A sixth aspect of the invention provides an expression system such as ahost cell comprising a polynucleotide according to the fourth aspect ofthe invention and/or a plasmid of the fifth aspect of the invention.Preferably the host cell is a mammalian cell such as a human or bovinecell, or a fungal cell such as a yeast cell. Alternatively, the hostcell may be a bacterial cell such as a Bacillus or Escherichia coli or aviral cell such as Baculovirus or a plant cell such as a rice e.g. Oryzasativa. Most preferably, the cell is a yeast cell such as aSaccharomyces (e.g. S. cerevisiae), a Pichia or an Aspergillus cell.

Conjugates

A seventh aspect of the invention provides a conjugate which comprises aconjugation partner, such as a bioactive compound, radiopharmaceuticalor imaging agent, and a polypeptide according to the first, second orthird aspect of the invention, wherein the conjugation partner is linkedto the polypeptide through a conjugation-competent cysteine residue ofthe polypeptide. The conjugation partner may be a bioactive,therapeutic, diagnostic or imaging compound such as those mentionedherein. The conjugate may comprise 2 or more, (several, for example 2,3, 4, 5, 6, 7,8, 9 or 10), conjugation partners which may each bedifferent and/or may be multiple copies of the same compound.Preferably, each conjugation partner is linked to the polypeptidethrough a conjugation-competent cysteine residue of the polypeptide,however conjugation partners may be linked by other means for example bya genetic fusion or covalent bonds to non-cysteine amino acids such aslysine.

A related aspect provides a use of a polypeptide according to theinvention for the production of a thio-albumin-conjugate.

Conjugation Partner

The term ‘conjugation partner’ includes bioactive agents, imagingagents, diagnostic agents, contrast agents, radiopharmaceuticals andtherapeutic compounds such as chemotherapeutic drugs andradiopharmaceuticals. A thio-albumin of the invention may be conjugatedto one or more (e.g. several) conjugation partners.

Imaging Agents, Diagnostic Compounds, Contrast Agents and TherapeuticCompounds

The use of diagnostic agents, imaging agents and biological “contrast”agents are well known to the art. A diagnostic agent is anypharmaceutical product used as part of a diagnostic test (i.e. togetherwith the equipment and procedures that are needed to assess the testresult). The diagnostic agent may be used in vivo, ex vivo or in vitro.

The ability of albumin to accumulate in damaged muscle fibres ofdystrophic muscle has been well described. For example, aGadolinium-DTPA-albumin conjugate may be used as a combined diagnosticand therapeutic tool to visualize and monitor, for example, dystrophicmuscle by magnetic resonance imaging (MRI) and for the delivery ofputative therapeutics bound to albumin for effective targeting todystrophic muscle (Amthor et al. (2004), Neuromuscular Disorders 14912:791-796). Malignant tumours often show an increased uptake andmetabolism of albumin. The use of gadolinium-albumin conjugate has alsobeen described for improved imaging of malignant tumours and todetermine by MRI tumours sensitive to a therapy with drug-conjugatedalbumin (Kiessling et al. (2002), Investigative Radiology 37(4):93-198).

Current imaging agents often degrade quickly whilst longer-lastingagents are often toxic. The use of albumin conjugates may be especiallyuseful to increase the half-life of imaging agents and would thereforepermit imaging over an extended period of time. WO 2005/082423(incorporated herein by reference) describes the use of serum albuminconjugated to fluorescent substances for imaging.

A thio-albumin of this invention may be conjugated to two or more(several) molecules selected from bioactive, imaging agents, diagnosticagents, therapeutic compounds and contrast agents.

Tumours (and muscle degeneration) show enhanced uptake of albumin (EPR:Enhanced Permeation and Retention). Albumin conjugates may be used forenhanced imaging, and also to assess whether tumours (or other tissuesand organs) would be suitable for albumin conjugated drugs.

Bioactive Compounds

The bioactive compound may be a therapeutic or diagnostic compound. Thetherapeutic compound may be a chemotherapy drug for use in cancerchemotherapy. It may be cytostatic or cytotoxic; it may be atumor-inhibiting agent.

The bioactive compound may already contain a free thiol group, e.g. apolypeptide containing a Cysteine residue with a free thiol group.Alternatively, the bioactive compound may be modified so as to contain afree thiol group. Thus, the amino acid sequence of a polypeptide may bealtered so as to include a Cysteine residue with a free thiol group, orthe bioactive compound may be chemically derivatized to include a freethiol group.

The bioactive compound may be a polypeptide (protein), particularly arecombinant protein pharmaceutical. It may be a chemotherapy orradiotherapy drug used to treat cancers and other related diseases.

The free thiol containing albumin mutein of the invention (thio-albumin)can be conjugated via the free thiol group, or groups if the albuminmutein of the invention contains more than one free thiol, to at leastone (e.g. several) bioactive compound by methods know to the art. Thebioactive compound includes but is not limited to, peptides,polypeptides or proteins (either natural, recombinant, or synthetic)(Debinski, (2002) Cancer Investigation 20, 801-809, O'Keefe and Draperet al., (1985) JBC 260, 932-937, Xia et al., (2000) J. PharmacologyExperimental Therapeutics 295, 594-600, Kavimandan et al., (2006),Bioconjugate Chem. 17, 1376-1384, Humphries, et al., (1994) J. TissueCulture Methods 16, 239-242, Wenning et al., (1998) Biotech. Bioeng. 57,484-496, Yazdi and Murphy, (1994), Cancer Research 54, 6387-6394, Weaverand Laske (2003) J. Neuro-Oncology 65, 3-13, Widera et al., (2003)Pharmaceutical Research 20, 1231-1238, Daniels, T. R. et al. (2006)Clinical Immunology 121, 159-176 and the references included therein);therapeutic and diagnostic drugs or compounds (Mishra et al., (2006) J.Drug Targeting 14, 45-53, Lim and Shen, (2004) Pharmaceutical Research21, 1985-1992, Fritzer et al., (1996) Biochemical Pharmacology 51,489-493, Lubgan and Jozwiak (2002) Cell. Mol. Biol. Lett. 7, 98,Daniels, T. R. et al. (2006) Clinical Immunology 121, 159-176 and thereferences included therein); high molecular weight complexes includingbut not limited to liposomes, viruses and nanoparticles (Mishra et al.,(2006) J. Drug Targeting 14, 45-53, Daniels, T. R. et al. (2006)Clinical Immunology 121, 159-176 and the references included therein);nucleic acids and radionuclides, including DNA, RNA (including siRNA)and their analogs (Lee et al., (2005), Arch. Pharm. Res. 28, 722-729,Huang et al., (2007) FASEB J. 21, 1117-1125, Daniels, T. R. et al.(2006) Clinical Immunology 121, 159-176 and the references includedtherein) and devices (Humphries, et al, (1994) J. Tissue Culture Methods16, 239-242 and the references included therein). Additionally theentity can itself be modified by methods known to the art.

Therapeutic Compounds

Examples of therapeutic compounds include: 4-1BB ligand, 5-helix, Ahuman C-C chemokine, A human L105 chemokine, A human L105 chemokinedesignated huL105_3, A monokine induced by gamma-interferon (MIG), Apartial CXCR4B protein, A platelet basic protein (PBP), al-antitrypsin,ACRP-30 Homologue, Complement Component C1q C, Adenoid-expressedchemokine (ADEC), aFGF, FGF-1, AGF, AGF Protein, albumin, an etoposide,angiostatin, Anthrax vaccine, Antibodies specific for collapsin,antistasin, Anti-TGF beta family antibodies, antithrombin III, APM-1,ACRP-30, Famoxin, apo-lipoprotein species, Arylsulfatase B, b57 Protein,BCMA, Beta-thromboglobulin protein (beta-TG), bFGF, FGF2, Bloodcoagulation factors, BMP Processing Enzyme Furin, BMP-10, BMP-12,BMP-15, BMP-17, BMP-18, BMP-2B, BMP-4, BMP-5, BMP-6, BMP-9, BoneMorphogenic Protein-2, calcitonin, Calpain-10a, Calpain-10b,Calpain-10c, Cancer Vaccine, Carboxypeptidase, C-C chemokine, MCP2, CCR5variant, CCR7, CCR7, CD11a Mab, CD137, 4-1BB Receptor Protein, CD20 Mab,CD27, CD27L, CD30, CD30 ligand, CD33 immunotoxin, CD40, CD40L, CD52 Mab,Cerebus Protein, Chemokine Eotaxin, Chemokine hIL-8, Chemokine hMCP1,Chemokine hMCP1a, Chemokine hMCP1b, Chemokine hMCP2, Chemokine hMCP3,Chemokine hSDF1b, Chemokine MCP-4, chemokine TECK and TECK variant,Chemokine-like protein IL-8M1 Full-Length and Mature, Chemokine-likeprotein IL-8M10 Full-Length and Mature, Chemokine-like protein IL-8M3,Chemokine-like protein IL-8M8 Full-Length and Mature, Chemokine-likeprotein IL-8M9 Full-Length and Mature, Chemokine-like protein PF4-414Full-Length and Mature, Chemokine-like protein PF4-426 Full-Length andMature, Chemokine-like protein PF4-M2 Full-Length and Mature, Choleravaccine, Chondromodulin-like protein, c-kit ligand, SCF, Mast cellgrowth factor, MGF, Fibrosarcoma-derived stem cell factor, CNTF andfragment thereof (such as CNTFA×15′(Axokinen™)), coagulation factors inboth pre and active forms, collagens, Complement C5 Mab, Connectivetissue activating protein-III, CTAA16.88 Mab, CTAP-III, CTLA4-Ig,CTLA-8, CXCR3, CXC chemokine receptor 3, cyanovirin-N, Darbepoetin,designated exodus, designated huL105_7, DIL-40, Dnase, EDAR, EGFReceptor Mab, ENA-78, Endostatin, Eotaxin, Epithelial neutrophilactivating protein-78, EPO receptor, EPOR, erythropoietin (EPO) and EPOmimics, Eutropin, Exodus protein, Factor IX, Factor VII, Factor VIII,Factor X and Factor XIII, FAS Ligand Inhibitory Protein (DcR3), FasL,FGF, FGF-12, Fibroblast growth factor homologous factor-1, FGF-15,FGF-16, FGF-18, FGF-3, INT-2, FGF-4, gelonin, HST-1, HBGF-4, FGF-5,FGF-6, Heparin binding secreted transforming factor-2, FGF-8, FGF-9,Glia activating factor, fibrinogen, flt-1, flt-3 ligand, Folliclestimulating hormone Alpha subunit, Follicle stimulating hormone Betasubunit, Follitropin, Fractalkine, fragment. myofibrillar proteinTroponin I, FSH, Galactosidase, Galectin-4, G-CSF, GDF-1, Gene therapy,Glioma-derived growth factor, glucagon, glucagon-like peptides,Glucocerebrosidase, glucose oxidase, Glucosidase, Glycodelin-A,Progesterone-associated endometrial protein, GM-CSF, gonadotropin,Granulocyte chemotactic protein-2 (GCP-2), Granulocyte-macrophage colonystimulating factor, growth hormone, Growth related oncogene-alpha(GRO-alpha), Growth related oncogene-beta (GRO-beta), Growth relatedoncogene-gamma (GRO-gamma), hAPO-4, TROY, hCG, Hepatitus B surfaceAntigen, Hepatitus B Vaccine, HER2 Receptor Mab, hirudin, HIV gp120, HIVgp41, HIV Inhibitor Peptide, HIV Inhibitor Peptide, HIV InhibitorPeptide, HIV protease inhibiting peptides, HIV-1 protease inhibitors,HPV vaccine, Human 6CKine protein, Human Act-2 protein, Humanadipogenesis inhibitory factor, human B cell stimulating factor-2receptor, Human beta-chemokine H1305 (MCP-2), Human C-C chemokine DGWCC,Human CC chemokine ELC protein, Human CC type chemokine interleukin C,Human CCC3 protein, Human CCF18 chemokine, Human CC-type chemokineprotein designated SLC (secondary lymphoid chemokine), Human chemokinebeta-8 short forms, Human chemokine C10, Human chemokine CC-2, Humanchemokine CC-3, Human chemokine CCR-2, Human chemokine Ckbeta-7, Humanchemokine ENA-78, Human chemokine eotaxin, Human chemokine GRO alpha,Human chemokine GROalpha, Human chemokine GRObeta, Human chemokineHCC-1, Human chemokine HCC-1, Human chemokine 1-309, Human chemokineIP-10, Human chemokine L105_3, Human chemokine L105_7, Human chemokineMIG, Human chemokine MIG-beta protein, Human chemokine MIP-1alpha, Humanchemokine MIP1beta, Human chemokine MIP-3alpha, Human chemokineMIP-3beta, Human chemokine PF4, Human chemokine protein 331D5, Humanchemokine protein 61164, Human chemokine receptor CXCR3, Human chemokineSDF1alpha, Human chemokine SDF1beta, Human chemokine ZSIG-35, HumanChr19Kine protein, Human CKbeta-9, Human CX3C 111 amino acid chemokine,Human DNAX interleukin-40, Human DVic-1 C-C chemokine, Human EDIRF Iprotein sequence, Human EDIRF II protein sequence, Human eosinocyte CCtype chemokine eotaxin, Human eosinophil-expressed chemokine (EEC),Human fast twitch skeletal muscle troponin C, Human fast twitch skeletalmuscle troponin I, Human fast twitch skeletal muscle Troponin subunit C,Human fast twitch skeletal muscle Troponin subunit I Protein, Human fasttwitch skeletal muscle Troponin subunit T, Human fast twitch skeletalmuscle troponin T, Human foetal spleen expressed chemokine, FSEC, HumanGM-CSF receptor, Human gro-alpha chemokine, Human gro-beta chemokine,Human gro-gamma chemokine, Human IL-16 protein, Human IL-1RD10 proteinsequence, Human IL-1RD9, Human IL-5 receptor alpha chain, Human IL-6receptor, Human IL-8 receptor protein hIL8RA, Human IL-8 receptorprotein hIL8RB, Human IL-9 receptor protein, Human IL-9 receptor proteinvariant #3, Human IL-9 receptor protein variant fragment, Human IL-9receptor protein variant fragment #3, Human interleukin 1 delta, Humaninterleukin 10, Human interleukin 18, Human interleukin 18 derivatives,Human interleukin-1 beta precursor, Human interleukin-1 beta precursor,Human interleukin-1 receptor accessory protein, Human interleukin-1receptor antagonist beta, Human interleukin-1 type-3 receptor, Humaninterleukin-10 (precursor), Human interleukin-11 receptor, Humaninterleukin-12 40 kD subunit, Human interleukin-12 beta-1 receptor,Human interleukin-12 beta-2 receptor, Human interleukin-12 p35 protein,Human interleukin-12 p40 protein, Human interleukin-12 receptor, Humaninterleukin-13 alpha receptor, Human interleukin-13 beta receptor, Humaninterleukin-15, Human interleukin-15 receptor from clone P1, Humaninterleukin-17 receptor, Human interleukin-18 protein (IL-18), Humaninterleukin-3, human interleukin-3 receptor, Human interleukin-3variant, Human interleukin-4 receptor, Human interleukin-5, Humaninterleukin-6, Human interleukin-7, Human interleukin-7, Humaninterleukin-8 (IL-8), Human intracellular IL-1 receptor antagonist,Human IP-10 and HIV-1 gp120 hypervariable region fusion protein, HumanIP-10 and human Muc-1 core epitope (VNT) fusion protein, human liver andactivation regulated chemokine (LARC), Human Lkn-1 Full-Length andMature protein, Human mammary associated chemokine (MACK) proteinFull-Length and Mature, Human mature chemokine Ckbeta-7, Human maturegro-alpha, Human mature gro-gamma polypeptide used to treat sepsis,Human MCP-3 and human Muc-1 core epitope (VNT) fusion protein, HumanMI10 protein, Human MI1A protein, Human monocyte chemoattractant factorhMCP-1, Human monocyte chemoattractant factor hMCP-3, Human monocytechemotactic proprotein (MCPP) sequence, Human neurotactin chemokine likedomain, Human non-ELR CXC chemokine H174, Human non-ELR CXC chemokineIP10, Human non-ELR CXC chemokine Mig, Human PAI-1 mutants, Humanprotein with IL-16 activity, Human protein with IL-16 activity, Humansecondary lymphoid chemokine (SLC), Human SISD protein, Human STCP-1,Human stromal cell-derived chemokine, SDF-1, Human T cell mixedlymphocyte reaction expressed chemokine (TMEC), Human thymus andactivation regulated cytokine (TARC), Human thymus expressed, HumanTNF-alpha, Human TNF-beta (LT-alpha), Human type CC chemokine eotaxin 3protein sequence, Human type II interleukin-1 receptor, Human wild-typeinterleukin-4 (hIL-4) protein, Human ZCHEMO-8 protein, HumanizedAnti-VEGF Antibodies, and fragments thereof, Humanized Anti-VEGFAntibodies, and fragments thereof, Hyaluronidase, ICE 10 kD subunit, ICE20 kD subunit, ICE 22 kD subunit, Iduronate-2-sulfatase, Iduronidase,IL-1 alpha, IL-1 beta, IL-1 inhibitor (IL-1i), IL-1 mature, IL-10receptor, IL-11, IL-11, IL-12 p40 subunit, IL-13, IL-14, IL-15, IL-15receptor, IL-17, IL-17 receptor, IL-19, IL-1i fragments, IL1-receptorantagonist, IL-21 (TIF), IL-3 containing fusion protein, IL-3 mutantproteins, IL-3 variants, IL-4, IL-4 muteins, IL-4 mutein Y124G, IL-4mutein Y124X, IL-5, IL-5 muteins, 11-5 receptor, IL-6, 11-6 receptor,IL-7 receptor clone, IL-8 receptor, IL-9 mature protein variant (Met117version), immunoglobulins or immunoglobulin-based molecules or fragmentof either (e.g. a Small Modular ImmunoPharmaceutical™ (“SMIP”) or dAb,Fab′ fragments, F(ab′)2, scAb, scFv or scFv fragment), including but notlimited to plasminogen, Influenza Vaccine, Inhibin alpha, Inhibin beta,insulin, insulin-like growth factor, Integrin Mab, inter-alpha trypsininhibitor, inter-alpha trypsin inhibitor, Interferon gamma-inducibleprotein (IP-10), interferons (such as interferon alpha species andsub-species, interferon beta species and sub-species, interferon gammaspecies and sub-species), interleukin 6, interleukin 8 (IL-8) receptor,interleukin 8 receptor B, interleukin-1alpha, interleukin-2 receptorassociated protein p43, interleukin-3, interleukin-4 muteins,interleukin-8 (IL-8) protein, interleukin-9, interleukin-9 (IL-9) matureprotein (Thr117 version), interleukins (such as IL10, IL11 and IL2),Japanese encephalitis vaccine, Kalikrein Inhibitor, Keratinocyte growthfactor, Kunitz domain protein (such as aprotinin, amyloid precursorprotein and those described in WO 03/066824, with or without albuminfusions), LACI, lactoferrin, Latent TGF-beta binding protein II, leptin,Liver expressed chemokine-1 (LVEC-1), Liver expressed chemokine-2(LVEC-2), LT-alpha, LT-beta, Luteinization Hormone, Lyme Vaccine,Lymphotactin, Macrophage derived chemokine analogue MDC (n+1),Macrophage derived chemokine analogue MDC-eyfy, Macrophage derivedchemokine analogue MDC-yl, Macrophage-derived chemokine (MDC), Maspin,Protease Inhibitor 5, MCP-1 receptor, MCP-1a, MCP-1b, MCP-3, MCP-4receptor, M-CSF, Melanoma inhibiting protein, Membrane-bound proteins,Met117 human interleukin 9, MIP-3 alpha, MIP-3 beta, MIP-Gamma, MIRAP,Modified Rantes, monoclonal antibody, MP52, Mutant interleukin 6 S176R,myofibrillar contractile protein Troponin I, Natriuretic Peptide, NerveGrowth Factor-beta, Nerve Growth Factor-beta2, Neuropilin-1,Neuropilin-2, Neurotactin, Neurotrophin-3, Neurotrophin-4,Neurotrophin-4a, Neurotrophin-4b, Neurotrophin-4c, Neurotrophin-4d,Neutrophil activating peptide-2 (NAP-2), NOGO-66 Receptor, NOGO-A,NOGO-B, NOGO-C, Novel beta-chemokine designated PTEC, N-terminalmodified chemokine GroHEK/hSDF-1alpha, N-terminal modified chemokineGroHEK/hSDF-1beta, N-terminal modified chemokine met-hSDF-1 alpha,N-terminal modified chemokine met-hSDF-1 beta, OPGL, OsteogenicProtein-1 (OP-1), BMP-7, Osteogenic Protein-2, OX40, ACT-4, OX40L,Oxytocin (Neurophysin I), parathyroid hormone, Patched, Patched-2,PDGF-D, Pertussis toxoid, Pituitary expressed chemokine (PGEC),Placental Growth Factor, Placental Growth Factor-2, PlasminogenActivator Inhibitor-1 (PAI-1), Plasminogen Activator Inhibitor-2(PAI-2), Platelet derived growth factor, Platelet derived growth factorBv-sis, Platelet derived growth factor precursor A, Platelet derivedgrowth factor precursor B, Platelet Mab, platelet-derived endothelialcell growth factor (PD-ECGF), Platelet-Derived Growth Factor A chain,Platelet-Derived Growth Factor B chain, polypeptide used to treatsepsis, Preproapolipoprotein “milano” variant, Preproapolipoprotein“paris” variant, pre-thrombin, Primate CC chemokine “ILINCK”, PrimateCXC chemokine “IBICK”, proinsulin, Prolactin, Prolactin2, prosaptide,Protease inhibitor peptides, Protein C, Protein S, pro-thrombin,prourokinase, RANTES, RANTES 8-68, RANTES 9-68, RANTES peptide, RANTESreceptor, Recombinant interleukin-16, Resistin, restrictocin, Retroviralprotease inhibitors, ricin, Rotavirus Vaccine, RSV Mab, saporin, sarcin,Secreted and Transmembrane polypeptides, serum cholinesterase, serumprotein (such as a blood clotting factor), Soluble BMP Receptor KinaseProtein-3, Soluble VEGF Receptor, Stem Cell Inhibitory Factor,Straphylococcus Vaccine, Stromal Derived Factor-1 alpha, Stromal DerivedFactor-1 beta, Substance P (tachykinin), T1249 peptide, T20 peptide, T4Endonuclease, TACI, Tarc, TGF-beta 1, TGF-beta 2, Thr117 humaninterleukin 9, thrombin, thrombopoietin, thrombopoietin derivative 1,thrombopoietin derivative 2, thrombopoietin derivative 3, thrombopoietinderivative 4, thrombopoietin derivative 5, thrombopoietin derivative 6,thrombopoietin derivative 7, Thymus expressed chemokine (TECK), Thyroidstimulating Hormone, tick anticoagulant peptide, Tim-1 protein,TNF-alpha precursor, TNF-R, TNF-RII, TNF p75 Receptor, Death Receptor,tissue plasminogen activator (tPA), transferrin, transforming growthfactor beta, Troponin peptides, Truncated monocyte chemotactic protein 2(6-76), Truncated RANTES protein (3-68), tumour necrosis factor, UrateOxidase, urokinase, Vasopressin (Neurophysin II), VEGF R-3, flt-4, VEGFReceptor, KDR, flk-1, VEGF-110, VEGF-121, VEGF-138, VEGF-145, VEGF-162,VEGF-165, VEGF-182, VEGF-189, VEGF-206, VEGF-D, VEGF-E, VEGF-X, vonWillebrand's factor, Wild type monocyte chemotactic protein 2, ZTGF-beta9.

Chemotherapy Drugs

Examples of chemotherapy drugs include: 13-cis-Retinoic Acid, 2-CdA,2-Chlorodeoxyadenosine, 5-Azacitidine, 5-Fluorouracil, 5-FU,6-Mercaptopurine, 6-MP, 6-TG, 6-Thioguanine, Abraxane, Accutane®,Actinomycin-D, Adriamycin®, Adrucil®, Agrylin®, Ala-Cort®, Aldesleukin,Alemtuzumab, ALIMTA, Alitretinoin, Alkaban-AQ®, Alkeran®,All-transretinoic Acid, Alpha Interferon, Altretamine, Amethopterin,Amifostine, Aminoglutethimide, Anagrelide, Anandron®, Anastrozole,Arabinosylcytosine, Ara-C, Aranesp®, Aredia®, Arimidex®, Aromasin®,Arranon®, Arsenic Trioxide, Asparaginase, ATRA, Avastin®, Azacitidine,BCG, BCNU, Bevacizumab, Bexarotene, BEXXAR®, Bicalutamide, BiCNU,Blenoxane®, Bleomycin, Bortezomib, Busulfan, Busulfex®, C225, CalciumLeucovorin, Campath®, Camptosar®, Camptothecin-11, Capecitabine, Carac™,Carboplatin, Carmustine, Carmustine Wafer, Casodex®, CC-5013, CCNU,CDDP, CeeNU, Cerubidine®, Cetuximab, Chlorambucil, Cisplatin, CitrovorumFactor, Cladribine, Cortisone, Cosmegen®, CPT-11, Cyclophosphamide,Cytadren®, Cytarabine, Cytarabine Liposomal, Cytosar-U®, Cytoxan®,Dacarbazine, Dacogen, Dactinomycin, Darbepoetin Alfa, Dasatinib,Daunomycin, Daunorubicin, Daunorubicin Hydrochloride, DaunorubicinLiposomal, DaunoXome®, Decadron, Decitabine, Delta-Cortef®, Deltasone®,Denileukin diftitox, DepoCyt™, Dexamethasone, Dexamethasone acetate,Dexamethasone Sodium Phosphate, Dexasone, Dexrazoxane, DHAD, DIC,Diodex, Docetaxel, Doxil®, Doxorubicin, Doxorubicin liposomal, Droxia,DTIC, DTIC-Dome®, Duralone®, Efudex®, Eligard™, Ellence™, Eloxatin™,Elspar®, Emcyt®, Epirubicin, Epoetin alfa, Erbitux™, Erlotinib, ErwiniaL-asparaginase, Estramustine, Ethyol, Etopophos®, Etoposide, EtoposidePhosphate, Eulexin®, Evista®, Exemestane, Fareston®, Faslodex®, Femara®,Filgrastim, Floxuridine, Fludara®, Fludarabine, Fluoroplex®,Fluorouracil, Fluoxymesterone, Flutamide, Folinic Acid, FUDR®,Fulvestrant, G-CSF, Gefitinib, Gemcitabine, Gemtuzumab ozogamicin,Gemzar®, Gleevec™, Gliadel® Wafer, GM-CSF, Goserelin, Granulocyte-ColonyStimulating Factor, Granulocyte Macrophage Colony Stimulating Factor,Halotestin®, Herceptin®, Hexadrol, Hexalen®, Hexamethylmelamine, HMM,Hycamtin®, Hydrea®, Hydrocort Acetate®, Hydrocortisone, HydrocortisoneSodium Phosphate, Hydrocortisone Sodium Succinate, HydrocortonePhosphate, Hydroxyurea, Ibritumomab, Ibritumomab Tiuxetan, Idamycin®,Idarubicin, Ifex®, IFN-alpha, Ifosfamide, IL-11, IL-2, Imatinibmesylate, Imidazole Carboxamide, Interferon alfa, Interferon Alfa-2b(PEG Conjugate), interleukin-2, interleukin-11, Intron A° (interferonalfa-2b), Iressa®, Irinotecan, Isotretinoin, Kidrolase®, Lanacort®,Lapatinib, L-asparaginase, LCR, Lenalidomide, Letrozole, Leucovorin,Leukeran, Leukine™, Leuprolide, Leurocristine, Leustatin™, LiposomalAra-C, Liquid Pred®, Lomustine, L-PAM, L-Sarcolysin, Lupron®, LupronDepot®, Matulane®, Maxidex, Mechlorethamine, MechlorethamineHydrochloride, Medralone®, Medrol®, Megace®, Megestrol, MegestrolAcetate, Melphalan, Mercaptopurine, Mesna, Mesnex™, Methotrexate,Methotrexate Sodium, Methylprednisolone, Meticorten®, Mitomycin,Mitomycin-C, Mitoxantrone, M-Prednisol®, MTC, MTX, Mustargen®, Mustine,Mutamycin®, Myleran®, Mylocel™, Mylotarg®, Navelbine®, Nelarabine,Neosar®, Neulasta™, Neumega®, Neupogen®, Nexavar®, Nilandron®,Nilutamide, Nipent®, Nitrogen Mustard, Novaldex®, Novantrone®,Octreotide, Octreotide acetate, Oncospar®, Oncovin®, Ontak®, Onxal™,Oprevelkin, Orapred®, Orasone®, Oxaliplatin, Paclitaxel, PaclitaxelProtein-bound, Pamidronate, Panitumumab, Panretin®, Paraplatin®,Pediapred®, PEG Interferon, Pegaspargase, Pegfilgrastim, PEG-INTRON™,PEG-L-asparaginase, PEMETREXED, Pentostatin, Phenylalanine Mustard,Platinol®, Platinol-AQ®, Prednisolone, Prednisone, Prelone®,Procarbazine, PROCRIT®, Proleukin®, Prolifeprospan 20 with CarmustineImplant, Purinethol®, Raloxifene, Revlimid®, Rheumatrex®, Rituxan®,Rituximab, Roferon-A® (Interferon Alfa-2a), Rubex®, Rubidomycinhydrochloride, Sandostatin®, Sandostatin LAR®, Sargramostim,Solu-Cortef®, Solu-Medrol®, Sorafenib, SPRYCEL™, STI-571, Streptozocin,SU11248, Sunitinib, Sutent®, Tamoxifen, Tarceva®, Targretin®, Taxol®,Taxotere®, Temodar®, Temozolomide, Teniposide, TESPA, Thalidomide,Thalomid®, TheraCys®, Thioguanine, Thioguanine Tabloid®,Thiophosphoamide, Thioplex®, Thiotepa, TICE®, Toposar®, Topotecan,Toremifene, Tositumomab, Trastuzumab, Tretinoin, Trexall™, Trisenox®,TSPA, TYKERB®, VCR, Vectibix™, Velban®, Velcade®, VePesid®, Vesanoid®,Viadur™, Vidaza®, Vinblastine, Vinblastine Sulfate, Vincasar Pfs®,Vincristine, Vinorelbine, Vinorelbine tartrate, VLB, VM-26, Vorinostat,VP-16, Vumon®, Xeloda®, Zanosar®, Zevalin™, Zinecard®, Zoladex®,Zoledronic acid, Zolinza, Zometa®.

Radiopharmaceuticals

Examples of radiopharmaceuticals include: Carbon-11, Carbon-14,Chromium-51, Cobalt-57, Cobalt-58, Erbium-169, Fluorine-18, Gallium-67,Gold-198, Indium-111, Indium-113m, Iodine-123, Iodine-125, Iodine-131,Iron-59, Krypton-81m, Nitrogen-13, Oxygen-15, Phosphorous-32,Rhenium-186, Rubidium-82, Samarium-153, Selenium-75, Strontium-89,Technetium-99m, Thallium-201, Tritium, Xenon-127, Xenon-133, Yttrium-90.

Imaging Agents

Examples of imaging agents include: Gadolinium, magnetite, manganese,technetium, 1125,1131, P32, TI201, Iopamidol, PET-FDG.

Preparation of a Polynucleotide

An eighth aspect of the invention provides a method of producing apolynucleotide comprising:

(a) providing a nucleic acid molecule encoding a parent albumin orfragment thereof; and

(b) modifying the nucleic acid sequence of the nucleic acid molecule toencode a conjugation-competent polypeptide which is at least 60%identical to human albumin, particularly residues 1 to 585 of the maturehuman albumin polypeptide sequence of SEQ ID NO. 2, or a fragmentthereof, wherein at least one (e.g. several) position equivalent to aposition selected from K93, E294, A226, E230, 1271, E358, L24, F49, V54,D56, L66, A92, Q94, E97, H128, F156, E227, D237, K240, D259, K262, N267,Q268, L275, E277, L284, E311, K317, A322, E333, D340, E354, K359, A362,E382, and L398, particularly from K93, E294, A226, E230, and 1271, ofSEQ ID NO. 2 comprises a conjugation-competent cysteine residue.

Suitably, modifying the nucleic acid sequence comprises introducing analteration such that at least one (e.g. several) conjugation-competentcysteine as provided for in step (b) is introduced into the encodedpolypeptide. Preferred alterations are as described in relation to thefirst and second aspects of the invention.

It is preferred that the parent albumin comprises or consists of:

(a) a polypeptide having at least 70% sequence identity to the maturepolypeptide of SEQ ID NO. 2;

(b) a polypeptide encoded by a polynucleotide that hybridizes under lowstringency conditions with (i) the mature polypeptide coding sequence ofSEQ ID NO. 2, or (ii) the full-length complement of (i);

(c) a polypeptide encoded by a polynucleotide having at least 60%identity to the mature polypeptide coding sequence of SEQ ID NO. 2;and/or

(d) a fragment of the mature polypeptide of SEQ ID NO. 2.

Suitably, the parent albumin comprises or consists of the HSApolypeptide sequence of SEQ ID NO. 2 or a variant or fragment thereof.

The variant polynucleotides can be prepared by those skilled personsusing any mutagenesis procedure known in the art, such as site-directedmutagenesis, synthetic gene construction, semi-synthetic geneconstruction, random mutagenesis, shuffling, etc.

Site-directed mutagenesis is a technique in which one or more (e.g.several) mutations (alterations) are created at one or more (e.g.several) defined sites in a polynucleotide encoding the parent.

Site-directed mutagenesis can be accomplished in vitro by PCR involvingthe use of oligonucleotide primers containing the desired mutation.Site-directed mutagenesis can also be performed in vitro by cassettemutagenesis involving the cleavage by a restriction enzyme at a site inthe plasmid comprising a polynucleotide encoding the parent andsubsequent ligation of an oligonucleotide containing the mutation in thepolynucleotide. Usually the restriction enzyme that digests at theplasmid and the oligonucleotide is the same, permitting ligation of theplasmid and insert to one another. See, e.g. Scherer and Davis, 1979,Proc. Natl. Acad. Sci. USA 76: 4949-4955; and Barton et al., 1990,Nucleic Acids Res. 18: 7349-4966.

Site-directed mutagenesis can also be accomplished in vivo by methodsknown in the art, see, e.g. U.S. Patent Application Publication:2004/0171154; Storici et al., 2001, Nature Biotechnol. 19: 773-776; Krenet al., 1998, Nat. Med. 4: 285-290; and Calissano and Macino, 1996,Fungal Genet. Newslett. 43: 15-16.

Any site-directed mutagenesis procedure can be used in the invention.There are many commercial kits available that can be used to preparevariants.

Synthetic gene construction entails in vitro synthesis of a designedpolynucleotide molecule to encode a polypeptide of interest. Genesynthesis can be performed utilizing a number of techniques, such as themultiplex microchip-based technology described by Tian et al. (2004,Nature 432: 1050-1054) and similar technologies wherein oligonucleotidesare synthesized and assembled upon photo-programmable microfluidicchips.

Single or multiple amino acid substitutions, deletions, and/orinsertions can be made and tested using known methods of mutagenesis,recombination, and/or shuffling, followed by a relevant screeningprocedure, such as those disclosed by Reidhaar-Olson and Sauer, 1988,Science 241: 53-57; Bowie and Sauer, 1989, Proc. Natl. Acad. Sci. USA86: 2152-2156; WO 95/17413; or WO 95/22625. Other methods that can beused include error-prone PCR, phage display (e.g. Lowman et al., 1991,Biochemistry 30: 10832-10837; U.S. Pat. No. 5,223,409; WO 92/06204) andregion-directed mutagenesis (Derbyshire et al., 1986, Gene 46: 145; Neret al., 1988, DNA 7: 127).

Mutagenesis/shuffling methods can be combined with high-throughput,automated screening methods to detect activity of cloned, mutagenizedpolypeptides expressed by host cells (Ness et al., 1999, NatureBiotechnology 17: 893-896). Mutagenized DNA molecules that encode activepolypeptides can be recovered from the host cells and rapidly sequencedusing standard methods in the art. These methods allow the rapiddetermination of the importance of individual amino acid residues in apolypeptide.

Semi-synthetic gene construction is accomplished by combining aspects ofsynthetic gene construction, and/or site-directed mutagenesis, and/orrandom mutagenesis, and/or shuffling. Semi-synthetic construction istypified by a process utilizing polynucleotide fragments that aresynthesized, in combination with PCR techniques. Defined regions ofgenes may thus be synthesized de novo, while other regions may beamplified using site-specific mutagenic primers, while yet other regionsmay be subjected to error-prone PCR or non-error prone PCRamplification. Polynucleotide sub sequences may then be shuffled.

Method of Producing a Polypeptide

A ninth aspect of the invention provides a method of producing apolypeptide of the invention comprising:

(a) culturing a host cell according to the invention under conditionsthat allow expression of the polypeptide; and

(b) recovering the polypeptide from the host cell and/or from host cellgrowth medium.

The method may or may not further comprise determining the receptorbinding capacity and/or the conjugation competence of the polypeptideand/or the tendency to exist as a monomer in solution, and optionallyselecting a polypeptide which does or does not have a receptor bindingcapacity and/or conjugation competence and/or selected range ofpercentage monomer tendency.

The variants of the invention can be prepared using techniques wellknown to the skilled person. One convenient way is by cloning a nucleicacid molecule encoding a parent albumin or a fragment thereof andmodifying the sequence of the nucleic acid molecule according to themethod of the eighth aspect of the invention, preparing a suitablegenetic construct where the modified nucleic acid molecule is placed inoperative connection with suitable regulatory genetic elements, such aspromoter, terminator, activation sites, ribosome binding sites etc.,introducing the genetic construct into a suitable host organism,culturing the transformed host organism under conditions leading toexpression of the variant and recovering the variant. All thesetechniques are known in the art and it is within the skills of theaverage practitioner to design a suitable method for preparing aparticular variant according to the invention.

The variant polypeptide of the invention may also be connected to asignal sequence in order to have the variant polypeptide secreted intothe growth medium during culturing of the transformed host organism. Itis generally advantageous to have the variant polypeptide secreted intothe growth medium in order to ease recovery and purification. Thepolypeptide may be prepared as a fusion polypeptide as described inrelation to the third aspect of the invention. Techniques for preparingvariant polypeptides have been disclosed in WO 2009/019314 (included byreference) and these techniques may also be applied to the invention.

Albumins have been successfully expressed as recombinant proteins in arange of hosts including fungi (including but not limited to Aspergillus(WO 06066595), Kluyveromyces (Fleer 1991, Bio/technology 9, 968-975),Pichia (Kobayashi 1998 Therapeutic Apheresis 2, 257-262) andSaccharomyces (Sleep 1990, Bio/technology 8, 42-46)), bacteria(Pandjaitab 2000, J. Allergy Clin. Immunol. 105, 279-285)), animals(Barash 1993, Transgenic Research 2, 266-276) and plants (including butnot limited to potato and tobacco (Sijmons 1990, Bio/technology 8, 217and Farran 2002, Transgenic Research 11, 337-346) and rice e.g. Oryzasativa) and mammalian cells such as CHO and HEK. The variant polypeptideof the invention is preferably produced recombinantly in a suitable hostcell. In principle any host cell capable of producing a polypeptide insuitable amounts may be used and it is within the skills of the averagepractitioner to select a suitable host cell according to the invention.A preferred host organism is yeast, preferably selected amongSaccharomycacae, more preferred Saccharomyces cerevisiae.

The variant polypeptides of the invention may be recovered and purifiedfrom the growth medium using a combination of known separationtechniques such as filtration, centrifugation, chromatography, andaffinity separation techniques etc. It is within the skills of theaverage practitioner to purify the variants of the invention using aparticular combination of such known separation steps. As an example ofpurification techniques that may be applied to the variants of theinvention can be mentioned the teaching of WO 00/44772.

In the method of the invention, the host cell may or may not exhibitenhanced chaperone activity. Accordingly, the present invention alsoprovides a method for producing a polypeptide (or protein) of theinvention, the method comprising: (a) providing a host cell of theinvention comprising a polynucleotide encoding protein product of choiceas defined above; and (b) growing the host cell (for example, culturingthe host cell in a culture medium); thereby to produce a cell culture orrecombinant organism comprising an increased level of the proteinproduct of choice compared to the level of production of the proteinproduct of choice achieved by growing (for example, culturing), underthe same conditions, the same host cell that has not been geneticallymodified to cause over-expression of one or more (e.g. several) helperproteins.

The step of growing the host cell may or may not involve allowing a hostcell derived from a multicellular organism to be regrown into amulticellular recombinant organism (such as a plant or animal) and,optionally, producing one or more (e.g. several) generations of progenytherefrom.

The thio-albumin may or may not be capable of being expressed at a levelof at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100% relative to theexpression of an unmodified albumin (such as SEQ ID NO. 2) from asuitable expression system, such as yeast (e.g. Saccharomyces, e.g. S.cerevisiae) or an Aspergillus. Relative expression levels can bedetermined, for example, by expression of the protein followed byquantification by SDS-PAGE, HPLC or Western Blotting. Relativeexpression levels may be determined in at least 10 liter scale.

The method may or may not further comprise the step of purifying thethus expressed protein product of choice from the cultured host cell,recombinant organism or culture medium.

The production method may comprise linking a conjugation partner to thepolypeptide of the invention through a conjugation competent cysteineresidue of the polypeptide. Suitable conjugation methods and conjugationpartners are described herein.

The thio-albumin or fusions of thio-albumin and another protein orproteins can be expressed as variants with reduced N-linkedglycosylation. Accordingly, in case of HSA, it may be particularlyadvantageous to use a yeast deficient in one or more (e.g. several)protein mannosyl transferases involved in O-glycosylation of proteins,for instance by disruption of the gene coding sequence. Recombinantlyexpressed proteins can be subject to undesirable post-. translationalmodifications by the producing host cell. The mannosylated albumin wouldbe able to bind to the lectin Concanavalin A. The amount of mannosylatedalbumin produced by the yeast can be reduced by using a yeast straindeficient in one or more (e.g. several) of the PMT genes (WO 94/04687).The most convenient way of achieving this is to create a yeast which hasa defect in its genome such that a reduced level of one of the Pmtproteins is produced. For example, there may or may not be a deletion,insertion or transposition in the coding sequence or the regulatoryregions (or in another gene regulating the expression of one of the PMTgenes) such that little or no Pmt protein is produced. Alternatively,the yeast could be transformed to produce an anti-Pmt agent, such as ananti-Pmt antibody. Alternatively, the yeast could be cultured in thepresence of a compound that inhibits the activity of one of the PMTgenes (Duffy et al, “Inhibition of protein mannosyltransferase 1 (PMT1)activity in the pathogenic yeast Candida albicans”, InternationalConference on Molecular Mechanisms of Fungal Cell Wall Biogenesis, 26-31Aug. 2001, Monte Verita, Switzerland, Poster Abstract P38). If a yeastother than S. cerevisiae is used, disruption of one or more (e.g.several) of the genes equivalent to the PMT genes of S. cerevisiae isalso beneficial, e.g. in Pichia pastoris or Kluyveromyces lactis. Thesequence of PMT1 (or any other PMT gene) isolated from S. cerevisiae maybe used for the identification or disruption of genes encoding similarenzymatic activities in other fungal species. The cloning of the PMT1homologue of Kluyveromyces lactis is described in WO 94/04687.

The variant polypeptides of the invention may be used for delivering atherapeutically beneficial compound (including prophylacticallybeneficial compound such as a vaccine) to an animal or a humanindividual in need thereof. Such therapeutically beneficial compoundsinclude, but are not limited to, labels and readily detectable compoundsfor use in diagnostics, such as various imaging techniques;pharmaceutical active compounds such as drugs, or specifically bindingmoieties such as antibodies. The variants of the invention may even beconnected to two or more (several) different therapeutically beneficialcompounds, e.g. an antibody and a drug, which gives the combinedmolecule the ability to bind specifically to a desired target andthereby provide a high concentration of the connected drug at thatparticular target.

The method may further comprise the step of purifying the polypeptiderecovered from the host cell and/or from the host cell growth medium.The purification step optionally comprises cell immobilisation, cellseparation and/or cell breakage, but always comprises at least one (e.g.several) other purification step different from the step or steps ofcell immobilisation, separation and/or breakage.

Thio-albumin of the invention may be purified from the culture medium byany technique that has been found to be useful for purifying suchproteins. Similarly, cell separation techniques, such as centrifugation,filtration (e.g. cross-flow filtration, expanded bed chromatography andthe like) are well known in the art. Likewise, methods of cell breakage,including beadmilling, sonication, enzymatic exposure and the like arewell known in the art.

The “at least one (e.g. several) other purification step” may be anyother step suitable for protein purification known in the art. Forexample purification techniques for the recovery of recombinantlyexpressed albumin have been disclosed in: WO 92/04367, removal ofmatrix-derived dye; EP 464590, removal of yeast-derived colorants; EP319067, alkaline precipitation and subsequent application of the albuminto a lipophilic phase; and WO 96/37515, U.S. Pat. No. 5,728,553 and WO00/44772, which describe complete purification processes; all of whichare incorporated herein by reference. Suitable methods include ammoniumsulphate or ethanol precipitation, acid or solvent extraction, anion orcation exchange chromatography, phosphocellulose chromatography,hydrophobic interaction chromatography, affinity chromatography,hydroxyapatite chromatography, lectin chromatography, concentration,dilution, pH adjustment, diafiltration, ultrafiltration, highperformance liquid chromatography (“HPLC”), reverse phase HPLC,conductivity adjustment and the like.

The polypeptide may be purified to a commercially or industriallyacceptable level of purity. By commercially or industrially acceptablelevel of purity, we include the provision of the thio-albumin and/orthio-albumin-conjugate in which other material (for example, one or more(e.g. several) contaminants) are present at a level of less than 50%,40%, 30%, 20%, 10%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.01%, 0.001%,0.0001%, 0.00001%, or 0.000001% and, most preferably at a level of 0%.

A commercially or industrially acceptable level of purity may beobtained by a relatively crude purification method by which the proteinproduct of choice is put into a form suitable for its intended purpose.A protein preparation that has been purified to a commercially orindustrially acceptable level of purity may, in addition to the proteinproduct of choice, also comprise, for example, cell culture componentssuch as host cells or debris derived therefrom. Alternatively, highmolecular weight components (such as host cells or debris derivedtherefrom) may or may not be removed (such as by filtration orcentrifugation) to obtain a composition comprising the protein productof choice and, optionally, a functionally acceptable level of lowmolecular weight contaminants derived from the cell culture process.

The protein may or may not be purified to achieve a pharmaceuticallyacceptable level of purity. A protein has a pharmaceutically acceptablelevel of purity if it is essentially pyrogen free and can be used forits intended purpose and hence be administered in a pharmaceuticallyefficacious amount without causing medical effects not associated withthe activity of the protein.

The thio-albumin and/or thio-albumin-conjugate may be provided at aconcentration of at least 10⁻⁴ g·L⁻¹, 10⁻³ g·L⁻¹, 0.01 g·L⁻¹, 0.02g·L⁻¹, 0.03 g·L⁻¹, 0.04 g·L⁻¹, 0.05 g·L⁻¹, 0.06 g·L⁻¹, 0.07 g·L⁻¹, 0.08g·L⁻¹, 0.09 g·L⁻¹, 0.1 g·L⁻¹, 0.2 g·L⁻¹, 0.3 g·L⁻¹, 0.4 g·L⁻¹, 0.5g·L⁻¹, 0.6 g·L⁻¹, 0.7 g·L⁻¹, 0.8 g·L⁻¹, 0.9 g·L⁻¹, 1 g·L⁻¹, 2 g·L⁻¹, 3g·L⁻¹, 4 g·L⁻¹, 5 g·L⁻¹, 6 g·L⁻¹, 7 g·L⁻¹, 8 g·L⁻¹, 9 g·L⁻¹, 10 g·L⁻¹,15 g·L⁻¹, 20 g·L⁻¹, 25 g·L⁻¹, 30 g·L⁻¹, 40 g·L⁻¹, 50 g·L⁻¹, 60 g·L⁻¹, 70g·L⁻¹, 80 g·L⁻¹, 90 g·L⁻¹, 100 g·L⁻¹, 150 g·L⁻¹, 200 g·L⁻¹, 250 g·L⁻¹,300 g·L⁻¹, 350 g·L⁻¹, 400 g·L⁻¹, 500 g·L⁻¹, 600 g·L⁻¹, 700 g·L⁻¹, 800g·L⁻¹, 900 g·L⁻¹, 1000 g·L⁻¹.

A method of the present invention may or may not further comprise thestep of formulating the purified protein product of choice with acarrier or diluent and optionally presenting the thus formulated proteinin a unit dosage form.

Although it is possible for a therapeutically useful protein obtained bya process of the invention to be administered alone, it is preferable topresent it as a pharmaceutical formulation, together with one or more(e.g. several) acceptable carriers or diluents. The carrier(s) ordiluent(s) must be “acceptable” in the sense of being compatible withthe desired protein. Typically, the carriers or diluents will be wateror saline which will be sterile and pyrogen free. Alternatively, amethod of the present invention may or may not further comprise the stepof lyophilising the thus purified protein product of choice.

The thio-albumin may be formulated by strategies given in “ProteinFormulation and Delivery”, E. J. McNally (Ed.), published by MarcelDekker Inc. New York 2000 and “Rational Design of Stable ProteinFormulations—Theory and Practice”; J. F. Carpenter and M. C. Manning(Ed.) Pharmaceutical Biotechnology Vol 13. Kluwer Academic/PlenumPublishers, New York 2002, Yazdi and Murphy, (1994), Cancer Research 54,6387-6394, Widera et al., (2003) Pharmaceutical Research 20, 1231-1238;Lee et al., (2005), Arch. Pharm. Res. 28, 722-729. Examples offormulation methods are as follows:

Method #1: Following purification the free thiol containing albuminmutein of the invention or the conjugate can be stored at 4° C., −20° C.or −80° C. in 0.01 M-0.1 M phosphate buffered saline (pH 7.0-8.0)containing 0.01 M-0.25 M NaCl.

Method #2: Following purification the free thiol containing albuminmutein of the invention or the conjugate can be stored at 4° C., −20° C.or −80° C. in 0.01 M-0.1 M phosphate buffered saline (pH 7.0-8.0)containing 0.01 M-0.25 M NaCl and containing 10-20 mg/L Polysorbate 80.

Method #3: Following purification the free thiol containing albuminmutein of the invention or the conjugate can be stored at 4° C., −20° C.or −80° C. in 0.01 M-0.25 M NaCl (pH 7.0-8.0).

Method #4: Following purification the free thiol containing albuminmutein of the invention or the conjugate can be stored at 4° C., −20° C.or −80° C. in 0.01 M-0.25 M NaCl (pH 7.0-8.0) containing 10-20 mg/LPolysorbate 80.

Freeze-Dried Formulations

Method #5: Following purification the free thiol containing albuminmutein of the invention or the conjugate can be dialysed against water,freeze dried and stored at 4° C., −20° C. or −80° C.

Method #6: Following purification the free thiol containing albuminmutein of the invention or the conjugate can be dialysed against 0.01M-0.25 M NaCl (pH 7.0-8.0), freeze dried and stored at 4° C., −20° C. or−80° C.

Conjugation Methods

A tenth aspect of the invention provides a method of producing theconjugate of the seventh aspect of the invention, the method comprisinglinking a polypeptide of the first, second or third aspect of theinvention, or produced by the method of the ninth aspect of theinvention, to a bioactive compound through a conjugation-competentcysteine residue of, the polypeptide. The linking may be carried outusing a linker.

The albumin mutein (thio-albumin) of the invention can be covalentlylinked to one or more (e.g. several) conjugation partners such asbioactive compounds by methods known in the art (for example thoseprovided by Pierce, Thermo Fisher Scientific, Rockford, Ill., USA;https://tools.lifetechnologies.com/content/sfs/brochures/1602163-Crosslinking-Reagents-Handbook.pdf).These include, but are not limited to incorporating or engineering athiol reactive group into or onto the conjugation partner, for exampleby incorporating or engineering another free thiol present on theconjugation partner; or by incorporating or engineering a pyridyldisulphide group on the conjugation partner; or by incorporating orengineering an haloacetyl group on the bioactive compound or byincorporating or engineering a maleimide group on the conjugationpartner, or by incorporating or engineering a thiosulfonate group on theconjugation partner, or by incorporating or engineering vinylsulfonegroup on the conjugation partner. For example, but not limited to,N-ethylmaleimide (NEM, Pierce), 2-amino-2′-aminoethanethiolsulfonate(Pierce), N-beta-maleimidoprpionic acid (BMPA Pierce), methyl methanethiosulfonate (MMTS, Pierce), fluorescein-5-maleimide (Pierce),5-iodoacetamido-fluorescein (5-IAF, Pierce) orN-[6-7-amino-4-methylcoumarin-3-acetamido) hexyl]-3′-[2′-pyridyldithio]propionamide (AMCA-HPDP, Pierce).

If the conjugation partner contains at least one (e.g. several) thiolgroup, then the conjugation partner may be cross-linked to the albuminmutein of the invention by methods known to the art such as, but notlimited to, oxidation or by the use of cross-linking reagents such as,but not limited to, 1,4-Bis-maleimidibutane (BMB, Pierce);1,4-Bis-maleimidyl-2,3-dihydroxybutane (BMDB, Pierce);Bis-maleimidohexane (BMH, Pierce), Bis-maleimidoethane (BMOE, Pierce);1,8-Bis-Maleimidotriethyleneglycol (BM[PEO]3 Pierce);1,11-Bis-Maleimidotetraethyleneglycol (BM[PEO]4 Pierce);1,4-DI-[3′-(2′-pyridyldithio)-propionamido]butane (DPDPB, Pierce);dithio-bis-maleimidoethane (DTME Pierce); 1,6-Hexane-bis-vinylsulfone(HBVS, Pierce) and Tris[2-maleimimidoethyl]amine (TMEA, Pierce).

If the conjugation partner does not contain a thiol reactive group thenit may be modified to incorporate one or more (e.g. several) such groupsby either chemical modification or genetic engineering by methods knowto the art (Chapman, A. P. (2002) Adv. Drug Deliv. Rev., 54 531-545:Humphreys, D. P. et al. Protein Engineering, Design & Selection vol. 20no. 5 pp. 227-234, 2007). While these two references describemethodologies to cross-link PEG to an engineered free thiol within anantibody or antibody fragment, the techniques may be used to cross-linka conjugation partner to an engineered free thiol within the albuminmutein of the invention. Alternatively the Drug Affinity Complex (DAC™)technology developed by ConjuChem Inc. (Montreal, Quebec, Canada, H2X3Y8) may be used, e.g. as described in WO 200069902. There are threeparts of each DAC™ construct: 1) the drug component (the portionresponsible for biologic activity); 2) a linker attached to the drugcomponent, and 3) a reactive chemistry group at the opposite end of thelinker, usually a soft electrophile selective for thiols; a maleimide isthe most useful embodiment. Other applicable conjugation methods aredescribed in WO 2007/071068 incorporated herein by reference.

If the conjugation partner does not contain a thiol reactive group butdoes contain one or more (e.g. several) amino groups then it may bemodified to incorporate one or more (e.g. several) thiol reactive groupsby chemical modification by methods known to the art such as the use ofcross-linking reagents such as, but not limited to,N-5-azido-2-nitrobenzoyloxysuccinimide (AMAS, Pierce),N-[beta-maleimidopropyloxy] succinimide ester (BMPS, Pierce),N-eta-maleimidocaproic acid (EMCA, Pierce),N-[eta-maleimidocaproyloxy]succinimide ester (EMCS, Pierce),N-[eta-maleimidocaproyloxy]sulfosuccinimide ester (sulfa-EMCS, Pierce),N-[gamma-maleimidobutyryloxy]succinimide ester (GMBS, Pierce),N-[gamma-maleimidobutyryloxy]sulfosuccinimide ester (sulfo-GMBS,Pierce), N-kappa-maleimidoundecanoic acid (KMUA, Pierce), N-[kappamaleimidoundecanoyloxy]sulfosuccinimide ester (sulfo-KMUS, Pierce),m-maleimidobenzoyl-N-hydroxysuccinimide (MBS, Pierce),m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester (sulfo-MBS, Pierce),N-succinimidyl S-acetylthio-acetate (SATA, Pierce), N-succinimidylS-acetylthiopropionate (SATP, Pierce), succinimidyl3-[bromoacetamido]propionate (SBAP, Pierce), N-succinimidyl iodoacetate(SIA, Pierce), N-succinimidyl[4-iodoacetyl]aminobenzoate (SIAB, Pierce),sulfosuccinimidyl[4-iodoacetyl]aminobenzoate (sulfo-SIAB, Pierce),succinimidyl [4[N-maleimidomethyl]cyclohexane-1-carboxylate (SMCC,Pierce), sulfosuccinimidyl[4-[N-maleimidomethyl]cyclohexane-1-carboxylate (sulfo-SMCC, Pierce),succinimidyl-[4-[N-maleimidomethyl]cyclohexane-1-carboxy-[6-amidocaproate(LC-SM CC, Pierce), 4-succinimidyloxycarbonyl-methyl-alpha[2-pyridyldithio]toluene (SMPT, Pierce),sulfosuccinimidyl6-[alpha-methyl-alpha-(2-pyridyldithio)toluamido]hexanoate(sulfo-LC-SMPT, Pierce), succinimidyl 4-[p-maleimidophenyl]-butyrate(SMPB, Pierce), sulfosuccinimidyl 4-[p-maleimidophenyl]-butyrate(sulfo-SMPB, Pierce),succinimidyl-6-[(beta-maleimidopropionamido)hexanoate] (SMPH, Pierce),N-succinimidyl 3-[2-pyridyld ithio]propionate (SP DP, Pierce),succinimidyl [3-(2-pyridyldithio)propionamido]hexanoate (LC-SPDP,Pierce), sulfosuccinimidyl [3′-(2-pyridyldithio)propionamido]hexanoate(sulfo-LC-SPDP, Pierce) and N-succinimidyl-[4-vinylsulfonyl]benzoate(SVSB Pierce). It may be advantageous to block certain amine residue asdescribed by Kavimandan et al., (2006), Bioconjugate Chem. 17,1376-1384.

Suitable linkers include bromomaleimide linkers such asmonobromomaleimide linkers. Monobromomaleimides are next generationmaleimides for the construction of stable conjugates, as described inSmith et al Organic & Biomolecular Chemistry, (2015), 13, pages7946-7949. Preferred monobromomaleimide linkers include those describedin WO 2011/018611 (incorporated herein by reference).

If the conjugation partner does not contain a thiol reactive group butdoes contain one or more (e.g. several) carbonyl (oxidised carbohydrate)groups then it can be modified to incorporate one or more (e.g. several)thiol reactive groups by chemical modification by methods known to theart such as the use of cross-linking reagents such as, but not limitedto, (N-β-maleimidopropionic acid hydrazide (BMPH, Pierce)N-[eta-maleimidocaproic acid]hydrazide (EMCH, Pierce),4-[N-maleimidomethyl]cyclohexane-1carboxylhydrazide.HCl.1/2 dioxane(MMCCH, Pierce), 3-maleimidophenyl boronic acid (MPBH, Pierce),N-[kappa-maleimidoundecanoic acid]hydrazide (KMUH, Pierce) and3-[2-pyridyldithio]propionyl hydrazide (PDPH, Pierce).

If the conjugation partner does not contain a thiol reactive group butdoes contain one or more (e.g. several) hydroxyl groups then it may bemodified to incorporate one or more (e.g. several) thiol reactive groupsby chemical modification by methods known to the art such as the use ofcross-linking reagents such as, but not limited to,N-[p-maleimidophenyl]isocyanate (PMPI, Pierce).

Associates

An eleventh aspect of the invention provides an associate comprising theconjugate of the seventh aspect of the invention and a bioactive,therapeutic, prophylactic, diagnostic, imaging or other beneficialmoiety.

The conjugates may further be used in the form of “associates”. In thisconnection the term “associate” is intended to mean a compoundcomprising a conjugate of a variant of albumin or a fragment thereof andanother compound bound or associated to the conjugate by non-covalentbinding. As an example of such an associate can be mentioned anassociate consisting of a variant albumin conjugate and a lipidassociated to albumin by a hydrophobic interaction. Such associates areknown in the art and they may be prepared using well known techniques.As an example of a preferred associate according to the invention can bementioned, an associate comprising a variant albumin conjugate and ataxane, a taxol or taxol derivative (e.g. paclitaxel). Further examplesof associates comprise a bioactive, therapeutic, prophylactic (includingvaccine), diagnostic, imaging or other beneficial moiety.

Methods for the preparation of associates are well-known to the skilledperson, for example, formulation (by association) of HSA withlipo-compounds is described in Hussain, R. and Siligardi, G. (2006),International Journal of Peptide Research and Therapeutics, Vol. 12, NO:3, pp. 311-315.

Nanoparticle, Microparticle or Liposome

A twelfth aspect of the invention provides a nanoparticle, amicroparticle or a liposome comprising the polypeptide or the first,second or third aspect of the invention, the conjugate of the seventhaspect of the invention or the associate of the eleventh aspect of theinvention.

Albumins and albumin particles are important for carrying and deliveringdrugs and prodrugs to their sites of action (Kratz (2008), Journal ofControlled Release, 132 (3), p. 171-183). Fusion and particletechnologies offer improved dosing regimens due to improvedpharmacokinetic properties, such as plasma half-life extension, and mayimprove bioavailability and protect the fused bioactive molecule frominactivation.

Techniques for incorporation of a molecule into nano- or microparticlesare known in the art. Preferred methods for preparing nano- ormicroparticles that may be applied to the variant albumin conjugate orassociate thereof according to the invention are disclosed in WO2004/071536 or WO 2008/007146 or Oner & Groves (Pharmaceutical Research,Vol 10(9), 1993, pages 1387 to 1388) which are incorporated herein byreference. Preferably the average diameter of a nano-particle is from 5to 1000 nm, more preferably from 5, 10, 20, 30, 40, 50, 80, 100, 130,150, 200, 300, 400, 500, 600, 700, 800, 900, or 999 to 5, 10, 20, 30,40, 50, 80, 100, 130, 150, 200, 300, 400, 500, 600, 700, 800, 900, or1000 nm. An advantage of a microparticle less than 200 nm diameter, andmore particularly less than 130 nm, is that is amenable to sterilizationby filtration through a 0.2 μm (micron) filter. Preferably, the averagediameter of a microparticle is from 1000 nm (1 μm (micron)) to 100 μm(micron), more preferably from 1, 2, 5, 10, 20, 30, 40, 50, 60, 70, 80,90, 100 to 1, 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 μm (micron).

The thio-albumin of the invention (and/or its conjugated form) may beused to produce nanoparticles and/or be entrapped within a nanoparticleor liposome.

The thio-albumin of the invention may be used with and/or in and/or as ananoparticle and/or liposome. A problem of current conjugationstrategies is maintaining both the pharmacological and immunologicalactivity of the conjugation partner, such as a bioactive-targetingligand conjugate. There is likely to be a maximum number of proteintargeting ligand or bioactive moieties (conjugation partners) possiblefor conjugation to a protein and if this number is exceeded thetargeting ligand does not retain its biological activity. Preferably thebiological activity of the conjugation partner is not reduced byconjugation to an albumin of the invention.

Liposomes and nanoparticles may be used to entrap bioactive compounds.They provide a mechanism for enhanced delivery of drugs such asbioactive compounds, or uptake by target cells and/or a reduction in thetoxicity of the free bioactive to non-target organs which may result inan increased therapeutic index and/or reduced side effects. In addition,many solvent-based formulations required for the delivery of somebioactive compounds (e.g. taxanes) are associated with toxicity whichlimits the maximum dose which can be given to a patient. Liposome andnanoparticle delivery may also be advantageous for such bioactivecompounds, since they would allow larger amounts of the bioactivecompound to be delivered whilst avoiding some of the toxicities ofsolvent-based formulations (Hawkins et al (2008), Advanced Drug DeliveryReviews, 60, 8, p876-885).

Methods for attaching targeting ligands to liposomes and nanoparticlesare known in the art (reviewed in Nobs et al (2004), Journal ofPharmaceutical Sciences Vol 93 p1980-1992) and may be used in accordancewith the invention. Attachment methods may be non-covalent or covalent.Covalent reactions appear to be favourable, because covalent linkage ismore stable than noncovalent methods. Lipids for the covalent ornon-covalent attachment of proteins, peptides, or drugs to the liposomesurface are available commercially (for example Avanti Polar Lipids IncAlabaster, Ala., USA). There are 3 major classes of functionality:conjugation through disulphide or thioether formation, amide bondformation, or biotin/streptavidin binding, any of these may be used inthe invention.

A number of methods relying on covalent coupling ligands to the surfaceof liposomes via thioether bonds have been described, most commonlyutilizing the highly efficient reaction of maleimide with thiol groups.Functionalized lipid anchors commonly added to liposomes, and which maybe used in or with the invention, include, but are not limited to thosecontaining maleimide such as N-[4-(p-maleimidophenyl) butyramide]-PE(N-MPB]-PE) or N-[4-(p-maleimidomethyl) cyclohexane-carboxamide)(MCC-PE) which allow convenient covalent coupling of the targetingmoiety via a stable thioether bond (Martin & Papahadjopoulos (1982), J.Biol. Chem. 257, 286-288).

Method #7: Following purification the free thiol containing albuminmutein of the invention or the conjugate can be formulated intonanoparticles prepared according to known procedures for preparingnanoparticles, such as procedures disclosed in WO 2004/071536 A1 and WO2008/007146 A1, both incorporated herein by reference.

Similarly materials for the formation of nanoparticles, including butare not limited to poly(lactic acid) (PLA), poly(lactic-co-glycolicacid) (PLGA), and COOH-PLA are commercially available and may befunctionalized with maleimide or other known chemistries according toknown literature for nanoparticle formation. Any of these may be used inor with the invention.

Another convenient way for covalent coupling of ligands to liposomesinvolves conjugation of two thiols to form a disulphide; however underthe reductive conditions in serum more stable conjugation chemistriesinvolving one free thiol group may be preferred. Chemistries such as(PDP-PE) allow covalent coupling via a disulphide bond. Modification ofthe ligand to introduce a free thiol group or a functionalized linkermay be used. An advantage of the thio-albumin of the invention is thatno ligand modification is required. However, ligand modification mayoptionally be used in addition to the invention.

Frequently thiol groups are not present in proteins, or are not presentin sufficient amounts or at the desired location. Thus, most cases ofcovalent coupling of one of more ligands to a liposome via thioether ordisulphide bonds requires the use of heterobifunctional cross linkingagents (described herein with reference to conjugation). Someheterobifunctional cross linking agents (such as SPDP and SATA) requirea de-protection step. The thio-albumin of the invention overcomes therequirement for this additional processing.

Alternatively thio-albumin could be conjugated to liposomes ornanoparticles by other chemistries, known to the art. For example,thio-albumin could be attached by an amide bond using a functionalisedlipid anchor with either amine or carboxyl functional groups (examplesinclude DSPE-PEG-COOH) which reacts with the primary amine of theligand. Direct cross linking between primary amines and the surface ofliposomes may also be used. The one or more (e.g. several) free thiolgroups of thio-albumin would then be available for conjugation toanother conjugation partner.

Following conjugation, a conjugation partner (e.g. bioactive molecule)may show a reduction in its activity (e.g. bioactivity). Thio-albumindescribed in this invention may overcome this problem by providing aconjugate, nanoparticle and/or liposome in which the conjugation partneris located and/or orientated with respect to a thio-albumin such thatthe conjugation partner retains at least 10, 20, 30, 40, 50, 60, 70, 80,90 or 100% of its unconjugated activity.

Nanoparticles may be used, for example, in angiogenic applications,anti-angiogenic applications and to coat a medical device such as astent. Nanoparticles are effective at targeting, for example to nontight-junctions, and therefore can be useful for targeting tumours suchas cancerous tumours. Nanoparticles can also be useful to target antigenin order to provoke an immune response since nanoparticles areparticularly susceptible to engulfment and presentation by phagocytes.The invention provides nanoparticles consisting only of thio-albuminaccording to the invention which may or may not be conjugated to amoiety (conjugation partner). The invention also provides nanoparticlescomprising thio-albumin according to the invention, which may or may notbe conjugated to a moiety, and one or more (e.g. several) otherconstituents of a nanoparticle which may or may not be albumin related.In a preferred embodiment, a thio-albumin according to the inventioncomprises at least two conjugation competent cysteine residues locatedon the surface of the polypeptide. Such a thio-albumin may be used forthe preparation of nanoparticles in which one or more (e.g. several)conjugation competent cysteine residues may be used in the formation ofa nanoparticle and one or more (e.g. several) conjugation competentresidues is used for conjugation to a conjugation partner, for exampleto a bioactive molecule.

Compositions

A thirteenth aspect of the invention provides a composition comprising apolypeptide, fusion polypeptide, conjugate, associate, nanoparticle,microparticle or liposome according to the invention and at least one(e.g. several) pharmaceutically acceptable carrier and/or diluent.

Various formulations are described herein in relation to thecorresponding products.

A related aspect of the invention provides a method for making apharmaceutical ingredient and/or a pharmaceutical product comprisingmaking a thio-albumin according to the present invention, optionallyconjugating a further molecule to the thio-albumin, optionallyformulating the resultant conjugate with a pharmaceutically acceptablediluent and/or carrier and optionally preparing the product in unitdosage form.

Medical Uses

A fourteenth aspect of the invention provides use of a polypeptide,fusion polypeptide, conjugate according to the invention and/or producedby a method according to the invention, or an associate, nanoparticle,microparticle or liposome for treatment of disease, treatment of illnessand/or diagnosis.

Various medical uses are described herein in relation to thecorresponding products.

In addition, in some embodiments, the thio-albumin or conjugate has abinding affinity to FcRn and/or plasma half-life that is alteredcompared to the parent or reference albumin or conjugate. This has theadvantage that the binding affinity to FcRn and/or plasma half-life ofconjugates, associates, nanoparticle, microparticle or liposomeaccording to the invention can be selected in accordance with theparticular therapeutic purpose. An increased half-life could have thebenefit that the administration would be needed less frequently or at areduced dose (and consequently with fewer side effects) compared to thesituation where the reference molecule or composition was used.Alternatively, a shorter plasma half-life than the reference molecule orcomposition would have the benefit that the administration can becarried out at a higher dose compared to the situation where thereference molecule or composition was used with the benefit that theadministered compound clears from the recipient more quickly than if thereference molecule or composition was used.

For example for a conjugate, associate or fusion polypeptide used forimaging purposes in animals or humans, where the imaging moiety has avery short half-life and a conjugate or a fusion polypeptide comprisingHSA has a plasma half-life that is far longer than needed for theimaging purposes it would be advantageous to use a variant albumin orfragment thereof of the invention having a shorter plasma half-life thanthe parent or reference albumin or fragment thereof, to provideconjugates or fusion polypeptides having a plasma half-life that issufficiently long for the imaging purpose but sufficiently short to becleared form the body of the particular patient on which it is applied.

In another example for a conjugate, an associate or fusion polypeptidecomprising a therapeutic compound effective to treat or alleviate aparticular condition in a patient in need for such a treatment it wouldbe advantageous to use the variant albumin or fragment thereof having alonger plasma half-life than the parent or reference albumin or fragmentthereof, to provide associates or conjugates or fusion polypeptideshaving longer plasma half-lives which would have the benefit that theadministration of the associate or conjugate or fusion polypeptide ofthe invention would be needed less frequently or at reduced dose withless side effects compared to the situation where the parent orreference albumin or associates thereof or fragment thereof was used.For example, the invention provides a method of treating a proliferativedisease in an individual, comprising administering the individual aneffective amount of an associate according to the invention in which theassociate comprises a taxane, a taxol or taxol derivative (e.g.paclitaxel).

Use to Increase Half-Life

A fifteenth aspect of the invention provides for use of a polypeptide asdefined in any previous aspect of the invention to increase thehalf-life of a molecule such as a bioactive agent, an imaging agent, adiagnostic agent, a contrast agent or a therapeutic compound such as achemotherapeutic drug or radiopharmaceutical. Preferably, the half-lifeis increased by at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or at least100% relative to the half-life of the molecule alone. Preferably, thehalf-life is increased by at least 2, 4, 6, 8, 10, 12, 14, 16, 18, 20,22 hours or by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or atleast 14 days relative to the half-life of the molecule alone.

For example, the half-life of a molecule may be increased by conjugatingit to the polypeptide as defined in any previous aspect of the inventionfor example via a conjugatable cysteine residue; by genetically fusingthe molecule to the polypeptide, by associating the molecule with thepolypeptide and/or by incorporating it into a particle according to anyprevious aspect of the invention.

Embodiments of the Invention

The invention is further described with reference to the followingnumbered paragraphs:1. A conjugation-competent polypeptide comprising an amino acid sequencewhich is at least 70% identical to human albumin, particularly residues1 to 585 of the mature human albumin polypeptide sequence of SEQ ID NO.2, or a fragment thereof;

wherein at least one (e.g. several) position equivalent to a positionselected from K93, E294, A226, E230, 1271, E358, L24, F49, V54, D56,L66, A92, Q94, E97, H128, F156, E227, D237, K240, D259, K262, N267,0268, L275, E277, L284, E311, K317, A322, E333, D340, E354, K359, A362,E382, and L398, particularly from K93, E294, A226, E230, and 1271, ofSEQ ID NO. 2 comprises a conjugation-competent cysteine residue; and

preferably wherein the conjugation-competent polypeptide has a tendencyto exist as a monomer in solution which is at least 70% of the tendencyof the polypeptide of SEQ ID NO. 2 to exist as a monomer in solution.

2. The conjugation-competent polypeptide of Paragraph 1, wherein thepolypeptide comprises one or more (e.g. several) of:

substitution of an amino acid, other than cysteine, with a cysteine at aposition corresponding to a position equivalent to any of residues K93,E294, A226, E230, 1271, E358, L24, F49, V54, D56, L66, A92, Q94, E97,H128, F156, E227, D237, K240, D259, K262, N267, Q268, L275, E277, L284,E311, K317, A322, E333, D340, E354, K359, A362, E382, and L398,particularly from K93, E294, A226, E230, and 1271, of SEQ ID NO. 2;and/or

insertion of a cysteine at a position adjacent the N- or C-side of anamino acid corresponding to a position equivalent to any of residuesK93, E294, A226, E230, 1271, E358, L24, F49, V54, D56, L66, A92, Q94,E97, H128, F156, E227, D237, K240, D259, K262, N267, Q268, L275, E277,L284, E311, K317, A322, E333, D340, E354, K359, A362, E382, and L398,particularly from K93, E294, A226, E230, and 1271, of SEQ ID NO. 2.

3. The conjugation-competent polypeptide of Paragraph 1 or 2 whereintwo, three, four, five or more (e.g. several) positions equivalent topositions selected from K93, E294, A226, E230, I271, E358, L24, F49,V54, D56, L66, A92, Q94, E97, H128, F156, E227, D237, K240, D259, K262,N267, Q268, L275, E277, L284, E311, K317, A322, E333, 0340, E354, K359,A362, E382, and L398, particularly from K93, E294, A226, E230, and 1271,of SEQ ID NO. 2 comprise a conjugation-competent cysteine residue.4. The conjugation-competent polypeptide of any preceding Paragraph,wherein the polypeptide has a tendency to exist as a monomer in solutionwhich is at least 75%, at least 80%, at least 85%, at least 90%, atleast 95% or at least 100% of the tendency of the polypeptide of SEQ IDNO. 2 to exist as a monomer in solution.5. The conjugation-competent polypeptide of any preceding Paragraphwherein the tendency of the polypeptide to exist as monomer in solutionis measured following storage for at least 7 weeks at a temperature from2 to 8° C. such as 5° C., at least 8 weeks at a temperature from 2 to 8°C. such as 5° C., at least 3 months at a temperature from 2 to 8° C.such as 5° C., at least 4 months at a temperature from 2 to 8° C. suchas 5° C., at least 6 months storage at a temperature from 2 to 8° C.such as 5° C., or at least 3 months storage at a temperature of about40° C.6. The conjugation-competent polypeptide of Paragraph 5 wherein thetendency of the polypeptide to exist as monomer in solution is measuredfollowing storage for at least 3 months at a temperature from 2 to 8°C., such as 5° C.7. The conjugation-competent polypeptide of paragraph 5 or 6, prior tostorage, wherein the polypeptide is purified using triazine (such asAlbuPure®) chromatography matrix or DE-FF chromatography matrix prior tostorage.8. The conjugation-competent polypeptide of any of paragraphs 5, 6, or 7wherein, prior to storage, the polypeptide is purified using triazine(such as AlbuPure®) chromatography matrix followed by DE-FFchromatography matrix.9. The conjugation-competent polypeptide of any of paragraphs 5 to 8wherein, prior to storage, the polypeptide is purified using triazine(such as AlbuPure®) chromatography matrix followed by DE-FFchromatography matrix followed by size exclusion (e.g size exclusionlimit (Mr) of about 5×10³ to 2.5×10⁵ such as Sephacryl 5-200 HR)chromatography.10. The conjugation-competent polypeptide of any of Paragraphs 5 to 9wherein the storage uses a polypeptide concentration of from 0.5 to 50mg/mL.11. The conjugation-competent polypeptide of any of Paragraphs 5 to 10wherein the storage uses a polypeptide concentration of about 5 mg/mL.12. The conjugation-competent polypeptide of any of Paragraphs 5 to 11wherein the storage is at a pH between about 6.0 and about 7.5.13. The conjugation-competent polypeptide of any of Paragraphs 5 to 12wherein the storage is at a pH about 7.14. The conjugation-competent polypeptide of any of Paragraphs 5 to 13wherein the storage uses a buffer comprising 50 mM ammonium acetate, 10mM sodium octanoate, pH 7.0, preferably at a polypeptide concentrationof from about 0.2 to about 2.5 mg/mL.15. The conjugation-competent polypeptide of any of Paragraphs 5 to 14wherein the storage, uses a buffer comprising 25 mM sodium phosphate,215 mM sodium chloride, pH 6.5, preferably at a polypeptideconcentration of from about 5 to about 50 mg/mL.16. The conjugation-competent polypeptide of any preceding Paragraph,wherein at least one (e.g. several) position equivalent to a positionselected from K93, E294, A226, E230, I271, E358, L24, F49, V54, D56,A92, Q94, E97, H128, F156, E227, D237, K240, D259, K262, N267, Q268,L275, L284, K317, A322, E333, D340, E354, K359, A362, E382, and L398,particularly from K93, E294, A226, E230, and 1271, of SEQ ID NO. 2comprises a conjugation-competent cysteine residue; and wherein thetendency to exist as monomer in solution is at least 75% of the tendencyof the polypeptide of SEQ ID NO. 2 to exist as a monomer in solution.17. The conjugation-competent polypeptide of any preceding Paragraphwherein the amino acid sequence is at least 95% identical to humanalbumin, particularly residues 1 to 585 of the mature human albuminpolypeptide sequence of SEQ ID NO. 2, or a fragment thereof and theconjugation-competent polypeptide has a tendency to exist as a monomerin solution which is at least 80% of the tendency of the polypeptide ofSEQ ID NO. 2 to exist as a monomer in solution.18. The conjugation-competent polypeptide of any preceding Paragraph,wherein at a position equivalent to position 34 of SEQ ID NO. 2 there isa conjugation-competent cysteine.19. The conjugation-competent polypeptide of any of Paragraphs 1 to 18,wherein at a position equivalent to position 34 of SEQ ID NO. 2 there isnot a conjugation-competent cysteine.20. The conjugation-competent polypeptide of any preceding Paragraph inwhich the polypeptide comprises two or more (several)conjugation-competent cysteine residues wherein, when the polypeptide isfolded, there is a distance of at least 5 Å between at least one pair ofthe conjugation-competent cysteine residues.21. The conjugation-competent polypeptide of any preceding Paragraph,wherein the polypeptide comprises substitution of an amino acid, otherthan cysteine, with a cysteine at one or both positions corresponding toa position equivalent to residues K93 or E294 of SEQ ID NO. 2.22. The conjugation-competent polypeptide of any preceding Paragraphwhich is capable of forming a conjugate withmaleimide-polyethylenglycol2-biotin, at a conjugation efficiency of atleast 90%, preferably at least 95%, suitably wherein the conjugate is at90%, preferably at least 95% stable upon controlled hydrolysis.23. The conjugation-competent polypeptide of Paragraph 22 wherein thecapability of forming a conjugate withmaleimide-polyethylenglycol2-biotin is determined by incubating atambient temperature overnight in phosphate buffered saline buffer pH7.4.24. The conjugation-competent polypeptide of Paragraph 22 or 23 whereinstability is determined by incubating at pH 9.0 and 37° C. for at least18 hours, preferably 24 hours, in a buffered salts solution, such asphosphate buffered saline.25. A conjugation-competent polypeptide comprising an amino acidsequence which is at least 70% identical to human albumin (SEQ ID NO.2), or a fragment thereof;

wherein at least one (e.g. several) position equivalent to a positionselected from K93, E294, A226, E230, 1271, E358, L24, F49, V54, D56,L66, A92, Q94, E97, H128, F156, E227, D237, K240, D259, K262, N267,Q268, L275, E277, L284, E311, K317, A322, E333, D340, E354, K359, A362,E382, and L398, particularly from K93, E294, A226, E230, and 1271, ofSEQ ID NO. 2 comprises a conjugation-competent cysteine residue; and

comprising at least one (e.g. several) further conjugation-competentcysteine, or at least one (e.g. several) modification that alters thebinding affinity of the polypeptide for FcRn, or alters the plasmahalf-life of the polypeptide.

26. The conjugation-competent polypeptide of Paragraph 25 wherein the atleast one (e.g. several) further modification comprises at least one(e.g. several) further conjugation-competent cysteine as defined in anyone of Paragraphs 1, 2, 3 or 21.27. The conjugation-competent polypeptide of any preceding Paragraphwherein at least one (e.g. several) position equivalent to a positionselected from D1, A2, H3, S5, A55, S58, C75, T76, T79, E82, T83, E86,C91, D121, V122, C124, T125, D129, C169, C177, A229, T236, E266, D269,S270, S273, S304, K313, D314, 0316, N318, A320, C361, A364, C369, A371,N386, Q390, Q397, S435, T478, T496, A504, E505, T506, T508, D549, C558,D562, C567, A581, L585 and A578 of SEQ ID NO. 2 comprises aconjugation-competent cysteine.28. The conjugation-competent polypeptide of any preceding Paragraph inwhich the polypeptide comprises one or more (e.g. several) of:

substitution of an amino acid, other than cysteine, with a cysteine at aposition corresponding to a position equivalent to any of residues D1,A2, H3, S5, A55, S58, C75, T76, T79, E82, T83, E86, C91, D121, V122,C124, T125, D129, C169, C177, A229, T236, E266, D269, S270, S273, S304,K313, D314, 0316, N318, A320, C361, A364, C369, A371, N386, Q390, Q397,5435, T478, T496, A504, E505, T506, T508, D549, C558, D562, C567, A581,L585 and A578 of SEQ ID NO. 2; and/or

insertion of a cysteine at a position adjacent the N- or C-side of anamino acid corresponding to a position equivalent to any of residues D1,A2, H3, S5, A55, S58, C75, T76, T79, E82, T83, E86, C91, D121, V122,C124, T125, D129, C169, C177, A229, T236, E266, D269, S270, S273, S304,K313, D314, C316, N318, A320, C361, A364, C369, A371, N386, Q390, Q397,5435, T478, T496, A504, E505, T506, T508, D549, C558, D562, C567, A581,L585 and A578 of SEQ ID NO. 2; and/or

deletion or substitution of a cysteine at a position corresponding toany of C360, C316, C75, C168, C558, C361, C91, C124, C169 and 0567 ofSEQ ID NO. 2 so as to generate a conjugation competent cysteine at anyof C369, 0361, C91, C177, C567, C316, C75, C169, C124 and C558; and/or

addition of a cysteine to the N-side of the N-terminal residue of analbumin sequence or to the C-side of the C-terminal residue of analbumin sequence.

29. The conjugation-competent polypeptide of any preceding Paragraph inwhich the polypeptide comprises conjugation-competent cysteines locatedat: (a) A2+L585, (b) A2+A364+D562+L585C, (c) A2 and adjacent the C-sideof the C-terminus of the albumin (d) T79+A364; (e) A364+D1; (f)T79+D562+A364; (g) D562+A364+D1; (h) T79+D562+A364+A504; (i)T79+D562+A364+L585; (j) T79+D562+A364+D1; (k) T79+D562+A364+L585+D1; (I)E86+D562+A364+A504+A2; (m) S270+A581; (n) 5270+D129; (o) 5270+A581+E82;(p) S270+A581+D129; (q) 5270+A581+E82+D129; (r) S270+A581+E82+D129+Q397;(s) C369+C177; (t) A364+A581; (u) T79+A364+A581; (v) A364+A581+D129; (w)A364+C177; (x) D562+C369; (y) D129+C369; (z) A581+C369; or (aa)D562+D129+C369.30. The conjugation-competent polypeptide of any preceding Paragraphwhich comprises or consists of albumin domain III or a variant thereofand at least one (e.g. several) additional albumin domain or fragmentthereof, such as a second albumin domain III or a variant thereof.31. The conjugation-competent polypeptide of any preceding Paragraphwhich comprises or consists of at least one (e.g. several) albumindomain III or variant or fragment thereof wherein at least one (e.g.several) albumin domain III comprises one or more (e.g. several)substitutions in positions corresponding to the positions in SEQ ID NO.2 selected among: 573, 500, 550, 417, 440, 464, 490, 492, 493, 494, 495,496, 499, 501, 503, 504, 505, 506, 510, 535, 536, 537, 538, 540, 541,542, 574, 575, 577, 578, 579, 580, 581, 582 and 584.32. The conjugation-competent polypeptide of Paragraph 31, wherein theone or more (e.g. several) substitutions in positions corresponding tothe positions in SEQ ID NO. 2 is selected among: K573Y, W, P, H, F, V,I, T, N, 5, G, M, C, A, E, Q, R, L, D, K500E, G, D, A, S, C, P, H, F, N,W, T, M, Y, V, Q, L, I, R, Q417A, H440A, H464Q, E492G, D494N,Q,A,E495Q,A, T496A, D494E+Q417H, D494N+T496A, E492G+V493P, P499A, E501A,Q,N503H,K, H510Q, H535Q, K536A, P537A, K538A, K541G,D, D550E,N,E492G+K573P,A, or E492G/N503H/K573P.33. The conjugation-competent polypeptide of any preceding Paragraphwherein the polypeptide comprises alterations at two or more (e.g.several) positions selected from positions corresponding to positions(a) 492 and 580; (b) 492 and 574; (c) 492 and 550; (d) 550 and 573; (e)550 and 574; (f) 550 and 580 in SEQ ID NO. 2.34. The conjugation-competent polypeptide of any preceding Paragraphcomprising: (i) an N-terminal region comprising a first albumin which isa human albumin variant, in which the N-terminal of the first albumincomprises all amino acids of the human albumin variant except theC-terminal 2 to 30 amino acids; and(ii) a C-terminal region of a second albumin, which is selected frommacaque albumin, mouse albumin, rabbit albumin, sheep albumin, humanalbumin, goat albumin, chimpanzee albumin, hamster albumin, guinea pigalbumin, rat albumin, cow albumin, horse albumin, donkey albumin, dogalbumin, chicken albumin, or pig albumin, or a variant thereof, in whichthe C-terminal of the second albumin or albumin variant comprises theC-terminal 2 to 30 amino acids of the second albumin or albumin variant;wherein the polypeptide has (i) an altered plasma half-life comparedwith the human albumin variant and/or (ii) an altered binding affinityto FcRn compared with the human albumin variant.35. The conjugation-competent polypeptide of any preceding Paragraphcomprising one or more (e.g. several) alterations in Domain I of themature human albumin polypeptide sequence of SEQ ID NO. 2; and one ormore (e.g. several) alterations in Domain III of the mature humanalbumin polypeptide sequence of SEQ ID NO. 2, wherein the one or more(e.g. several) alterations cause the polypeptide to have an alteredbinding affinity to FcRn.36. The conjugation-competent polypeptide of Paragraph 35 wherein thealteration(s) in Domain I are selected from positions corresponding toany of positions 78 to 120 of SEQ ID NO. 2, such as any of positions 78to 88 and/or from any of 105 to 120; and the alteration(s) in Domain IIIare selected from positions corresponding to any of positions 425, 505,510, 512, 524, 527, 531, 534, 569, 573, or 575 of SEQ ID NO. 2.37. The conjugation-competent polypeptide of Paragraph 36 wherein thealteration at the position corresponding to positions is selected among78 to 120 or 425, 505, 510, 512, 524, 527, 531, 534, 569, 573, and/or575 of SEQ ID NO. 2 is a substitution; and the alteration is optionallya substitution selected from (i) 83N, K or S; (ii) 111D, G, H, R, Q orE; or (iii) 573P, Y, W, H, F, T, I or V.38. The conjugation-competent polypeptide of any preceding Paragraphcomprising one or more (e.g. several) alterations in Domain II of themature human albumin polypeptide sequence of SEQ ID NO. 2 selected fromthe group consisting of positions corresponding to positions 349, 342,381, 345, 384, 198, 206, 340, 341, 343, 344, 352, 382, 348, and/or 383in SEQ ID NO. 2; wherein the one or more (e.g. several) alterationscauses the conjugation-competent polypeptides to have (i) an alteredplasma half-life and/or (ii) an altered binding affinity to FcRn.39. The conjugation-competent polypeptide of Paragraph 38 wherein thealteration at the position corresponding to position 349, 342, 381, 345,384, 198, 206, 340, 341, 343, 344, 352, 382, 348, and/or 383 is asubstitution; and the alteration is optionally a substitution selectedfrom (i) 349F, W, Y, H, P, K or Q, preferably F; (ii) 342Y, W, F, H, T,N, Q, A, C, I, L, P, V, preferably Y; (iii) 381G or A, preferably G; or(iv) 345E, H, I or Q.40. The conjugation-competent polypeptide of any preceding Paragraphcomprising one or more (e.g. several) alterations in the mature humanalbumin polypeptide sequence of SEQ ID NO. 2 selected from the groupconsisting of positions corresponding to positions V418, T420, V424,E505, V547, K573 in SEQ ID NO. 2; wherein the one or more (e.g. several)alterations causes the conjugation-competent polypeptides to have (i) analtered plasma half-life and/or (ii) an altered binding affinity toFcRn.41. The conjugation-competent polypeptide of any preceding Paragraphcomprising one or more (e.g. several) alterations in the mature humanalbumin polypeptide sequence of SEQ ID NO. 2 selected from the groupconsisting of positions corresponding to positions V381, preferablyV381N or Q; E383, preferably E383A, G, I, L, or V; N391, preferablyN391A, G, I, L or V; Y401 preferably Y401D or E; K402, preferably K402A,G, I, L, or V; L407, preferably L407F, N, Q, W, or Y; Y411, preferablyY411Q, or N; K413, preferably K4130, S, or T; K414, preferably K414S orT; V415C, preferably V415C, S, or T; Q416, preferably Q416H or P; V424,preferably V424A, G, I, L, N, or Q; V426D, preferably V426D, E, H, or P;G434, preferably G434C, S, or T; E442, preferably E442K or R; R445,preferably R445F, W or Y; P447, preferably P447S or T; E450, preferablyE450D or E; S454, preferably S454C, M or T; V455, preferably V455N or Q;V456, preferably V456N or Q; L457, preferably L457F, W or Y; Q459,preferably Q459K or R; L463, preferably L463N or Q; E495, preferablyE495D; T506, preferably T506F, W or Y; T508, preferably T508K, R, or S;F509, preferably F5090, I, L, M, V, W or Y; A511, preferably A511F, W,or Y; D512, preferably D512F, W or Y; T515, preferably T515C, H, N, P, Qor S; L516, preferably L516F, S, T, W or Y; S517, preferably S517C, F,M, T, W or Y; K519, preferably K519A, G, I, L, or V; R521, preferablyR521F, W or Y; 1523, preferably I523A, D, E, F, G, K, L, N, Q, R, V, Wor Y; K524, preferably K524A, G, I, L or V; K525, preferably K525A, G,1, L or V; Q526, preferably Q526C, M, S, T or Y; T527, preferably T527F,W or Y; E531, preferably E531A, G, I, L or V; H535, preferably H535D, Eor P; K538, preferably K538F, W or Y; A539, preferably A5391, L or V;K541, preferably, K541F, W or Y; K557, preferably K557A, G, 1, L or V;A561, preferably A561F, W or Y; T566, preferably T566F, W or Y; A569,preferably A569H or P in SEQ ID NO. 2; wherein the one or more (e.g.several) alterations causes the conjugation-competent polypeptides tohave (i) an altered plasma half-life and/or (ii) an altered bindingaffinity to FcRn.42. The conjugation-competent polypeptide of any preceding Paragraphcomprising one or more (e.g. several) alterations in the mature humanalbumin polypeptide sequence of SEQ ID NO. 2 selected from the groupconsisting of positions corresponding to positions V547, preferablyV457A; K573, preferably K573P or Y; 1523, preferably I523A or G, T527,preferably T527M, K500, preferably K500A; or E505, preferably E505Q inSEQ ID NO. 2; wherein the one or more (e.g. several) alterations causesthe conjugation-competent polypeptides to have (i) an altered plasmahalf-life and/or (ii) an altered binding affinity to FcRn.43. The conjugation-competent polypeptide of any preceding Paragraphcomprising one or more (e.g. several) alterations in the mature humanalbumin polypeptide sequence of SEQ ID NO. 2 selected from the groupconsisting of positions corresponding to positions 573,523,527 or 505 ofSEQ ID NO. 2, preferably K573Y; I523G; 1523A; T527M; E505Q; or K573P.44. The conjugation-competent polypeptide of Paragraph 43 comprising oneor more (e.g. several) alterations in the mature human albuminpolypeptide sequence of SEQ ID NO. 2 selected from the group consistingof positions corresponding to positions K573Y and I523G; K573Y, I523Gand T527M; K573Y, E505Q and T527M; K573Y and T527M; K573P and I523G;K573P, I523G and T527M; K573P, E505Q and T527M; K573P and T527M; V547A;V547A and K573P; V547A, E505Q, K573P and T527M; or K500A and H510Q.45. The conjugation-competent polypeptide of any of Paragraphs 25 to 44wherein the conjugation-competent polypeptide has a tendency to exist asa monomer in solution which is at least 70% of the tendency of thepolypeptide of SEQ ID NO. 2 to exist as a monomer in solution, andoptionally at least 75%, at least 80%, at least 90%, at least 95% or atleast 100%.46. The conjugation-competent polypeptide of any preceding Paragraph, inwhich the polypeptide has at least 70, 75, 80, 85, 90, 95, 96, 97, 98,99, 99.2, 99.4, 99.6, 99.8% sequence identity to SEQ ID NO. 2.47. The conjugation-competent polypeptide of any preceding Paragraphwherein, when the polypeptide is folded, there are at least 1, 2, 3, 4,5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, and preferably all 17 of thenative disulphide bonds of the polypeptide of SEQ ID NO. 2.48. The conjugation-competent polypeptide of any preceding Paragraph inwhich the polypeptide further comprises a further linker to which abioactive compound, radiopharmaceutical or imaging agent may be linked.49. The conjugation-competent polypeptide of any preceding Paragraphwherein the alteration(s) to provide a conjugation competent cysteineresidue(s) result in a polypeptide with acceptable immunogenicity inhuman, preferably an immunogenicity which is comparable to or lower thanthat of wild-type HSA (SEQ ID NO. 2).50. The conjugation-competent polypeptide of any preceding Paragraphwherein the alteration(s) to provide a conjugation competent cysteineresidue(s) does not adversely affect the immunogenicity of thepolypeptide in human, e.g. relative to the immunogenicity of wild-typeHSA (SEQ ID NO. 2).51. The conjugation-competent polypeptide of Paragraph 49 or 50 whereinthe immunogenicity of the polypeptide is determined or predicted byscreening for T-cell epitopes and/or for B-cell epitopes.52. The conjugation-competent polypeptide of any of Paragraphs 50 to 51wherein the immunogenicity of the polypeptide is determined or predictedby an ex vivo T cell activation assay.53. The conjugation-competent polypeptide of Paragraph 52 wherein the Tcell activation assay comprises measuring T cell responses using aproliferation assay, e.g. [3H]-thymidine uptake.54. The conjugation-competent polypeptide of Paragraph 52 or 53 whereinthe polypeptide has less than 10% reactivity in the T cell proliferationassay, preferably less than 8, 6, 4, or 2% reactivity, most preferably0%.55. The conjugation-competent polypeptide of any of Paragraphs 52 to 54wherein the T cell activation assay comprises measuring T cell responsesusing a cytokine secretion assay, e.g. IL-2 ELISpot.56. The conjugation-competent polypeptide of Paragraph 55 wherein thepolypeptide has less than 10% reactivity in the cytokine secretionassay, preferably less than 8, 6, 4, or 2% reactivity, most preferably0%.57. The conjugation-competent polypeptide of any of Paragraphs 49 to 56wherein the polypeptide has less than 10% reactivity in a T cellproliferation assay and in a cytokine secretion assay.58. The conjugation-competent polypeptide of any preceding Paragraphwherein the polypeptide does not stimulate an adverse antibody responsein human.59. A fusion polypeptide comprising a conjugation-competent polypeptideof any preceding Paragraph and a fusion partner polypeptide.60. A polynucleotide which encodes the polypeptide of any of Paragraphs1 to 59.61. A plasmid comprising the polynucleotide of Paragraph 60.62. A host cell comprising a polynucleotide of Paragraph 60 and/or aplasmid of Paragraph 61.63. The host cell of Paragraph 62, which is a yeast cell, particularly aSaccharomyces cerevisiae cell.64. A conjugate which comprises a bioactive compound,radiopharmaceutical or imaging agent, and a polypeptide according to anyof Paragraphs 1 to 59, wherein the bioactive compound isradiopharmaceutical or imaging agent, linked to the polypeptide througha conjugation-competent cysteine residue of the polypeptide.65. The conjugate of Paragraph 64 further comprising one or more (e.g.several) further bioactive compounds radiopharmaceuticals or imagingagents, each bioactive compound, radiopharmaceutical or imaging agent,being linked to the polypeptide through a conjugation-competent cysteineresidue of the polypeptide.66. A method of producing the polynucleotide of Paragraph 60 comprising:

-   -   (a) providing a nucleic acid molecule encoding a parent albumin        or fragment thereof; and    -   (b) modifying the nucleic acid sequence of the nucleic acid        molecule to encode a conjugation-competent polypeptide which is        at least 70% identical to human albumin, particularly residues 1        to 585 of the mature human albumin polypeptide sequence of SEQ        ID NO. 2, or a fragment thereof, wherein at least one position        equivalent to a position selected from K93, E294, A226, E230,        1271, E358, L24, F49, V54, D56, L66, A92, Q94, E97, H128, F156,        E227, D237, K240, D259, K262, N267, Q268, L275, E277, L284,        E311, K317, A322, E333, D340, E354, K359, A362, E382, and L398,        particularly from K93, E294, A226, E230, and I271, of SEQ ID NO.        2 comprises a conjugation-competent cysteine residue.        67. A method of producing the polypeptide of any of Paragraphs 1        to 59, comprising:    -   (a) culturing the host cell of Paragraph 62 or 63 under        conditions that allow expression of the polypeptide; and    -   (b) recovering the polypeptide from the host cell and/or from        host cell growth medium.        68. The method of paragraph 67 in which the host cell exhibits        enhanced chaperone activity.        69. The method of Paragraph 67 or 68 further comprising        purifying the polypeptide obtained in step (b).        70. A method of producing the conjugate of Paragraph 64 or 65        which comprises linking a polypeptide of any one of Paragraphs 1        to 59, or produced by the method of any one of Paragraphs 67 to        69, to a bioactive compound, radiopharmaceutical or imaging        agent, through a conjugation-competent cysteine residue of the        polypeptide.        71. An associate comprising the conjugate of Paragraph 64 or 65        and a bioactive, therapeutic, prophylactic, diagnostic, imaging        or other beneficial moiety.        72. A nanoparticle or a microparticle or a liposome comprising        the polypeptide of any one of Paragraphs 1 to 59, the conjugate        of Paragraph 64 or 65 or the associate of Paragraph 71.        73. A composition comprising the conjugate of Paragraph 64 or        65, the associate of Paragraph 71 or the nanoparticle or        microparticle or liposome of Paragraph 72 and at least one (e.g.        several) pharmaceutically acceptable carrier or diluent.        74. The conjugate of Paragraph 64 or 65, the associate of        Paragraph 71, the nanoparticle or microparticle or liposome of        Paragraph 72, or the composition of Paragraph 73, wherein the        bioactive molecule, radiopharmaceutical or imaging agent, is        selected from those described herein.        75. The conjugate of Paragraph 64, 65 or 74, or the associate of        Paragraph 71, the nanoparticle or microparticle or liposome of        Paragraph 72 for treatment of disease, treatment of illness        and/or for diagnosis.        76. Use of a polypeptide as defined in any of Paragraphs 1 to 59        to increase half-life of a bioactive molecule,        radiopharmaceutical or imaging agent.        The invention is further described by the following examples        that should not be construed as limiting the scope of the        invention.

Examples Example 1: Preparation of Variants Preparation of Specific HSAVariant Expression Plasmids.

Methods for the expression of HSA variants were performed using severaltechniques, employing standard molecular biology techniques throughout,such as described in Sambrook, J. and D. W. Russell, 2001 (MolecularCloning: a laboratory manual, 3^(rd) ed. Cold Spring Harbor LaboratoryPress, Cold Spring Harbor, N.Y).

Method 1.

Single amino acid mutations (K93C, A226C, E230C, I271C, E294C, andE358C) were introduced into the pDB5155 plasmid (encoding mutated C34AHSA, SEQ ID NO. 30) using a mutagenic forward primer and non-mutagenicreverse primer (Table 3). pDB5155, encoding a C34A mutant, based on theplasmid pDB5102 was made using a mutagenic forward primer and anon-mutagenic reverse primer (Table 3). pDB5102 is described in WO2015/036579. Methylated template DNA was prepared by mixing about 1.7 μgof plasmid DNA with 5 μL 10× buffer (50 mM Tris-HCl mMβ-mercaptoethanol, 10 mM EDTA pH 7.5 at 25° C.—New England Biolabs), 1μL dam methyltransferase (New England Biolabs), 12.5 μLs-adenosylmethionine (New England Biolabs 80 μM final concentration) andwater to 50 μl final volume and incubating at 37° C. for 1.5 hours.Reaction mixtures were then purified using a QIAquick PCR purificationkit (Qiagen) according to the manufacturer's instructions. The relevantprimers were employed in the PCR reaction (described in Tables 4 and 5)using dam-methylated pDB5102 as template and Q5 DNA polymerase (NewEngland Biolabs). Amplification of the plasmid was confirmed by analysisof 5 μl of PCR product on a 1% TBE agarose gel. The remaining PCRproduct was supplemented with 5 μl buffer 4 (50 mM potassium acetate, 20mM Tris-acetate, 10 mM magnesium acetate, 1 mM DTT, pH 7.9 at 25° C.—NewEngland Biolabs) and 1 μl DpnI enzyme, followed by incubation at 37° C.for two hours. The reaction mixtures were then purified using a QIAquickPCR purification kit (Qiagen) according to the manufacturer'sinstructions. 1 μl of purified plasmid was transformed into E. co/i10-beta cells (New England Biolabs) and plated onto LB plates (5 g/Lyeast extract, 10 g/L peptone from casein, 10 g/L NaCl, 12 g/L agar agar(Millers LB agar, Merck Millipore)) supplemented with 50 μg/mLampicillin. Plasmids were isolated using a Qiagen Plasmid Plus Kit(Qiagen—according to manufacturer's instructions) and sequenced toconfirm the presence of the desired mutation within the HSA sequence andthe plasmid named pDB5155.

Methylated pDB5155 template DNA was prepared by mixing about 3.0 μg ofplasmid DNA with 5 μL 10x buffer (50 mM Tris-HCl mM β-mercaptoethanol,10 mM EDTA pH 7.5 at 25° C. —New England Biolabs), 1 μL dammethyltransferase (New England Biolabs), 12.5 μL 80 μMs-adenosylmethionine (New England Biolabs 80 μM final concentration) andwater to 50 μl final volume and incubating at 37° C. for two hours.Reaction mixtures were then purified using a QIAquick PCR purificationkit (Qiagen) according to the manufacturer's instructions.

The relevant primers were employed in the PCR reaction (described inTables 4 and 5) using dam-methylated pDB5155 as template and Q5 DNApolymerase (New England Biolabs).

TABLE 3 Oligonucleotides for mutagenic amplification with mutated codonsunderlined (R = reverse, = F Forward) and the resultant protein. OligoSequence (5′ to 3′) SEQ ID NO. C34A RTTGTTGCAAGTATTGAGCGAAAGCGATCAAGACCAA  31 C34A FTTCGCTCAATACTTGCAACAAGCTCCATTCGAAGATCACGTCAAG  32 L24C FGAAGAAAACTTCAAGGCTTTGGTCTGTATCGCTTTCGCTCAATACTTGCA  33 F49C FAGTTGGTCAACGAAGTTACCGAATGTGCTAAGACTTGTGTTGCTGACG  34 V54C FGTTACCGAATTCGCTAAGACTTGTTGTGCTGACGAATCCGCGGAAAAC  35 D56C FGAATTCGCTAAGACTTGTGTTGCTTGTGAATCCGCGGAAAACTGTGACA  36 L66C FCGCGGAAAACTGTGACAAGTCCTGTCACACCTTGTTCGGTGATAAGTT  37 A92C FCGGTGAAATGGCTGACTGTTGTTGTAAGCAAGAACCAGAAAGAAACGAA  38 K93C FGTGAAATGGCTGACTGTTGTGCTTGTCAAGAACCAGAAAGAAACGAATGT  39 Q94C FAAATGGCTGACTGTTGTGCTAAGTGTGAACCAGAAAGAAACGAATGTTTC  40 E97C FACTGTTGTGCTAAGCAAGAACCATGTAGAAACGAATGTTTCTTGCAACAC  41 H128C FTTGACGTCATGTGTACTGCTTTCTGTGACAACGAAGAAACCTTCTTGAAG  42 F156C FACTTCTACGCTCCAGAATTGTTGTGTTTCGCTAAGAGATACAAGGCTGC  43 A226C FAGATTGTCTCAAAGATTCCCAAAGTGTGAATTCGCTGAAGTTTCTAAGTTG  44 E227C FTGTCTCAAAGATTCCCAAAGGCTTGTTTCGCTGAAGTTTCTAAGTTGGTT  45 E230C FGATTCCCAAAGGCTGAATTCGCTTGTGTTTCTAAGTTGGTTACTGACTTG  46 D237C FGCTGAAGTTTCTAAGTTGGTTACTTGTTTGACTAAGGTTCACACTGAATGT  47 K240C FTCTAAGTTGGTTACTGACTTGACTTGTGTTCACACTGAATGTTGTCACGG  48 D259C FGGAATGTGCTGATGACAGAGCTTGTTTGGCTAAGTACATCTGTGAAAAC  49 K262C FTGATGACAGAGCTGACTTGGCTTGTTACATCTGTGAAAACCAAGACTCT  50 N267C FGACTTGGCTAAGTACATCTGTGAATGTCAAGACTCTATCTCTTCCAAGTTG  51 Q268C FTTGGCTAAGTACATCTGTGAAAACTGTGACTCTATCTCTTCCAAGTTGAAG  52 I271C FTACATCTGTGAAAACCAAGACTCTTGTTCTTCCAAGTTGAAGGAATGTTGT  53 L275C FACCAAGACTCTATCTCTTCCAAGTGTAAGGAATGTTGTGAAAAGCCATTG  54 E277C FGACTCTATCTCTTCCAAGTTGAAGTGTTGTTGTGAAAAGCCATTGTTGGAA  55 L284C FAAGGAATGTTGTGAAAAGCCATTGTGTGAAAAGTCTCACTGTATTGCTGAA  56 E294C FAAGTCTCACTGTATTGCTGAAGTTTGTAACGATGAAATGCCAGCTGACTT  57 E311C FCATCTTTGGCTGCTGACTTCGTTTGTTCTAAGGACGTTTGTAAGAACTAC  58 K317C FTTCGTTGAATCTAAGGACGTTTGTTGTAACTACGCTGAAGCTAAGGACG  59 A322C FGACGTTTGTAAGAACTACGCTGAATGTAAGGACGTCTTCTTGGGTATGTT  60 E333C FGTCTTCTTGGGTATGTTCTTGTACTGTTACGCTAGAAGACACCCAGACT  61 D340C FCGAATACGCTAGAAGACACCCATGTTACTCCGTTGTCTTGTTGTTGAG  62 E354C FTGTTGAGATTGGCTAAGACCTACTGTACTACCCTCGAGAAGTGTTGTG  63 E358C FCTAAGACCTACGAAACTACCCTCTGTAAGTGTTGTGCTGCTGCTGACC  64 K359C FGACCTACGAAACTACCCTCGAGTGTTGTTGTGCTGCTGCTGACCCA  65 A362C FAAACTACCCTCGAGAAGTGTTGTTGTGCTGCTGACCCACACGAATGT  66 E382C FTCGATGAATTCAAGCCATTGGTCTGTGAACCACAAAACTTGATCAAGCAA  67 L398C FGCAAAACTGTGAATTGTTCGAACAATGTGGTGAATACAAGTTCCAAAACGC  68 L24C RGACCAAAGCCTTGAAGTTTTCTTCACCCAAGTCCT  69 F49C RTTCGGTAACTTCGTTGACCAACTTGACGTGATCTT  70 V54C RACAAGTCTTAGCGAATTCGGTAACTTCGTTGACCAA  71 D56C RAGCAACACAAGTCTTAGCGAATTCGGTAACTTCGTT  72 L66C RGGACTTGTCACAGTTTTCCGCGGATTCGTCAGC  73 A92C RACAACAGTCAGCCATTTCACCGTAGGTTTCTCTC  74 K93C RAGCACAACAGTCAGCCATTTCACCGTAGGTTTCTC  75 Q94C RCTTAGCACAACAGTCAGCCATTTCACCGTAGGTT  76 E97C RTGGTTCTTGCTTAGCACAACAGTCAGCCATTTCAC  77 H128C RGAAAGCAGTACACATGACGTCAACTTCTGGTCTAA  78 F156C RCAACAATTCTGGAGCGTAGAAGTATGGGTGTCTTC  79 A226C RCTTTGGGAATCTTTGAGACAATCTAGCGACAGCC  80 E227C RAGCCTTTGGGAATCTTTGAGACAATCTAGCGACAG  81 E230C RAGCGAATTCAGCCTTTGGGAATCTTTGAGACAATCT  82 D237C RAGTAACCAACTTAGAAACTTCAGCGAATTCAGCCTT  83 K240C RAGTCAAGTCAGTAACCAACTTAGAAACTTCAGCGAA  84 D259C RAGCTCTGTCATCAGCACATTCCAACAAGTCACCG  85 K262C RAGCCAAGTCAGCTCTGTCATCAGCACATTCCAAC  86 N267C RTTCACAGATGTACTTAGCCAAGTCAGCTCTGTCATC  87 Q268C RGTTTTCACAGATGTACTTAGCCAAGTCAGCTCTGT  88 I271C RAGAGTCTTGGTTTTCACAGATGTACTTAGCCAAGTC  89 L275C RCTTGGAAGAGATAGAGTCTTGGTTTTCACAGATGTA  90 E277C RCTTCAACTTGGAAGAGATAGAGTCTTGGTTTTCACAG  91 L284C RCAATGGCTTTTCACAACATTCCTTCAACTTGGAAGA  92 E294C RAACTTCAGCAATACAGTGAGACTTTTCCAACAATGG  93 E311C RAACGAAGTCAGCAGCCAAAGATGGCAAGTCAGCT  94 K317C RACAAACGTCCTTAGATTCAACGAAGTCAGCAGCC  95 A322C RTTCAGCGTAGTTCTTACAAACGTCCTTAGATTCAACG  96 E333C RGTACAAGAACATACCCAAGAAGACGTCCTTAGCTTC  97 D340C RTGGGTGTCTTCTAGCGTATTCGTACAAGAACATAC  98 E354C RGTAGGTCTTAGCCAATCTCAACAACAAGACAACGG  99 E358C RGAGGGTAGTTTCGTAGGTCTTAGCCAATCTCAACA 100 K359C RCTCGAGGGTAGTTTCGTAGGTCTTAGCCAATCTC 101 A362C RACAACACTTCTCGAGGGTAGTTTCGTAGGTCTTAG 102 E382C RGACCAATGGCTTGAATTCATCGAAAACCTTAGCGT 103 L398C RTTGTTCGAACAATTCACAGTTTTGCTTGATCAAGTTTTG 104

TABLE 4 PCR reaction components Template (5 ng/μL) 1 μL Forward primer(10 μM) 2.5 μL 5x buffer 10 μL Reverse primer (10 μM) 2.5 μL dNTP (2.5mM) 1 μL Q5 polymerase 0.5 μL Sterile water 32.5 μL

TABLE 5 PCR reaction conditions Temperature Cycle Length Number ofcycles 98° C. 2 min 1 98° C. 10 sec 30 60° C. 30 sec 72° C. 5 min 72° C.7 min 1

Amplification of the plasmid was confirmed by analysis of 5 μl of PCRproduct on a 1% TBE agarose gel. The remaining PCR product wassupplemented with 4 μl buffer 4 (50 mM potassium acetate, 20 mMTris-acetate, 10 mM magnesium acetate, 1 mM OTT, pH 7.9 at 25° C. —NewEngland Biolabs) and 1 μl DpnI enzyme, followed by incubation at 37° C.for one hour. The reaction mixtures were then purified using a QIAquick96 PCR purification kit (Qiagen) according to the manufacturer'sinstructions. 2 μl of purified plasmid was transformed into competent E.coli DH5-alpha cells and grown in a 96 deep well block in 1.2 mL LBmedia (1% w/v bacteriological tryptone, 0.5% w/v yeast extract, 0.5% w/vNaCl) supplemented with 50 μg/mL ampicillin to repair nicks in the DNAbackbone. Plasmids were isolated using a QiaPrep 96 turbo miniprep kit(Qiagen—according to manufacturer's instructions). The thio-albuminconstructs are detailed in Table 6.

Plasmid DNA was prepared for transformation into S. cerevisiae asdescribed in WO 2015/036579 (incorporated herein by reference), Method4, except that 9723 bp Acc651-BamHI fragment from pDB4164 was used asthe gapped vector fragment instead of the 9721 bp fragment from pDB3936,which has two additional bases GC next to the BamHI site to create aNotI restriction site GCGGCCGC (additional bases in bold). pDB3936 isdescribed in WO 2011/124718 (incorporated herein by reference). pDB4164also differs from pDB3936 in containing a 1368 bp sequence between theAcc65I and BamHI sites containing an apramycin resistance selectablemarker which was excised by the Acc65I and BamHI digestion and was notused in the gap-repair transformation. The host strain for theconstructs was S. cerevisiae BXP10 cir⁰ (WO 2015/036759, incorporatedherein by reference). Transformed cells were grown as single colonies onselective agar plates (BMMD+CSM-Leu or BMMD) from which isolatedcolonies were patched out, also on selective agar plates, for thepreparation of cryopreserved yeast stocks and samples for analysis.Cryopreserved stocks were made from 5 mL of a 48 hour BMMD+CSM-Leu shakeflask culture mixed with an equal volume of 40% [w/v] trehalose and 1 mLaliquots transferred to cryovials for storage at −80° C. 0.5 mL BMMD in48-well microtitre plate wells was inoculated with yeast from the patchplates and grown for 4-days at 30° C. with shaking as described in WO2015/036579, Method 4 (incorporated herein by reference). Shake flaskcultures were inoculated from trehalose stocks. Purification of thesevariants from shake flask was performed as described in WO 2012/150319(incorporated herein by reference).

Preparation of the expression plasmids for the L24C, F49C, V54C, D56C,L66C, A92C, Q94C, E97C, H128C, F156C, E227C, D237C, K240C, D259C, K262C,N267C, Q268C, L275C, E277C, L284C, E311C, K317C, A322C, E333C, D340C,E354C, K359C, A362C, E382C, and L398C (all in C34A background) wasslightly different to that described above:

Single amino acid mutations were introduced into the pDB5155 plasmid(encoding mutated C34A HSA, SEQ ID NO. 30) using a mutagenic forwardprimer and non-mutagenic reverse primer (Table 3).

Methylated template DNA was prepared by mixing about 2.5 μg of plasmidDNA with 5 μL 10x buffer (50 mM Tris-HCl mM β-mercaptoethanol, 10 mMEDTA pH 7.5 at 25° C.—New England Biolabs), 1 μL dam methyltransferase(New England Biolabs), 12.5 μL 80 μM s-adenosylmethionine (New EnglandBiolabs 80 μM final concentration) and water to 50 μl final volume andincubating at 37° C. for one hour. Reaction mixtures were then purifiedusing a QIAquick PCR purification kit (Qiagen) according to themanufacturer's instructions.

The relevant primers were employed in the PCR reaction (described inTables 4 and 5, above) using dam-methylated pDB5155 as template and Q5DNA polymerase (New England Biolabs).

Amplification of the plasmid was confirmed by analysis of 5 μl of PCRproduct on a 1% TBE agarose gel. The remaining PCR product wassupplemented with 4 μl buffer 4 (50 mM potassium acetate, 20 mMTris-acetate, 10 mM magnesium acetate, 1 mM DTT, pH 7.9 at 25° C. —NewEngland Biolabs) and 1 μl DpnI enzyme, followed by incubation at 37° C.for one hour. The reaction mixtures were then purified using a QIAquick96 PCR purification kit (Qiagen) according to the manufacturer'sinstructions. 1 μl of purified plasmid was transformed into competent E.coli DH5-alpha cells and grown in a 96 deep well block in 1.2 mL LBmedia (1% w/v bacteriological tryptone, 0.5% w/v yeast extract, 0.5% w/vNaCl) supplemented with 50 μg/mL ampicillin to repair nicks in the DNAbackbone. Plasmids were isolated using a QiaPrep 96 turbo miniprep kit(Qiagen—according to manufacturer's instructions). The thio-albuminconstructs are detailed in Table 6.

Plasmid DNA was prepared for transformation into S. cerevisiae asdescribed in WO 2015/036579, Method 4 (incorporated herein byreference). The host strain for the constructs was S. cerevisiae DYB7(Payne et al. (2008) Applied and Environmental Microbiology Vol74(24):7759-7766). The yeast microtitre plate growth diverged from themethod as described in WO 2015/036579 in that transformations wereperformed in duplicate and the initial growth was for two days. Stockswere produced from the two days growth by transfer of 50 μl culture to afresh microtitre plate containing 50 μl 40% (w/v) trehalose. 50 μl ofthe two day culture was also added to a fresh microtitre platecontaining 450 μL of BMMD+CSM-leu and incubated at 30° C. with shaking(200 rpm, 2.5 cm orbit at in a sealed chamber at 100% humidity in anEppendorf Innova 44 incubated shaker) for a further four days. Culturesupernatants were harvested by centrifugation at 3000 rpm for 5 minutesand 375 μl of supernatant was transferred to a fresh 48-well microtitreplate.

Production of Expression Plasmid and Yeast Stocks.

Preparation of the expression plasmids and transformation of S.cerevisiae was performed as described in WO 2011/051489 and WO2012/150319 (incorporated herein by reference) by the 48-hour stockingmethod, using equal volumes of culture and trehalose. The host strainfor the constructs was S. cerevisiae BXP10 Cir° (WO 2015/036759,incorporated herein by reference). Purification of variants from shakeflask was performed as described in WO 2012/150319 unless otherwisestated.

The resultant albumin variants are summarized in Table 6.

TABLE 6 Albumin variant SEQ ID NO. C34A 30 C34A + L24C 105 C34A + F49C106 C34A + V54C 107 C34A + D56C 108 C34A + L66C 109 C34A + A92C 110C34A + K93C 111 C34A + Q94C 112 C34A + E97C 113 C34A + H128C 114 C34A +F156C 115 C34A + A226C 116 C34A + E227C 117 C34A + E230C 118 C34A +D237C 119 C34A + K240C 120 C34A + D259C 121 C34A + K262C 122 C34A +N267C 123 C34A + Q268C 124 C34A + I271C 125 C34A + L275C 126 C34A +E277C 127 C34A + L284C 128 C34A + E294C 129 C34A + E311C 130 C34A +K317C 131 C34A + A322C 132 C34A + E333C 133 C34A + D340C 134 C34A +E354C 135 C34A + E358C 136 C34A + K359C 137 C34A + A362C 138 C34A +E382C 139 C34A + L398C 140

Example 2. Thiol Determination of DTNB Incubated Thio-Albumin Variants

The free thiol content of thiol albumin variants was determined at smallscale using microtitre plate (MTP) grown cultures. The tested thiolalbumin variants included the C34A substitution, and thus should lackthe thiol group of native albumin. As such, they were each expected tohave only one free thiol.

The number of free thiols on a protein can be determinedspectrophotometrically using Ellman's reagent. Ellman's reagent(5′5′-dithio-bis(2-nitrobenzoic acid) (DTNB)) is an aromatic disulphidewhich reacts with thiol groups to form a mixed disulphide of the proteinand one mole of 5-thio-2-nitrobenzoic acid (TNB) (per mole of proteinsulfhydryl group). This reaction also results in a yellow colour fromfree TNB being released in solution. Alternatively the number of freethiols on a protein can be determined using mass spectrometric analysisof protein sample treated with DTNB reagent. 5-thio-2-nitrobenzoic acid(TNB) has a molecular weight of 199 Da, thus an increase in mass of 197Da (TNB minus H₂ lost during disulphide bond formation with the freethiol group on the test protein) indicates the presence of one freethiol group on the protein sample.

4 μl Buffer 2 (4 mg/mL DTNB, 500 mM sodium phosphate, pH 7.0) was addedto 200 μL of the test protein culture sample in a 96-well MTP format.The preparation was allowed to incubate for 25 minutes at ambienttemperature (20±5° C.) to allow TNB labelling. Protein intact mass wasdetermined by UltraPerformance Liquid Chromatography Mass Spectrometry(UPLC-MS). UPLC separation was carried out on 10 μL of sample using aWaters Acquity on a BEH 50×2.1 mm ACQUITY BEH 1.7 μm 300 Å C4 column anda 5 min analytical gradient of buffer A 0.1% formic acid and Buffer B100% acetonitrile 0.1% formic acid. Eluted proteins were directlyintroduced to a Bruker MicrOTOF II mass spectrometer via an ElectrosprayIonisation (ESI) source. All instrument control and sample tables werecontrolled using BioPharma Compass™. All data were manually processedover the leading edge of the protein peak between 2.9-3.0 minutes inData Analysis. This included spectral smoothing using a Gauss smoothingalgorithm set at 0.0765 Da and a baseline correction setting of 0.8flatness. Deconvoluted intact mass spectra were obtained using the Max.Entropy algorithm, all methods and parameters were set within BioPharmaCompass™.

The results of the above thiol analysis of the thio-albumin samples aresummarised in Table 7. An increase in mass of 197 Da upon DTNBincubation is predicted to be indicative of the presence of one freethiol group on the protein in the sample. A mass increase of 197±15 Daas actually measured by MS was taken as indicative of the correct mass.All variants successfully bound a molecule of TNB.

TABLE 7 Mass Spectrometry DTNB thiol screening results Molecular weight(Da) Post DTNB treatment Variant Difference description Variant Actual(Actual minus (all C34A) Theoretical Theoretical measured theoretical)L24C 66397 66594 66599 5 F49C 66363 66560 66568 8 V54C 66411 66608 666135 D56C 66395 66592 66600 8 L66C 66397 66594 66599 5 A92C 66439 6663666641 5 K93C 66382 66579 66588 9 Q94C 66382 66579 66581 2 E97C 6638166578 66580 2 H128C 66373 66570 66572 2 F156C 66363 66560 66564 4 A226C66439 66636 66637 1 E227C 66381 66578 66584 6 E230C 66381 66578 66582 4D237C 66395 66592 66593 1 K240C 66382 66579 66584 5 D259C 66395 6659266594 2 K262C 66382 66579 66584 5 N267C 66396 66593 66592 −1 Q268C 6638266579 66584 5 I271C 66397 66594 66596 2 L275C 66397 66594 66597 3 E277C66381 66578 66583 5 L284C 66397 66594 66592 −2 E294C 66381 66578 66581 3E311C 66381 66578 66589 11 K317C 66382 66579 66582 3 A322C 66439 6663666640 4 E333C 66381 66578 66582 4 D340C 66395 66592 66602 10 E354C 6638166578 66583 5 E358C 66381 66578 66583 5 K359C 66382 66579 66583 4 A362C66439 66636 66641 5 E382C 66381 66578 66586 8 L398C 66397 66594 66597 3

Example 3. Aggregation Screening of Thio-Albumin Variants

Variants were tested for tendency to remain as a monomer in solution.Each variant has a single free thiol group. Therefore, they were testedin comparison with wild-type HSA, which also has a single free thiolgroup.

Shake flask culturing of S. cerevisiae and purification was performed asdescribed in WO 2012/150319 (incorporated herein by reference) with thefollowing modifications. BMMS media (10 mL) was inoculated with S.cerevisiae and grown for 2 days at 30° C. with orbital shaking at 200rpm. An aliquot of each starter culture (5 mL) was used to inoculate2×200 mL BMMS media and grown for 5 days at 30° C. with orbital shakingat 200 rpm. Cells were harvested by filtration through a 0.2 μm vacuumfilter membrane (Nalgene Sterile Top Filter) and the supernatantretained for purification.

A single step chromatography procedure was used to prepare purifiedmaterial from the thio-albumin variants. The purification step used acolumn (bed volume approximately 2 mL) packed with AlbuPure® matrix(ProMetic BioSciences Ltd, Cambridge UK or Albumedix Ltd (formerlyNovozymes Biopharma UK Ltd)). This was equilibrated with 50 mM sodiumacetate, pH 5.3, and loaded with neat shake flask culture supernatants,at approximately pH 5.5-6.5, to approximately 20 mg protein/mL matrix.The column was washed with approximately 10 column volumes each of 50 mMsodium acetate, pH 5.3, and 50 mM ammonium acetate, pH 8.0,respectively. Bound protein was eluted using approximately 10 columnvolumes of 50 mM ammonium acetate, 10 mM octanoate, pH 7.0. The flowrate throughout was 240 cm/h using an AKTA Explorer system (GEHealthcare). Eluate samples were approximately 20 mL in volume. Theconcentration and percentage monomer of the eluate samples wasdetermined by Gel Permeation High Pressure Liquid Chromatography(GP-HPLC). Protein concentrations were determined using a LC2010 HPLCsystem (Shimadzu) equipped with UV detection under Shimadzu VP7.3 clientserver software control. Injections of 25 μL were made onto a 7.8 mminternal diameter x 300 mm length TSK G3000SWXL column (TosohBioscience), with a 6.0 mm internal diameter x 40 mm length TSK SW guardcolumn (Tosoh Bioscience). Samples were chromatographed in 25 mM sodiumphosphate, 100 mM sodium sulphate, 0.05% (w/v) sodium azide, pH 7.0 at 1mL·min⁻¹, with a run time of 15 minutes. Samples were quantified by UVdetection at 280 nm, by peak area, relative to a recombinant humanalbumin standard of known concentration (10 mg/mL).

The samples were reanalysed to determine the change in percentagemonomer post seven weeks storage at 2-8° C., and post 6 months storageat 2-8° C. The percentage monomer (in brackets) was determined for eachsample relative to its wild type control under the same storageconditions. The results are summarised in Table 8A. Final eluateconcentrations were in the range of 0.6-1.2 mg/mL, resulting in 12-24 mgprotein recovered post purification. All variants had a monomerpercentage equivalent to or higher than that of the wild type control atT=0, which had a monomer percentage of 87%. The variants maintainedtheir monomeric protein percentage over 7 weeks' storage at 2-8° C.,with no significant evidence of aggregation propensity during 6 monthsstorage at 2-8° C. observed for at least four variants.

TABLE 8A GPHPLC aggregation screening results GPHPLC % Monomer Δ%Monomer conc. T = 7 T = 6 0-7 0-6 Sample (mg/mL) T = 0 week month weekmonth WT albumin 1.1 87 (100) 88 (100) 89 (100) 1 2 control C34A + K93C0.7 91 (105) 92 (105) 92 (103) 1 1 C34A + A226C 1.1 93 (107) 93 (106) 93(105) 0 0 C34A + E230C 0.6 90 (103) 91 (103) ND (ND) 1 ND C34A + I271C1.2 91 (105) 91 (103) 91 (102) 0 0 C34A + E294C 0.9 96 (110) 96 (109) 96(108) 0 0 C34A + E358C 1.0 89 (102) 83 (94) 80 (90) −6 −9  ND: Notdetermined

Further variants were analysed using the method previously described inExample 3, or alternatively using an Agilent 1260 isocratic UHPLC(Ultra-High Performance Liquid Chromatography) instrument. For the UHPLCmethod, injections of 4 μL were made onto a 4.6 mm id×150 mm length BEH200 Å, 1.7 μm column (Waters), using the mobile phase described inExample 3, at 0.5 mL·min⁻¹, with a run time of 5 minutes. Samples werequantified by UV detection at 280 nm, by peak height relative to arecombinant human albumin standard of known concentration (10 mg/mL).

The samples were reanalysed post eight weeks storage at 2-8° C., andpost 4 months storage at 2-8° C. to determine the change in percentagemonomer. The percentage monomer (in brackets) was determined for eachsample relative to its wild type control under the same storageconditions. The results are summarised in Table 8B. Final eluateconcentrations were in the range of 0.1-1.0 mg/mL, resulting in 2-20 mgprotein recovered post purification. The majority of variants had amonomer percentage equivalent to or higher than that of the wild typecontrol at T=0, which had a monomer percentage of 86%. These variantsmaintained their monomeric protein over 8 weeks' storage at 2-8° C.,with no significant evidence of aggregation propensity during 4 monthsstorage at 2-8° C. observed. However, it was evident that variantsC34A+L66C, C34A+E277C, and C34A+E311C had a relatively low percentagemonomer at T=0, and consequently had a propensity to form aggregates.

TABLE 8B GPHPLC aggregation screening results GPHPLC % Monomer Δ %Monomer conc. T = 8 T = 4 0-8 0-4 Sample (mg/mL) T = 0 week month weekmonth WT albumin 0.6 86 (100) 88 (100) 87 (100) 2 1 control C34A + L24C0.7 94 (109) 96 (109) 97 (112) 2 3 C34A + F49C 0.5 94 (109) 95 (108) 94(108) 1 0 C34A + V54C 0.5 93 (108) 94 (107) 93 (107) 1 0 C34A + D56C 0.385 (99) 77 (88) 75 (86) −8 −10 C34A + L66C 0.2 7 (8) 12 (14) 6 (7) 5 −1C34A + A92C 0.9 93 (108) 94 (107) 94 (108) 1 1 C34A + Q94C 0.1 95 (111)96 (109) 95 (109) 1 0 C34A + E97C 0.5 88 (102) 85 (97) 85 (98) −3 −3C34A + H128C 0.6 92 (107) 93 (106) 93 (107) 1 1 C34A + F156C 1.0 92(107) 94 (107) 94 (108) 2 2 C34A + E227C 0.5 86 (100) 88 (100) 88 (101)2 2 C34A + D237C 0.5 93 (108) 95 (108) 94 (108) 2 1 C34A + K240C 0.6 93(108) 94 (107) 94 (108) 1 1 C34A + D259C 0.5 93 (108) 95 (108) 94 (108)2 1 C34A + K262C 0.6 92 (107) 93 (106) 93 (107) 1 1 C34A + N267C 0.6 94(109) 95 (108) 95 (109) 1 1 C34A + Q268C 0.8 95 (111) 96 (109) 96 (110)1 1 C34A + L275C 0.5 94 (109) 95 (108) 94 (108) 1 0 C34A + E277C 0.7 65(76) 60 (68) 59 (68) −5 −6 C34A + L284C 0.7 92 (107) 94 (107) 94 (108) 22 C34A + E311C 0.7 54 (63) 48 (55) 46 (53) −6 −8 C34A + K317C 0.6 83(97) 82 (93) 82 (94) −1 −1 C34A + A322C 0.8 81 (94) 84 (96) 83 (95) 3 2C34A + E333C 0.3 94 (109) 97 (110) 95 (109) 3 1 C34A + D340C 0.6 93(108) 94 (107) 94 (108) 1 1 C34A + E354C 0.7 89 (104) 90 (102) 90 (103)1 1 C34A + K359C 0.6 86 (100) 87 (99) 87 (100) 1 1 C34A + A362C 0.6 89(104) 89 (101) 88 (101) 0 −1 C34A + E382C 0.6 86 (100) 84 (96) 84 (97)−2 −2 C34A + L398C 0.7 90 (105) 92 (105) 87 (100) 2 −3

Example 4. Conjugation Efficiency and Controlled Hydrolysis ofThio-Albumin Variants

Thio-albumin variants from Example 3 were conjugated with biotin (ThermoScientific, EZ-Link Maleimide-PEG2-Biotin) using a 3.2 fold molar excessof maleimide-PEG2-biotin to protein. A reaction schematic is shown inFIG. 4. The thio-albumin AlbuPure® eluates were diluted with phosphatebuffered saline (PBS buffer), pH 7.4 to give 10 mL solutions at 0.3mg/mL (45.15 nmol) and conjugated as described below Table 9A.

The MS spectrum for the thio-albumin variant C34A+A226C indicated thatno conjugation had occurred post an overnight incubation withmaleimide-PEG2-biotin. The results are summarised in Table 9A. The MSspectra for the thio-albumin variants C34A+E230C, and C34A+I271Cindicated that conjugation had occurred post an overnight incubation,giving approximately 72% or 72% monoconjugate respectively (i.e. thesame level of monoconjugate) when comparing the relative peak heights ofconjugated and unconjugated species. The MS spectrum for C34A+I271C isshown in FIG. 5A. The MS spectrum for thio-albumin variant C34A+K93Cshown in FIG. 5B, exhibited a single species at 66908 Da indicating thecorrect molecular weight for the thio-albumin variant plus a singleaddition of maleimide-PEG2-biotin (+525 Da). This confirmed the varianthad a single free thiol available for conjugation. Comparable resultswere obtained for thio-albumin variants C34A+E294C and C34A+E358C.

TABLE 9A Conjugation efficiency results Reference Mr TheoreticalConjugate % Sample unconjugated conjugate intact mass conju- Description(Da) mass (Da) result (Da) gation WT control 66439 66964 * * C34A + K93C66382 66907 66908 100 C34A + A226C 66439 66964 66440 0 C34A + E230C66381 66906 66908 72 C34A + I271C 66397 66922 66924 72 C34A + E294C66381 66906 66909 >95 C34A + E358C 66381 66906 66909 100 * WT controlsample failed to inject on MS during sequence run.

Further variants were analysed and the results are shown in Table 9B.For samples C34A+L66C and C34A+Q94C the protein concentrations were low,hence 10 mL solutions at 0.15 mg/mL (22.58 nmol) were used. Stocksolutions of 2 mg/mL biotin were prepared by the addition of 5×200 μLaliquots of PBS buffer, pH 7.4, to each of two 2 mg pre-weighed EZ-Linkmicotubes, the vials were rinsed to maximise recovery of the lyophilisedproduct. The two 1 mL volumes were pooled into a 7 mL container with alid. From the biotin stock solution, 38 μL (144.5 nmol) was added to the10 mL albumin samples to give approximately a 3.2-fold molar excess ofbiotin over albumin. However, for the C34A+L66C and C34A+Q94C samplesonly 19 μL biotin was added to maintain a 3.2 fold excess ofmaleimide-PEG2-biotin to protein. Samples were gently mixed andincubated at ambient temperature overnight. Post incubation, the sampleswere subjected to mass spectrometry to determine the intact protein masspost conjugation according to the method described in Example 2, butusing a 15 minute analytical gradient, and processing data for theprotein peak between approximately 7 and 10 minutes. The MS spectraresults summarised in Table 9B indicated that thio-albumin variantsC34A+L66C, C34A+A92C, C34A+Q94C, C34A+D259C, C34A+L275C, and C34A+L284Cdid not conjugate post an overnight incubation withmaleimide-PEG2-biotin. The MS spectra for the WT control, and thethio-albumin variants C34A+L24C, C34A+V54C, C34A+H128C, C34A+E227C,C34A+K240C, C34A+K262C, C34A+Q268C, C34A+E277C, C34A+K317C, C34A+A322C,C34A+K359C and C34A+A362C indicated 90% conjugation or greater withmaleimide-PEG2-biotin.

TABLE 9B Conjugation efficiency results Reference Mr TheoreticalConjugate % Sample unconjugated conjugate intact mass conju- Description(Da) mass (Da) result (Da) gation WT control 66439 66964 66966 93 C34A +L24C 66397 66922 66924 96 C34A + F49C 66363 66888 66889 84 C34A + V54C66411 66936 66938 100 C34A + D56C 66395 66920 66922 79 C34A + L66C 6639766922 66400 0 C34A + A92C 66439 66964 66407 0 C34A + Q94C 66382 6690766409 0 C34A + E97C 66381 66906 66907 9 C34A + H128C 66373 66898 66899100 C34A + F156C 66363 66888 66890 76 C34A + E227C 66381 66906 66907 95C34A + D237C 66395 66920 66921 73 C34A + K240C 66382 66907 66908 100C34A + D259C 66395 66920 67424 0 C34A + K262C 66382 66907 66908 100C34A + N267C 66396 66921 66922 47 C34A + Q268C 66382 66907 66908 92C34A + L275C 66397 66922 66897 0 C34A + E277C 66381 66906 66908 90C34A + L284C 66397 66922 67427 0 C34A + E311C 66381 66906 66909 76C34A + K317C 66382 66907 66909 91 C34A + A322C 66439 66964 66965 94C34A + E333C 66381 66906 66907 83 C34A + D340C 66395 66920 66923 12C34A + E354C 66381 66906 66908 32 C34A + K359C 66382 66907 66908 95C34A + A362C 66439 66964 66966 94 C34A + E382C 66381 66906 66909 83C34A + L398C 66397 66922 66925 36

The stability of maleimide conjugate bonds is not robust. Thesuccinimide can revert back to maleimide and free thiol via aretro-Michael pathway (FIG. 4). Thus, highly undesirably, the releasedmaleimide may react with other thiol reactive species and the releasedthiol may react with other compounds in vivo. To avoid retro-Michaelreactivity, the succinimide may be hydrolysed to succinic acid,effectively taking on H₂O (+18 Da) and locking the conjugate to bethiol-stable. The property of thiol-stability by hydrolysis is desirableas it would ensure that there was no unwanted thiol transfer takingplace in various environments in vivo. Therefore, controlled hydrolysisof the succinimide was performed by increasing the pH and temperature.Post conjugation the samples were transferred to Vivaspin 20 centrifugalconcentrators (Sartorius) and balanced with PBS buffer pH 7.4. Thesamples were centrifuged at 4,500×g for 15 minutes to reduce the volumeto approximately 200 μL. A diafiltration cup was fitted to the Vivaspin20 vessels and subsequently filled with 15 mL of PBS buffer pH 9.0. Thesamples were centrifuged at 4,500×g for 15 minutes a second time. Afurther 15 mL PBS buffer pH 9.0 was added and the samples centrifuged athird time to ensure that all the free maleimide-PEG2-biotin was removedfrom solution. The remaining retentate was removed and made up to afinal volume of 10 mL with PBS buffer pH 9.0 (i.e. assuming no lossesthen to a concentration of 0.3 mg/mL). The samples were incubated at 37°C. for at least 24 hours for controlled hydrolysis to occur to determinethe stability of the thio ether conjugate bond. The results aresummarised in Table 10.

The yield of the hydrolysed thiol stable wild type control conjugate wasin the order of 53%, likely due to the competing retro-Michaeldeconjugation during hydrolysis (FIG. 6A). Also observed was an averageconjugate mass shift of +14 Da indicating that partial hydrolysis hadoccurred. It was apparent that the thio-albumin variants that had thehighest conjugation efficiency also had improved conjugate stabilityupon controlled hydrolysis. Specifically the reaction favoured thehydrolysis of the succinimide rather than the retro-Michaeldeconjugation pathway. An example of C34A+E294C is shown in FIG. 6Bindicating no conjugate losses following incubation at pH 9.0, 37° C.Comparable results were obtained for thio-albumin variants C34A+K93C,C34A+E294C and C34A+E358C with no significant losses during controlledhydrolysis.

TABLE 10 Controlled hydrolysis stability results Reference MrTheoretical Conjugate Conjugate % conjugation Sample unconjugatedconjugate intact mass mass increase post Description (Da) mass (Da)result (Da) (Da) hydrolysis WT control 66439 66964 66978 14 53 C34A +K93C 66382 66907 66911 4 100 C34A + A226C 66439 66964 66441 2 0 C34A +E230C 66381 66906 66926 20 63 C34A + I271C 66397 66922 66939 6 61 C34A +E294C 66381 66906 66926 20 100 C34A + E358C 66381 66906 66927 21 100

The combined aggregation results and conjugation results are summarisedtogether in Table 11. It was apparent that the variants C34A+K93C andC34A+E294C had improved aggregation profiles compared to wild typealbumin, conjugated to a high percentage with maleimide-PEG2-biotin, andhad minimal loss of conjugate following controlled hydrolysis at pH 9.0,37° C. These variants were selected for further evaluation.

TABLE 11 Thio-albumin variant aggregation screen and conjugation resultssummary No losses Improved during Sample aggregation Conjugationcontrolled Variant Description profile efficiency >95% hydrolysisselected WT control C34A + K93C ✓ ✓ ✓ ✓ C34A + A226C ✓ C34A + E230C ✓C34A + I271C ✓ C34A + E294C ✓ ✓ ✓ ✓ C34A + E358C ✓ ✓

Example 5: Combination Variants Method 2.

Combination variants (Table 12) were produced to combine the mutationsK93C and E294C described both with and without the HSA C34A mutation.Briefly, plasmids comprising the individual mutations were prepared, andthe mutations combined by restriction enzyme digestion and ligation.

1 μl of purified plasmid produced in Method 1 corresponding to themutations K93C or E294C was transformed into E. coli NEB 5-alpha (NewEngland Biolabs) and plated onto LB plates (as described above)supplemented with 50 μg/mL ampicillin. Plasmids were isolated using aQiagen Plasmid Plus Kit (Qiagen—according to manufacturer'sinstructions) and sequenced to confirm the presence of the desiredmutation within the HSA sequence. These plasmids were named pDB5623(C34A+K93C) and pDB5624 (C34A+E294C).

A fragment was removed from plasmid pDB5624 using the NheI and SphIrestriction sites and was purified using a QIAquick Gel Extraction Kit(Qiagen) and ligated into pDB5623 digested with the same enzymes toproduce construct pDB5625. pDB5626 and pDB5627 were constructed byinsertion of the fragment produced by digestion of pDB5102 with SacIIand PstI restriction enzymes into similarly digested pDB5623 andpDB5624. pDB5102 is described in WO 2015/036579 (incorporated herein byreference). The ligated plasmids were all transformed into E. coli NEB5-alpha and plated onto LB plates (as described above) supplemented with50 μg/mL ampicillin. Plasmids were isolated using a Qiagen Plasmid PlusKit (Qiagen—according to manufacturer's instructions) and sequenced toconfirm the presence of the desired mutation within the HSA sequence.

To produce pDB5628 a fragment was removed from plasmid pDB5102 using theSacII and PstI restriction sites and was purified using a QIAquick GelExtraction Kit (Qiagen) and ligated into pDB5625 digested with the sameenzymes. The ligated plasmids were all transformed into E. coli NEB5-alpha and plated onto LB plates supplemented with 50 μg/mL ampicillin.Plasmids were isolated using a Qiagen Plasmid Plus Kit (Qiagen—accordingto manufacturer's instructions) and sequenced to confirm the presence ofthe desired mutation within the HSA sequence.

TABLE 12 Summary information for combination variants Protein VariantNumber of thiols Plasmid SEQ ID NO. C34A + K93C 1 pDB5623 111 C34A +E294C 1 pDB5624 129 C34A + K93C + E294C 2 pDB5625 141 K93C 2 pDB5626 142E294C 2 pDB5627 143 K93C + E294C 3 pDB5628 144

Production of Expression Plasmid and Yeast Stocks.

Preparation of the expression plasmids and transformation of S.cerevisiae was performed as described in WO 2012/150319 by the 48-hourstocking method (incorporated herein by reference). The host strain forthe constructs was S. cerevisiae BXP10 Cir° (WO 2015/036579,incorporated herein by reference). Purification of variants from shakeflask was performed as described in WO 2012/150319 (incorporated hereinby reference) unless otherwise stated.

Example 6. Production, Purification and Conjugation of Thio-AlbuminVariants

Cryopreserved yeast stocks each in 1 mL aliquots were inoculated intoseparate shake flasks containing 100 mL BMMS growth medium (yeastnitrogen base without amino acids or (NH₄)₂SO₄, Difco 1.7 g/L; citricacid monohydrate 6.09 g/L; Na₂HPO₄.2H₂O 25.27 g/L; (NH₄)₂SO₄ 5.0 g/L; pH6.5±0.2; sucrose added to 20 g/L). Cells were transferred from the shakeflask to the fermenter (10 L working volume, Sartorius Biostat C 10-3fermenter) when the concentration of cells in the shake flask reached0.8-1.2 mg/mL achieving a cell inoculum concentration of ≥10 mg/L(greater than or equal to 10 mg/L) in the fermenter.

The thio-albumin variants were produced by axenic culture of each of theyeast strains in high cell density (HCD) fed-batch fermentation. The aimof the fermentation was to achieve maximum biomass and productivity bycontrolling feed rate addition so that formation of by-products such asethanol and acetate were avoided. Further details of the fermentationprocess are described in WO 96/37515 (incorporated herein by reference).The temperature and pH were controlled at 30° C. and pH 6.2respectively. Culture supernatant was harvested by centrifugation usinga Sorvall RC 3C centrifuge (DuPont) to provide materials for immediatepurification and the remaining materials were frozen (−20° C.) forstorage, before being thawed for subsequent purifications. Final productconcentrations were determined by GP-HPLC using a LC2010 HPLC system(Shimadzu) equipped with UV detection under Shimadzu VP7.3 client serversoftware control as described in Example 3. Table 13 provides the yieldsof each thio-albumin variant (in mg/mL culture supernatant) and showsthat high product titres of greater than 1 mg/mL culture supernatantwere obtained in all cases.

TABLE 13 Thio-albumin variant protein concentration by GP-HPLCConcentration Number of by GPHPLC Sample Description thiols (mg/mL) SEQID NO. C34A + K93C 1 3.1 111 C34A + E294C 1 4.6 129 C34A + K93C + E294C2 2.3 141 K93C 2 1.8 142 E294C 2 3.9 143 K93C + E294C 3 1.6 144

The variants were purified at scale by a two-step chromatographyprocess. The first purification step was using AlbuPure® chromatographyas previously described in Example 3 but washing the column withapproximately 4 column volumes of 50 mM sodium acetate, pH 5.3, 10column volumes of 50 mM sodium phosphate, pH 8.0, and 10 column volumesof 50 mM ammonium acetate pH 8.0 respectively. Bound protein was elutedusing between 1 and 3 column volumes of 50 mM ammonium acetate, 10 mMsodium octanoate, pH 7.0. The AlbuPure® eluates were then furtherpurified using ion exchange chromatography via DE-FF as described inEvans et al. (2010), Protein Expression and Purification Volume 73,Issue 2, Pages 113-124. Post purification, the DE-FF eluate samples wereconcentrated and buffer exchanged by ultrafiltration/diafiltration using10,000 molecular weight cut-off Vivacell 100 centrifugal concentrators(Sartorius). The samples were centrifuged at 2,000×g for 30 minutes(multiple times) to reduce the volume to below 10 mL beforediafiltration against 10 volumes of 25 mM sodium phosphate, 215 mMsodium chloride, pH 6.5. Post diafiltration, sample concentrations werein the range of 124 to 177 mg/mL. The samples were diluted to a finalformulation concentration of 50 mg/mL in 25 mM sodium phosphate, 215 mMsodium chloride, pH 6.5.

The thio-albumin variants were conjugated with maleimide-PEG2-biotin asdescribed in Example 4, but with a 3.2-fold molar excess of biotin overthe free thiol content (number of free thiols). Due to some variantshaving multiple free thiol sites available for conjugation, the expectedmolecular weights for all biotin conjugation permutations are summarisedin Table 14. The variants with two or three thiol groups increased by2×525 Da, and 3×525 Da respectively. The relative peak heights of eachpeak species were used to calculate the percentage of target conjugate,i.e. the correct percentage of a single, double or triple biotinlabelled thio-albumin variant. The K93C+E294C variant had a total of 3free thiol residues, the MS spectrum for this variant is shown in FIG.7A. It was evident from the single peak species on the MS spectrum thatthe variant has successfully conjugated 3 moles of maleimide-PEG2-biotinper mole protein, as indicated by a mass increase of 1575 Da (3×525 Da)to 67968 Da (Table 15). The samples were incubated at 37° C., pH 9, forat least 24 hours for controlled hydrolysis to occur to determine thestability of the thio ether conjugate bond as previously described inExample 4. The results are summarised in Table 15. The yield of thehydrolysed thiol stable K93C+E294C conjugate was in the order of 20%triple conjugate, due to the competing retro-Michael deconjugation ofthe C34 conjugate during hydrolysis (FIG. 7B). The main species was nowa hydrolysed thiol stable double conjugate with a mass of 67476 Daindicating that hydrolysis had occurred to the double conjugate species.It was evident that the variants containing a cysteine at position C34had significant deconjugation during hydrolysis compared to the variantswith a C34A mutation. The double thiol variant C34A+K93C+E294C was 62%double conjugated pre hydrolysis and 56% post hydrolysis. An observedpeak species with a mass 66443 Da confirmed that hydrolysis had occurredwith minimal conjugate loss (FIG. 7C) compared to the K93C+E294Cconjugate which contained a cysteine at C34 (FIG. 7B) highlighting thatthe K93C and E294C variants had improved conjugate stability when usinga maleimide linker.

TABLE 14 Expected molecular weights post conjugation and hydrolysisSingle Double Triple conjugate Mr conjugate Mr conjugate Mr No. Free+biotin Hydro- +2x Hydro- +3x Hydro- Sample thiols Mr (525 Da) lysedbiotin lysed biotin lysed C34A + K93C 1 66382 66907 66925 n/a n/a n/an/a C34A + E294C 1 66381 66906 66924 n/a n/a n/a n/a C34A + K93C + 266356 66881 66899 67406 67442 n/a n/a E294C K93C 2 66414 66939 6695767464 67500 n/a n/a E294C 2 66413 66938 66956 67463 67499 n/a n/a K93C +E294C 3 66388 66913 66931 67438 67474 67963 68017 n/a: not applicable

TABLE 15 Conjugation efficiency and controlled hydrolysis results Postconjugation Post hydrolysis Conjugate Conjugate Number intact % targetintact % target Sample of mass con- mass con- Description thiols result(Da) jugate result (Da) jugate C34A + K93C 1 66910 68 66927 70 C34A +E294C 1 66908 52 66927 46 C34A + 2 67410 62 67443 56 K93C + E294C K93C 267467 99 67502 36 E294C 2 67467 87 67501 40 K93C + E294C 3 67968 9868020 20

The formulated samples were subjected to a six month stabilityassessment at 2-8° C. by GPHPLC, using the method described in Example3. The percentage monomer (in brackets) was determined for each samplerelative to its wild type control under the same storage conditions. Thepercentage monomer results are summarized in Table 16, and indicatedthat aggregation levels were within acceptable limits when the albuminvariants were formulated at 50 mg/mL and stored for six months at 2-8°C.

TABLE 16 GPHPLC protein stability assessment at 50 mg/mL, post storageat 2-8° C. Δ % Protein Sample Number % Monomer at Monomer SEQDescription of thiols T = 0 T = 1 m T = 2 m T = 3 m T = 6 m 0-6 month IDNO. WT control 1 93.8 (100) 94.5 (100) 94.5 (100) 94.4 (100) 94.9 (100)1.1 2 C34A + K93C 1 92.1 (98) 91.2 (97) 90.2 (95) 89.3 (95) 88.1 (93)−4.0 111 C34A + E294C 1 92.4 (99) 92.7 (98) 91.6 (97) 91.0 (96) 90.8(96) −1.6 129 C34A + K93C + 2 84.4 (90) 81.8 (87) 79.7 (84) 78.4 (83)75.9 (80) −8.5 141 E294C K93C 2 88.2 (94) 86.9 (92) 85.5 (91) 84.9 (90)84.2 (89) −4.0 142 E294C 2 89.3 (95) 90.2 (95) 89.7 (95) 89.0 (94) 88.9(94) −0.4 143 K93C + E294C 3 82.1 (88) 79.8 (84) 78.4 (83) 77.3 (82)76.8 (81) −5.3 144 m = month

Example 7: Combination Variants Having Altered FcRn Binding

HSA having the K573P substitution, as described in WO 2011/051489(incorporated herein by reference), has a higher affinity for FcRn thandoes wild type HSA. Constructs were produced to combine the mutations inthe variants described in Table 12 with the HSA K573P mutation fromplasmid pDB4673.

Method 3.

A fragment was removed from plasmids pDB5623, 5624, 5625, 5626, 5627 and5628 using the PstI and XhoI restriction sites and was purified using aQIAquick Gel Extraction Kit (Qiagen) and ligated into pDB4673 digestedwith the same enzymes to produce constructs pDB5704, 5707, 5710, 5713,5716 and 5719 (Table 17). The ligated plasmids were all transformed intoE. coli NEB 5-alpha (New England Biolabs) and plated onto LB platessupplemented with 50 μg/mL ampicillin. Plasmids were isolated using aQiagen Plasmid Plus Kit (Qiagen—according to manufacturer'sinstructions) and sequenced to confirm the presence of the desiredmutations within the HSA sequence.

TABLE 17 Summary information for variants having altered FcRn bindingVariant Plasmid Protein SEQ ID NO. K573P pDB4673 145 C34A + K93C + K573PpDB5704 146 C34A + E294C + K573P pDB5707 147 C34A + K93C + E294C + K573PpDB5710 148 K93C + K573P pDB5713 149 E294C + K573P pDB5716 150 K93C +E294C + K573P pDB5719 151

Production of Expression Plasmid and Yeast Stocks.

Preparation of the expression plasmids and transformation of S.cerevisiae was performed as described in WO 2012/150319 by the 48-hourstocking method (incorporated herein by reference). The host strain forthe constructs was S. cerevisiae BXP10 Cir° (WO 2015/036579,incorporated herein by reference)). Purification of variants from shakeflask was performed as described in WO 2012/150319 (incorporated hereinby reference) unless otherwise stated.

Example 8. Aggregation Screening of Combination Variants Having AlteredFcRn Binding

Shake flask culturing of S. cerevisiae and purification was performed asdescribed in Example 3. A single step AlbuPure chromatography procedurewas used to prepare purified material from 6 variants as described inExample 3. Post purification the 20 mL eluates were concentrated to lessthan 200 μL using Vivaspin centrifugal concentrators as described inExample 4. Post concentration the samples were buffer exchanged by theaddition of 10 mL of 25 mM sodium phosphate, 215 mM sodium chloride, pH6.5 and the samples centrifuged as before. The final volumes recoveredwere between 75 μL and 200 μL. The concentration and percentage monomerof the eluate samples was determined by Gel Permeation High PressureLiquid Chromatography (GP-HPLC) as described in Example 3. The resultsare summarised in Table 18. Final product concentrations were in therange of 47 to 154 mg/mL. A typical wild type albumin control in Example4 resulted in a monomer percentage of 87% at 1.1 mg/mL (Table 8A). Allvariants analysed had monomer percentages equal to or greater than 87%even at significantly higher protein concentrations. This indicated thatall variants had minimal propensity to aggregate.

TABLE 18 GPHPLC aggregation screening results GPHPLC monomerconcentration % Monomer Sample description (mg/mL) at T = 0 C34A +K93C + K573P 48.2 91.8 C34A + E294C + K573P 153.5 90.8 C34A + K93C +E294C + 98.8 88.4 K573P K93C + K573P 101.7 86.9 E294C + K573P 115.5 87.6K93C + E294C + K573P 46.5 91.2

Example 9. Conjugation Efficiency and Controlled Hydrolysis ofCombination Variants Having Altered FcRn Binding

The thio-albumin combination variants (Table 17) were conjugated with a3.2 fold excess of maleimide-PEG2-biotin as described in Example 6. Dueto some variants having multiple free thiol sites available forconjugation, the expected molecular weights for all biotin conjugationpermutations are summarised in Table 19.

TABLE 19 Expected molecular weights of albumin variants post conjugationand hydrolysis Single Double Triple conjugate Mr conjugate Mr conjugateMr No. Free +biotin Hydro- +2x Hydro- +3x Hydro- Sample thiols Mr (525Da) lysed biotin lysed biotin lysed C34A + K93C + 1 66351 66876 66894n/a n/a n/a n/a K573P C34A + E294C + 1 66350 66875 66893 n/a n/a n/a n/aK573P C34A + K93C + 2 66325 66850 66868 67375 67411 n/a n/a E294C + 573PK93C + K573P 2 66383 66908 66926 67433 67469 n/a n/a E294C + K573P 266382 66907 66925 67432 67468 n/a n/a K93C + E294C + 3 66357 66882 6690067407 67443 67932 67986 K573P n/a: not applicable

The molecular weight of the variants with two or three thiol groupsincreased by 2×525 Da, and 3×525 Da respectively. The relative peakheights of each peak species were used to calculate the percentage oftarget conjugate, i.e. the percentage of a single, double or triplebiotin labelled thio-albumin variant. The K93C+E294C+K573P variant had atotal of 3 free thiol residues (the third thiol being provided by nativeCys34); the MS spectrum for this variant is shown in FIG. 8A. It wasevident from the single peak species on the MS spectrum that the varianthas successfully conjugated with 3 moles of maleimide-PEG2-biotin permole protein, as indicated by a mass increase of 1575 Da (3×525 Da) to67940.8 Da. The samples were incubated at 37° C., pH 9, for at least 18hours for controlled hydrolysis to occur to determine the stability ofthe thio ether conjugate bond as previously described in Example 4. Theresults are summarized in Table 20.

The yield of the hydrolysed thiol stable K93C+E294C+K573P conjugate wasin the order of 23% triple conjugate, likely due to the competingretro-Michael deconjugation of the C34 conjugate during hydrolysis (FIG.8B). The main species was now a hydrolysed thiol stable double conjugatewith a mass of 67447.3 Da indicating that hydrolysis had occurred tothis double conjugate species. It was evident that the variantscontaining a cysteine at position C34 underwent more pronounceddeconjugation during hydrolysis compared to the variants with a C34Amutation.

TABLE 20 Conjugation efficiency and controlled hydrolysis results Postconjugation Post hydrolysis Conjugate Conjugate Number intact % targetintact % target Sample of mass con- mass con- Description thiols result(Da) jugate result (Da) jugate C34A + K93C + 1 66878 100 66896 100 K573P C34A + E294C + 1 66880 85 66897 89 K573P C34A + K93C + 2 6738290 * * E294C + K573P K93C + K573P 2 67438 100 67473 32 E294C + K573P 267441 100 67474 25 K93C + E294C + 3 67941 100 67989 23 K573P * lowintensity MS spectrum, unable to accurately quantify data

Example 10. Surface Plasmon Resonance (SPR) Analysis of CombinationVariants Having Altered FcRn Binding, Pre and Post Conjugation withMaleimide-PEG2-Biotin

Thio-albumin combination variants detailed in Tables 12 and 17 wereproduced by fed-batch fermentation and purified according to Example 6.Post purification, the samples were concentrated and the buffer wasexchanged against a minimum of 7 continuous volumes of 25 mM sodiumphosphate, 215 mM sodium chloride, pH 6.5 using 10,000 molecular weightcut-off Centramate Tangential Flow Filtration Membrane cassettes (PALL)before final formulation at 20 mg/mL in buffer (25 mM sodium phosphate,215 mM sodium chloride, pH 6.5). Subsequently, a size exclusionchromatography step (Sephacryl® 5200, GE Healthcare) was performed. Foreach sample 25 mL was split equally between two Vivaspin 20 centrifugalconcentrators and centrifuged at 4,500×g for two 20 minute time periodsto reduce the total volume to 5 mL. The concentrated material was loadedonto a 483 mL S200 column and the monomer peak collected to generatemonomeric protein at greater than 98% for FcRn binding analysis by SPR.Post purification, eluates were diluted to 5 mg/mL (±5%). The bindingaffinity of each variant for the human FcRn receptor was determined bothpre and post conjugation with maleimide-PEG2-biotin. Variants wereconjugated with a 3.2 fold excess of maleimide-PEG2-biotin as describedin Example 6. The percentage conjugation was determined by MS asdescribed in Example 2, but using a 15 minute analytical gradient, andprocessing data for the protein peak between approximately 7 and 10minutes. The results are shown in Table 21 and indicated all samples hadconjugated to varying extent, depending on the number of thiols.

TABLE 21 Conjugation efficiency for samples for SPR Protein SampleNumber Unconju- Mono- Di- Tri- SEQ Description of thiols gated %conjugate % conjugate % conjugate % ID NO. WT control 1 0 100 n/a n/a 2C34A + K93C 1 0 100 n/a n/a 111 C34A + E294C 1 74 26 n/a n/a 129 C34A +K93C + 2 0 74 26 n/a 141 E294C K93C 2 0 26 74 n/a 142 E294C 2 0 81 19n/a 143 K93C + E294C 3 0 0 80 20 144 K573P 1 8 93 n/a n/a 145 C34A +K93C + 1 0 100 n/a n/a 146 K573P C34A + E294C + 1 20 80 n/a n/a 147K573P C34A + K93C + 2 0 10 90 n/a 148 E294C + K573P K93C + K573P 2 0 0100  n/a 149 E294C + K573P 2 0 18 82 n/a 150 K93C + E294C + 3 0 0 40 60151 K573P n/a: not applicable

SPR analyses were carried out using a Biacore 3000 instrument (GEHealthcare). Flow cells of CM5 sensor chips were coupled with solublehuman FcRn (1200-1600 RU) using amine coupling chemistry as described inthe protocol provided by the manufacturer (GE Healthcare). The couplingwas performed by injecting 5 μg/mL of the protein in 10 mM sodiumacetate pH 4.5 (GE healthcare). Phosphate buffer (67 mM phosphatebuffer, 0.15 M NaCl, 0.005% Tween 20) at pH 5.5 was used as runningbuffer and dilution buffer. Regeneration of the surfaces were performedusing injections of HBS-EP buffer (0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA,0.005% surfactant P20) at pH 7.4 (GE Healthcare). Post immobilisation,the chip was left to stabilise with a constant flow (5 μL/min) ofrunning buffer. Chip surface was conditioned by injecting 3× injectionsof running buffer followed by 3× injections of regeneration buffer.Surfaces were checked for activity with native sequence HSA control. Fordetermination of binding kinetics, serial dilutions of albumin variants(10-0 μM) were injected over immobilized receptor at a constant flowrate (30 μL/min) at 25° C. In all analyses, data were zero adjusted andthe reference cell subtracted. Data evaluations were performed usingBIAevaluation 4.1 software (BIAcore AB). The results pre and postconjugation are shown in Tables 22 and 23 respectively.

The thio-albumin variants screened over human FcRn bound to the receptorin a reversible, pH-dependent manner.

The thio-albumin variants in a wild type background (i.e. the only aminoacid alterations were those that were introduced to affect the number ofconjugatable cysteine residues) gave a similar fold increase in bindingaffinity to FcRn compared to the wild type control (SEQ ID NO. 2) bothpre and post conjugation. The thio-albumin variants which also includeda K573P mutation (to increase the affinity of the albumin variant toFcRn) maintained their increase in FcRn affinity, compared to the K573Pcontrol (SEQ ID NO. 145), pre and post conjugation indicating thatneither the change in conjugatable cysteine residues nor the conjugationpartner had an observable influence on the binding affinity of thealbumin variant to FcRn.

TABLE 22 FcRn affinity for variants pre conjugation Protein SampleNumber Ka Kd KD SEQ Description of thiols (10³/Ms) (10³/Ms) (μM) Fold >WT ID NO. WT control 1 7.38 54.0 7.32 n/a 2 C34A + K93C 1 12.4 44.9 3.622.02 111 C34A + E294C 1 6.13 46.7 7.61 0.96 129 C34A + K93C + E294C 210.41 39.5 3.79 1.93 141 K93C 2 8.19 43.45 5.30 1.38 142 E294C 2 5.046.3 9.25 0.79 143 K93C + E294C 3 7.65 37.9 4.95 1.48 144 K573P 1 5.703.76 0.66 11.10 145 C34A + K93C + K573P 1 8.06 3.83 0.48 15.25 146C34A + E294C + K573P 1 6.07 3.96 0.65 11.26 147 C34A + K93C + E294C +K573P 2 8.11 3.67 0.45 16.27 148 K93C + K573P 2 8.37 4.07 0.48 15.25 149E294C + K573P 2 5.65 4.17 0.74 9.89 150 K93C + E294C + K573P 3 6.8 3.820.56 13.07 151 n/a: not applicable Fold > WT = KD (μM) WT control/KD(μM) variant

TABLE 23 FcRn affinity for samples post conjugation withmaleimide-PEG2-biotin Protein Sample Number Ka Kd KD SEQ Description ofthiols (10³/Ms) (10³/Ms) (μM) Fold > WT ID NO. WT control 1 9.26 25.42.74 n/a 2 C34A + K93C 1 12.95 19.85 1.53 1.79 111 C34A + E294C 1 8.0720.15 2.50 1.09 129 C34A + K93C + E294C 2 11.55 17.4 1.51 1.80 141 K93C2 10.2 21.0 2.06 1.33 142 E294C 2 9.38 19.9 2.12 1.29 143 K93C + E294C 311.8 19.3 1.63 1.68 144 K573P 1 9.25 3.12 0.337 8.13 145 C34A + K93C +K573P 1 14.35 2.97 0.207 13.24 146 C34A + E294C + K573P 1 10.42 2.970.285 9.61 147 C34A + K93C + E294C + K573P 2 13.7 2.71 0.198 13.84 148K93C + K573P 2 13.7 2.93 0.214 12.80 149 E294C + K573P 2 11.4 3.22 0.2839.68 150 K93C + E294C + K573P 3 13.05 3.31 0.254 10.79 151 n/a: notapplicable Fold > WT = KD (μM) WT control/KD (μM) variant

Example 11. Aggregation Analysis of Combination Variants Having AlteredFcRn Binding

The thio-albumin combination variants formulated at 5 mg/mL in Example10 were analysed for their tendency to remain as a monomer in solution.WT HSA, the variant K573P and the variant C34A+L302C were prepared asdescribed in Example 10 and included as controls. The free thiol contentfor each variant was determined at T=0 and following 3 months storage at5° C. by mass spectrometric analysis of protein sample treated with DTNBreagent, similar to the method of Example 2. For this example, 80 μL ofeach variant sample was diluted with 920 μL of buffer 1 (100 mMTris-HCl, 10 mM EDTA, pH 8.0). To each variant sample, 50 μL of buffer 2(4 mg/mL DTNB, 500 mM sodium phosphate, pH 7.0) was added. The resultantpreparation incubated for at least 25 minutes at ambient temperature(20±5° C.) to allow TNB labelling. Post incubation, the samples weresubjected to mass spectrometry to determine the intact protein mass postconjugation as per the method described in Example 2, but using a 15minute analytical gradient, and processing data for the protein peakbetween approximately 7 and 10 minutes. The results are summarised inTable 24A and Table 24B. An increase in mass of 197 Da upon DTNBincubation is indicative of the presence of one free thiol group on theprotein in the sample. An increase of 394 Da and 591 Da is indicative oftwo or three free thiol groups respectively. All samples had high levelsof free thiol at the start of the stability study, and the majoritymaintained a high free thiol level following 3 months storage at 5° C.

TABLE 24A Mass Spectrometry DTNB free thiol results Protein SampleNumber Unconju- Mono- Di- Tri- SEQ Description of thiols gated %conjugate % conjugate % conjugate % ID NO. WT control 1 0 91 0 9 2C34A + L302C 1 0 100 0 0 152 C34A + K93C 1 0 91 0 9 111 C34A + E294C 1 694 0 0 129 C34A + K93C + 2 0 39 61 0 141 E294C K93C 2 16 0 84 0 142E294C 2 0 28 84 0 143 K93C + E294C 3 0 0 51 49 144 K573P 1 0 91 0 9 145C34A + K93C + 1 0 93 0 7 146 K573P C34A + E294C + 1 7 87 0 6 147 K573PC34A + K93C + 2 0 5 89 0 148 E294C + K573P K93C + K573P 2 0 0 92 0 149E294C + K573P 2 0 7 87 0 150 K93C + E294C + 3 0 0 22 78 151 K573P

TABLE 24B Mass Spectrometry DTNB free thiol results, post storage at 5°C. Protein Sample Number Unconju- Mono- Di- Tri- SEQ Description ofthiols gated % conjugate % conjugate % conjugate % ID NO. WT control 1 094 6 0 2 C34A + L302C 1 0 100 0 0 152 C34A + K93C 1 0 95 0 5 111 C34A +E294C 1 55 45 0 0 129 C34A + K93C + 2 0 54 46 0 141 E294C K93C 2 23 0 770 142 E294C 2 0 50 50 0 143 K93C + E294C 3 0 0 73 27 144 K573P 1 0 94 06 145 C34A + K93C + 1 0 95 0 5 146 K573P C34A + E294C + 1 14 86 0 0 147K573P C34A + K93C + 2 0 10 90 0 148 E294C + K573P K93C + K573P 2 0 0 940 149 E294C + K573P 2 0 13 87 0 150 K93C + E294C + 3 0 0 32 68 151 K573P

Samples were stored for 3 months at 5° C. and 40° C. and the aggregationprofile determined at various time points by GPHPLC as described inExample 3. The percentage monomer (in brackets) was determined for eachsample relative to its wild type control under the same storageconditions. The results for 5° C. and 40° C. are provided in Tables 25and 26 respectively. All variants had a monomer greater than 98% at T=0.The majority of thio-albumin variants maintained a monomeric proteinpercentage equal to or greater than 97% during 3 month's storage at 5°C. Relative to the other variants analysed, variant C34A+L302C was moreprone to aggregation. It was also evident that the majority ofthio-albumin variants maintained a monomeric protein percentage equal toor greater than 80% during 3 months storage at 40° C., even thosecontaining two or three thiol residues. However, it was evident thatvariant C34A+L302C was more prone to aggregation with a monomerpercentage of 73.2% following 3 months storage at 40° C.

TABLE 25 GPHPLC protein stability assessment at 5 mg/mL, post storage at5° C. % Monomer at Protein Sample Number T = 1 T = 2 T = 3 SEQDescription of thiols T = 0 month month month ID NO. WT control 1 99.8(100) 99.3 (100) 99.7 (100) 99.7 (100) 2 C34A + L302C 1 98.3 (99) 95.5(96) 94.9 (95) 95.0 (95) 152 C34A + K93C 1 99.5 (100) 99.2 (100) 98.9(99) 98.7 (99) 111 C34A + E294C 1 99.5 (100) 99.4 (100) 99.2 (100) 99.2(100) 129 C34A + K93C + 2 99.1 (99) 98.5 (99) 97.9 (98) 97.5 (98) 141E294C K93C 2 99.5 (100) 99.3 (100) 99.0 (99) 98.8 (99) 142 E294C 2 99.6(100) 99.4 (100) 99.2 (100) 99.1 (99) 143 K93C + E294C 3 99.2 (99) 98.8(100) 98.3 (99) 97.9 (98) 144 K573P 1 99.7 (100) 99.7 (100) 99.6 (100)98.5 (99) 145 C34A + K93C + 1 99.6 (100) 99.2 (100) 99.0 (99) 98.6 (99)146 K573P C34A + E294C + 1 99.4 (100) 99.1 (100) 98.8 (99) 98.5 (99) 147K573P C34A + K93C + 2 99.3 (100) 98.5 (99) 97.7 (98) 96.9 (97) 148E294C + K573P K93C + K573P 2 99.8 (100) 99.7 (100) 99.6 (100) 98.5 (100)149 E294C + K573P 2 99.7 (100) 98.9 (99) 99.0 (99) 98.8 (99) 150 K93C +E294C + 3 99.5 (100) 99.1 (100) 98.8 (99) 98.5 (99) 151 K573P

TABLE 26 GPHPLC protein stability assessment at 5 mg/mL, post storage at40° C. % Monomer at Protein Sample Number T = 0.5 T = 1 T = 2 T = 3 SEQDescription of thiols T = 0 month month month month ID NO. WT control 199.8 (100) 99.4 (100) 99.3 (100) 99.0 (100) 97.6 (100) 2 C34A + L302C 198.3 (99) 87.6 (88) 80.9 (82) 75.6 (76) 73.2 (75) 152 C34A + K93C 1 99.5(100) 96.1 (97) 93.4 (94) 90.3 (91) 86.6 (89) 111 C34A + E294C 1 99.5(100) 98.6 (99) 96.6 (97) 96.0 (97) 95.4 (98) 129 C34A + K93C + 2 99.1(99) 93.8 (94) 89.3 (90) 85.1 (86) 80.4 (82) 141 E294C K93C 2 99.5 (100)96.6 (97) 94.5 (95) 90.4 (91) 88.8 (91) 142 E294C 2 99.6 (100) 98.1 (99)95.7 (96) 95.1 (96) 94.2 (97) 143 K93C + E294C 3 99.2 (99) 93.9 (95)89.3 (90) 82.9 (84) 80.0 (82) 144 K573P 1 99.7 (100) 99.3 (100) 99.0(100) 98.7 (100) 97.4 (100) 145 C34A + K93C + 1 99.6 (100) 95.5 (96)93.0 (94) 89.5 (90) 86.5 (89) 146 K573P C34A + E294C + 1 99.4 (100) 97.3(98) 95.9 (97) 95.0 (96) 94.4 (97) 147 K573P C34A + K93C + 2 99.3 (100)91.8 (92) 88.3 (89) 82.7 (84) 80.9 (83) 148 E294C + K573P K93C + K573P 299.8 (100) 98.1 (99) 96.7 (97) 94.5 (96) 92.6 (95) 149 E294C + K573P 299.7 (100) 97.5 (98) 95.8 (97) 94.5 (96) 94.4 (97) 150 K93C + E294C + 399.5 (100) 94.9 (96) 92.0 (93) 88.7 (90) 84.1 (86) 151 K573P

Example 12. Conjugation of Combination Variants Having Altered FcRnBinding, with Fluorescent Probes

Thio-albumin combination variants formulated at 5 mg/mL in Example 10,following 6 weeks storage at 2-8° C., were conjugated using a 3-foldexcess of Alexa Fluor® 488-PEG4-Lys(monobromomaleimide)-NH2 dye (FIG.9A) or 5-carboxyfluorescein-PEG4-Lys(monobromomaleimide)-NH2 dye (FIG.10A) (Almac Group Ltd., UK, custom synthesis). Variants were dilutedwith PBS buffer, pH 7.4 to give 1 mL solutions at 1 mg/mL (15.05 nmol).A 1 mg/mL stock solution of Alexa Fluor®488-PEG4-Lys(monobromomaleimide)-NH2 dye was prepared by reconstituting1.6 mg material with 1.6 mL PBS buffer pH 7.4. From the Alexa Fluor®488-PEG4-Lys(monobromomaleimide)-NH2 dye stock solution, 51.5 μL (45.15nmol) was added to the single thiol variants, 103 μL (90.3 nmol) dyestock solution was added to the double thiol variants, and 154.5 μL(135.3 nmol) dye stock solution was added to the triple thiol variantsto give a threefold excess of Alexa Fluor®488-PEG4-Lys(monobromomaleimide)-NH2 dye over the number of free thiols.A 0.5 mg/mL stock solution of5-carboxyfluorescein-PEG4-Lys(monobromomaleimide)-NH2 dye was preparedby reconstituting 1.7 mg material with 1.7 mL dimethyl sulfoxide (DMSO)and 1.7 mL PBS pH 7.4 buffer. From the5-carboxyfluorescein-PEG4-Lys(monobromomaleimide)-NH2 dye stock solution44.3 μL (45.15 nmol) was added to the single thiol variants, 88.6 μL(90.3 nmol) dye stock solution was added to the double thiol variants,and 132.9 μL (135.3 nmol) dye stock solution was added to the triplethiol variants to give a threefold excess of5-carboxyfluorescein-PEG4-Lys(monobromomaleimide)-NH2 dye over thenumber of free thiols. Samples were gently mixed and incubated atambient temperature overnight in the dark. Post incubation the sampleswere analysed by mass spectrometry to determine the intact protein masspost conjugation as per the MS method described in Example 2, but usinga 15 minute analytical gradient, and processing data for the proteinpeak between approximately 7 and 10 minutes. The results are summarisedin Table 27 and Table 28.

The MS spectrum for the altered FcRn binding variant K573P shown in FIG.9B, exhibited a single species at 67468.5 Da indicating the correctmolecular weight for a K573P variant plus a single addition of AlexaFluor® 488-PEG4-Lys(monobromomaleimide)-NH2 dye (+1058 Da). Thisconfirmed the variant had a single free thiol located at Cys34 availablefor conjugation. The thio-albumin variant K93C+E294C+K573P shown in FIG.9C indicated that conjugation had occurred post an overnight incubation,giving approximately 42% diconjugate and 58% triconjugate speciesrespectively, when comparing the relative peak heights of conjugatedspecies. It was evident that the main peak species had increased byapproximately 3174 Da (3×1058 Da) to 69536 Da. This indicated thevariant had three free thiols available for conjugation.

The MS spectrum for the altered FcRn binding variant K573P shown in FIG.10B, exhibited a single species at 67310.6 Da indicating the correctmolecular weight for a K573P variant plus a single addition of5-carboxyfluorescein-PEG4-Lys(monobromomaleimide)-NH2 dye (+901 Da). Thethio-albumin variant C34A+K93C+E294C+K573P shown in FIG. 10C indicatedthat conjugation had occurred post an overnight incubation, givingapproximately 9% monoconjugate and 91% diconjugate species respectively,when comparing the relative peak heights of conjugated species. It wasevident that the main peak species had increased by approximately 1802Da (2×901 Da) to 68129.7 Da. This indicated the variant had two freethiols available for conjugation.

TABLE 27 Conjugation efficiency results of thio-albumin variants withAlexa Fluor ® 488-PEG4-Lys(monobromomaleimide)-NH2 dye Protein SampleNumber Unconju- Mono- Di- Tri- SEQ Description of thiols gated %conjugate % conjugate % conjugate % ID NO. WT control 1 0 93 n/a n/a 2C34A + K93C 1 0 100 n/a n/a 111 C34A + E294C 1 100  0 n/a n/a 129 C34A +K93C + 2 * * * n/a 141 E294C K93C 2 17  0 83 n/a 142 E294C 2 0 89 11 n/a143 K93C + E294C 3 * * * * 144 K573P 1 0 100 n/a n/a 145 C34A + K93C + 10 100 n/a n/a 146 K573P C34A + E294C + 1 8 92 n/a n/a 147 K573P C34A +K93C + 2 0 7 93 n/a 148 E294C + K573P K93C + K573P 2 0 0 91 n/a 149E294C + K573P 2 0 0 100  n/a 150 K93C + E294C + 3 0 0 42 58 151 K573Pn/a: not applicable * low intensity MS spectrum, unable to accuratelyquantify data

TABLE 28 Conjugation efficiency results of thio-albumin variants with5-carboxyfluorescein-PEG4-Lys(Bromomaleimide)-NH2 dye Protein SampleNumber Unconju- Mono- Di- Tri- SEQ Description of thiols gated %conjugate % conjugate % conjugate % ID NO. WT control 1 0 96 n/a n/a 2C34A + K93C 1 0 100 n/a n/a 111 C34A + E294C 1 100  0 n/a n/a 129 C34A +K93C + 2 * * * n/a 141 E294C K93C 2 30  0 70 n/a 142 E294C 2 * * * n/a143 K93C + E294C 3 * * * 144 K573P 1 0 100 n/a n/a 145 C34A + K93C + 1 0100 n/a n/a 146 K573P C34A + E294C + 1 18  82 n/a n/a 147 K573P C34A +K93C + 2 0 9 91 n/a 148 E294C + K573P K93C + K573P 2 1 0 99 n/a 149E294C + K573P 2 * * * n/a 150 K93C + E294C + 3 * * * * 151 K573P n/a:not applicable * low intensity MS spectrum, unable to accuratelyquantify data

Example 13. Conjugation of Combination Variants Having Altered FcRnBinding, with Paclitaxel

Thio-albumin combination variants formulated at 5 mg/mL in Example 10,following 3 months storage at 2-8° C., were conjugated using a 1.5 foldexcess of paclitaxel which was via an ester group activated with amonobromomaleimide moiety, as shown in FIG. 11A, resulting in themolecule monobromomaleimide-paclitaxel (Almac Group Ltd., UK customsynthesis). Variants were diluted with PBS buffer, pH 7.4 to give 1 mLsolutions at 1 mg/mL (15.05 nmol). A 2 mg/mL stock solution ofmonobromomaleimide-paclitaxel was prepared by reconstituting 6.6 mgmaterial with 3.3 mL DMSO. From the monobromomaleimide-paclitaxel stocksolution, 12.24 μL (22.58 nmol) was added to the single thiol variants,24.47 μL (45.15 nmol) stock solution was added to the double thiolvariants, and 36.71 μL (67.73 nmol) stock solution was added to thetriple thiol variants to give a threefold excess ofmonobromomaleimide-paclitaxel over the number of free thiols. Sampleswere gently mixed and incubated at ambient temperature overnight. Postincubation the samples were subjected to mass spectrometry to determinethe intact protein mass post conjugation as per the MS method describedin Example 2, but using a 15 minute analytical gradient, and processingdata for the protein peak between approximately 7 and 10 minutes. Theresults are summarised in Table 29.

The MS spectrum for the altered FcRn binding variant K573P shown in FIG.11B indicated that conjugation had occurred post an overnightincubation, giving approximately 77% monoconjugated and 23% unconjugatedspecies respectively, when comparing the relative peak heights of theprotein species. It was evident that the main peak species at 67412.2 Dahad increased by approximately 1004 Da due to a single addition ofmonobromomaleimide-paclitaxel. The MS spectrum for the thio-albuminvariant K93C+E294C+K573P shown in FIG. 11C indicated that conjugationhad occurred post an overnight incubation, giving approximately 6%monoconjugate, approximately 60% diconjugate and 30% triconjugatespecies respectively, when comparing the relative peak heights ofconjugated species. It was evident that the main peak species hadincreased by approximately 2008 Da (2×1004 Da) to 68364.2 Da, with a69383.7 Da species indicative of a 3012 Da triple addition.

TABLE 29 Conjugation efficiency results of thio-albumin variants withmonobromomaleimide-paclitaxel Protein Sample Number Unconju- Mono- Di-Tri- SEQ Description of thiols gated % conjugate % conjugate % conjugate% ID NO. WT control 1 24 76 n/a n/a 2 C34A + K93C 1 50 50 n/a n/a 111C34A + E294C 1 100 0 n/a n/a 129 C34A + K93C + 2 * * * n/a 141 E294CK93C 2 30 26 44 n/a 142 E294C 2 0 100  0 n/a 143 K93C + E294C 3 * * *  0144 K573P 1 23 77 n/a n/a 145 C34A + K93C + 1 59 41 n/a n/a 146 K573PC34A + E294C + 1 34 66 n/a n/a 147 K573P C34A + K93C + 2 10 50 40 n/a148 E294C + K573P K93C + K573P 2 8 40 52 n/a 149 E294C + K573P 2 0 18 68n/a 150 K93C + E294C + 3 0 6 60 30 151 K573P n/a: not applicable * lowintensity MS spectrum, unable to accurately quantify data

Example 14. Conjugation of Combination Variants Having Altered FcRnBinding, with Exenatide Peptide

Thio-albumin combination variants formulated at 5 mg/mL in Example 10,following 3 months storage at 2-8° C., were conjugated using a 1.5 foldexcess of monobromomaleimide-PEG2-exenatide peptide as shown in FIG. 12A(Almac Group Ltd., UK, custom synthesis). Variants were diluted with PBSbuffer, pH 7.4 to give 1 mL solutions at 1 mg/mL (15.05 nmol). A 5 mg/mLstock solution of monobromomaleimide-PEG2-exenatide peptide was preparedby reconstituting 5 mg material with 1 mL PBS buffer pH 7.4. From themonobromomaleimide-PEG2-exenatide peptide stock solution, 21.17 μL(22.58 nmol) was added to the single thiol variants, 42.35 μL (45.15nmol) peptide stock solution was added to the double thiol variants, and63.52 μL (67.73 nmol) peptide stock solution was added to the triplethiol variants to give a threefold excess ofmonobromomaleimide-PEG2-exenatide peptide over the number of freethiols. Samples were gently mixed and incubated at ambient temperatureovernight. Post incubation the samples were subjected to massspectrometry to determine the intact protein mass post conjugation asper the MS method described in Example 2, but using a 15 minuteanalytical gradient, and processing data for the protein peak betweenapproximately 7 and 10 minutes. The results are summarised in Table 30.

The MS spectrum for the altered FcRn binding variant K573P shown in FIG.12B indicated that conjugation had occurred post an overnightincubation, giving approximately 33% monoconjugate and 67% unconjugatedspecies respectively, when comparing the relative peak heights ofprotein species. It was evident that the main peak species at 66409.2 Dawas unconjugated K573P variant. The second species had increased byapproximately 4609 Da due to a single addition ofmonobromomaleimide-PEG2-exenatide peptide. The thio-albumin variantC34A+K93C+E294C+K573P shown in FIG. 12C indicated that conjugation hadoccurred post an overnight incubation, giving approximately 33%diconjugate species, approximately 45% monoconjugate species, andapproximately 22% unconjugated species respectively, when comparing therelative peak heights of protein species. It was evident that the mainpeak species had increased by approximately 4609 Da to 70941.7 Da, witha 75557.3 Da species indicative of a 9218 Da addition representing adouble conjugation of monobromomaleimide-PEG2-exenatide peptide.

TABLE 30 Conjugation efficiency results of thio-albumin variants withexenatide peptide Protein Sample Number Unconju- Mono- Di- Tri- SEQDescription of thiols gated % conjugate % conjugate % conjugate % ID NO.WT control 1 71 29 n/a n/a 2 C34A + K93C 1 74 26 n/a n/a 111 C34A +E294C 1 100   0 n/a n/a 129 C34A + K93C + 2 * * * n/a 141 E294C K93C 279  0 21 n/a 142 E294C 2 * * * n/a 143 K93C + E294C 3 * * * * 144 K573P1 67 33 n/a n/a 145 C34A + K93C + 1 74 26 n/a n/a 146 K573P C34A +E294C + 1 51 49 n/a n/a 147 K573P C34A + K93C + 2 22 45 33 n/a 148E294C + K573P K93C + K573P 2 60  0 39 n/a 149 E294C + K573P 2 21 33 47n/a 150 K93C + E294C + 3 * * * * 151 K573P n/a: not applicable * lowintensity MS spectrum, unable to accurately quantify data

Example 15. Conjugation of Combination Variants Having Altered FcRnBinding Affinity, with FLAG Peptide

Thio-albumin combination variants formulated at 5 mg/mL in Example 10,following 3 months storage at 2-8° C., were conjugated using a 1.5 foldexcess of maleimide-propyl-FLAG peptide as shown in FIG. 13A (PeptideProtein Research Ltd., UK, custom synthesis). Variants were diluted withPBS buffer, pH 7.4 to give 1 mL solutions at 1 mg/mL (15.05 nmol). A 1mg/mL stock solution of maleimide-propyl-FLAG peptide was prepared byreconstituting 5.4 mg material with 5.4 mL PBS buffer pH 7.4. From themaleimide-propyl-FLAG peptide stock solution, 26.28 μL (22.58 nmol) wasadded to the single thiol variants, 52.56 μL (45.15 nmol) peptide stocksolution was added to the double thiol variants, and 78.84 μL (67.73nmol) peptide stock solution was added to the triple thiol variants togive a threefold excess of maleimide-propyl-FLAG peptide over the numberof free thiols. Samples were gently mixed and incubated at ambienttemperature overnight. Post incubation the samples were subjected tomass spectrometry to determine the intact protein mass post conjugationas per the MS method described in Example 2 but using a 15 minuteanalytical gradient, and processing data for the protein peak betweenapproximately 7 and 10 minutes. The results are summarised in Table 31.

The MS spectrum for the altered FcRn binding variant K573P shown in FIG.13B indicated that conjugation had occurred post an overnightincubation, giving approximately 29% monoconjugate and 71% unconjugatedspecies respectively, when comparing the relative peak heights ofprotein species. It was evident that the main peak species at 66409.1 Dawas unconjugated K573P variant. The second most abundant peak specieshad increased by approximately 1164 Da due to a single addition ofmaleimide-propyl-FLAG peptide. The MS spectrum for the thio-albuminvariant K93C+E294C+K573P shown in FIG. 13C indicated that conjugationhad occurred post an overnight incubation, giving approximately 29%triconjugate species, approximately 50% diconjugate species,approximately 20% monoconjugate species, and approximately 2%unconjugated species respectively, when comparing the relative peakheights of the protein species. It was evident that the main peakspecies had increased by approximately 2328 Da to 68685.5 Da, with a69850.5 Da species indicative of a 3492 Da addition representing atriple conjugation of maleimide-propyl-FLAG peptide.

TABLE 31 Conjugation efficiency results of albumin variants with FLAGpeptide Protein Sample Number Unconju- Mono- Di- Tri- SEQ Description ofthiols gated % conjugate % conjugate % conjugate % ID NO. WT control 173 27 n/a n/a 2 C34A + K93C 1 48 52 n/a n/a 111 C34A + E294C 1 80 20 n/an/a 129 C34A + K93C + 2 12 77 10 n/a 141 E294C K93C 2 45 30 25 n/a 142E294C 2 26 63 11 n/a 143 K93C + E294C 3 * * * * 144 K573P 1 71 29 n/an/a 145 C34A + K93C + 1 47 53 n/a n/a 146 K573P C34A + E294C + 1 22 78n/a n/a 147 K573P C34A + K93C + 2  5 34 61 n/a 148 E294C + K573P K93C +K573P 2 23 50 27 n/a 149 E294C + K573P 2 10 51 39 n/a 150 K93C + E294C +3  2 20 50 29 151 K573P n/a: not applicable * low intensity MS spectrum,unable to accurately quantify data

Example 16. Immunogenicity Assessment of Thio-Albumin Variants UsingEpiScreen™ Time Course T Cell Assay

Thio-albumin variants K93C (SEQ ID NO. 142) and E294C (SEQ ID NO. 143)were prepared as described in Example 10 along with a wild type albumincontrol (SEQ ID NO. 2). In contrast to Example 10, the size exclusionchromatography eluates were diluted to 4 mg/mL (±5%). Albumin testsamples were assessed for their ability to induce CD4+ T cell responsesusing the EpiScreen™ time course T cell assay (Abzena, Cambridge UK).Briefly, the EpiScreen™ assay was carried out as follows: peripheralblood mononuclear cells from a cohort of 50 healthy donors representingthe European and North American population (based on HLA allotypes) wereincubated with the test samples. T cell responses were measured usingproliferation assays ([3H]-Thymidine uptake) and cytokine secretionassays (IL-2 ELISpot).

The frequency of positive responses in the proliferation assay were lowfor all samples (ranges from 0% to 8%) and no positive responses wereobserved in the IL-2 ELISpot assay suggesting a low risk of clinicalimmunogenicity for all three samples.

1. (canceled)
 2. A conjugation-competent polypeptide comprising an aminoacid sequence which is at least 90% identical to a human albumin havinga sequence as set forth in SEQ ID NO: 2, or a fragment thereof, andcomprising a substitution to cysteine at a position equivalent to E294of SEQ ID NO:
 2. 3. The conjugation-competent polypeptide of claim 2,wherein at a position equivalent to position 34 of SEQ ID NO: 2 there isa conjugation-competent cysteine.
 4. The conjugation-competentpolypeptide of claim 2, wherein at a position equivalent to position 34of SEQ ID NO: 2 there is not a conjugation-competent cysteine.
 5. Theconjugation-competent polypeptide of claim 2, in which the polypeptidehas at least 98% sequence identity to SEQ ID NO:
 2. 6. A method forincreasing the plasma half-life of a molecule selected from the groupconsisting of a bioactive agent, imaging agent, diagnostic agent,contrast agent, and therapeutic compound, the method comprisingconjugating, fusing or associating the molecule with aconjugation-competent polypeptide according to claim
 2. 7. A fusionpolypeptide comprising a conjugation-competent polypeptide of claim 2and a fusion partner polypeptide.
 8. A polynucleotide which encodes thepolypeptide of claim
 2. 9. A plasmid comprising the polynucleotide ofclaim
 8. 10. A host cell comprising a polynucleotide of claim
 8. 11. Aconjugate comprising: (i) a bioactive agent, imaging agent, diagnosticagent, contrast agent or therapeutic compound; and (ii) the polypeptideaccording to claim 2, wherein the bioactive agent, imaging agent,diagnostic agent, contrast agent, or therapeutic compound is linked tothe polypeptide through a conjugation-competent cysteine residue of thepolypeptide.
 12. The conjugate of claim 11, further comprising one ormore additional molecules, wherein the additional molecule is abioactive agent, imaging agent, diagnostic agent, contrast agent ortherapeutic compound, each of the one or more additional molecules beinglinked to the polypeptide through a conjugation-competent cysteineresidue of the polypeptide.
 13. A method of producing the polynucleotideof claim 2 comprising: providing a nucleic acid molecule encoding aparent albumin or fragment thereof; and modifying the nucleic acidsequence of the nucleic acid molecule to encode a conjugation-competentpolypeptide, which is at least 90% identical to human albumin, or afragment thereof, comprising a conjugation-competent cysteine residue ata position equivalent to E294 of SEQ ID NO.
 2. 14. A method of producingthe polypeptide of claim 2, comprising: (a) culturing the host cell ofclaim 10 under conditions that allow expression of the polypeptide; and(b) recovering the polypeptide from the host cell and/or from host cellgrowth medium.
 15. The method of claim 14, further comprising purifyingthe polypeptide obtained in step (b).
 16. A method of producing theconjugate of claim 11, wherein the method comprises linking thepolypeptide of claim 2, or the polypeptide produced by the method ofclaim 13, to a bioactive agent, imaging agent, diagnostic agent,contrast agent or therapeutic compound through a conjugation-competentcysteine residue of the polypeptide.
 17. A particle comprising thepolypeptide of claim 2, wherein the particle is a nanoparticle, amicroparticle, or a liposome.
 18. A composition comprising the conjugateof claim 11, and at least one pharmaceutically acceptable carriers ordiluents.
 19. The conjugate of claim 11, wherein the bioactive agent,imaging agent, diagnostic agent, contrast agent or therapeutic compoundis selected from: (i) therapeutic compounds comprising 4-1BB ligand,5-helix, A human C-C chemokine, A human L105 chemokine, A human L105chemokine designated huL105_3, A monokine induced by gamma-interferon(MIG), A partial CXCR4B protein, A platelet basic protein (PBP),al-antitrypsin, ACRP-30 Homologue, Complement Component C1q C,Adenoid-expressed chemokine (ADEC), aFGF, FGF-1, AGF, AGF Protein,albumin, an etoposide, angiostatin, Anthrax vaccine, Antibodies specificfor collapsin, antistasin, Anti-TGF beta family antibodies, antithrombinIII, APM-1, ACRP-30, Famoxin, apo-lipoprotein species, Arylsulfatase B,b57 Protein, BCMA, Beta-thromboglobulin protein (beta-TG), bFGF, FGF2,Blood coagulation factors, BMP Processing Enzyme Furin, BMP-10, BMP-12,BMP-15, BMP-17, BMP-18, BMP-2B, BMP-4, BMP-5, BMP-6, BMP-9, BoneMorphogenic Protein-2, calcitonin, Calpain-10a, Calpain-10b,Calpain-10c, Cancer Vaccine, Carboxypeptidase, C-C chemokine, MCP2, CCR5variant, CCR7, CCR7, CD11 a Mab, CD137, 4-1BB Receptor Protein, CD20Mab, CD27, CD27L, CD30, CD30 ligand, CD33 immunotoxin, CD40, CD40L, CD52Mab, Cerebus Protein, Chemokine Eotaxin, Chemokine hIL-8, ChemokinehMCP1, Chemokine hMCP1a, Chemokine hMCP1b, Chemokine hMCP2, ChemokinehMCP3, Chemokine hSDF1b, Chemokine MCP-4, chemokine TECK and TECKvariant, Chemokine-like protein IL-8M1 Full-Length and Mature,Chemokine-like protein IL-8M10 Full-Length and Mature, Chemokine-likeprotein IL-8M3, Chemokine-like protein IL-8M8 Full-Length and Mature,Chemokine-like protein IL-8M9 Full-Length and Mature, Chemokine-likeprotein PF4-414 Full-Length and Mature, Chemokine-like protein PF4-426Full-Length and Mature, Chemokine-like protein PF4-M2 Full-Length andMature, Cholera vaccine, Chondromodulin-like protein, c-kit ligand, SCF,Mast cell growth factor, MGF, Fibrosarcoma-derived stem cell factor,CNTF and fragment thereof (such as CNTFAx15′(Axokine™)), coagulationfactors in both pre and active forms, collagens, Complement C5 Mab,Connective tissue activating protein-III, CTAA16.88 Mab, CTAP-III,CTLA4-Ig, CTLA-8, CXC3, CXC chemokine receptor 3, cyanovirin-N,Darbepoetin, designated exodus, designated huL105 7, DIL-40, Dnase,EDAR, EGF Receptor Mab, ENA-78, Endostatin, Eotaxin, Epithelialneutrophil activating protein-78, EPO receptor, EPOR, erythropoietin(EPO) and EPO mimics, Eutropin, Exodus protein, Factor IX, Factor VII,Factor VIII, Factor X and Factor XIII, FAS Ligand Inhibitory Protein(DcR3), FasL, FGF, FGF-12, Fibroblast growth factor homologous factor-1,FGF-15, FGF-16, FGF-18, FGF-3, INT-2, FGF-4, gelonin, HST-1, HBGF-4,FGF-5, FGF-6, Heparin binding secreted transforming factor-2, FGF-8,FGF-9, Glia activating factor, fibrinogen, flt-1, flt-3 ligand, Folliclestimulating hormone Alpha subunit, Follicle stimulating hormone Betasubunit, Follitropin, Fractalkine, fragment. myofibrillar proteinTroponin I, FSH, Galactosidase, Galectin-4, G-CSF, GDF-1, Gene therapy,Glioma-derived growth factor, glucagon, glucagon-like peptides,Glucocerebrosidase, glucose oxidase, Glucosidase, Glycodelin-A,Progesterone-associated endometrial protein, GM-CSF, gonadotropin,Granulocyte chemotactic protein-2 (GCP-2), Granulocyte-macrophage colonystimulating factor, growth hormone, Growth related oncogene-alpha(GRO-alpha), Growth related oncogene-beta (GRO-beta), Growth relatedoncogene-gamma (GRO-gamma), hAPO-4, TROY, hCG, Hepatitus B surfaceAntigen, Hepatitus B Vaccine, HER2 Receptor Mab, hirudin, HIV gp120, HIVgp41, HIV Inhibitor Peptide, HIV Inhibitor Peptide, HIV InhibitorPeptide, HIV protease inhibiting peptides, HIV-1 protease inhibitors,HPV vaccine, Human 6CKine protein, Human Act-2 protein, Humanadipogenesis inhibitory factor, human B cell stimulating factor-2receptor, Human beta-chemokine H1305 (MCP-2), Human C-C chemokine DGWCC,Human CC chemokine ELC protein, Human CC type chemokine interleukin C,Human CCC3 protein, Human CCF18 chemokine, Human CC-type chemokineprotein designated SLC (secondary lymphoid chemokine), Human chemokinebeta-8 short forms, Human chemokine C10, Human chemokine CC-2, Humanchemokine CC-3, Human chemokine CCR-2, Human chemokine Ckbeta-7, Humanchemokine ENA-78, Human chemokine eotaxin, Human chemokine GRO alpha,Human chemokine GROalpha, Human chemokine GRObeta, Human chemokineHCC-1, Human chemokine HCC-1, Human chemokine 1-309, Human chemokineIP-10, Human chemokine L105 3, Human chemokine L105 7, Human chemokineMIG, Human chemokine MIG-beta protein, Human chemokine MIP-1 alpha,Human chemokine MIP1beta, Human chemokine MIP-3alpha, Human chemokineMIP-3beta, Human chemokine PF4, Human chemokine protein 331D5, Humanchemokine protein 61164, Human chemokine receptor CXCR3, Human chemokineSDF1alpha, Human chemokine SDF1beta, Human chemokine ZSIG-35, HumanChr19Kine protein, Human CKbeta-9, Human CX3C 111 amino acid chemokine,Human DNAX interleukin-40, Human DVic-1 C-C chemokine, Human EDIRF Iprotein sequence, Human EDIRF II protein sequence, Human eosinocyte CCtype chemokine eotaxin, Human eosinophil-expressed chemokine (EEC),Human fast twitch skeletal muscle troponin C, Human fast twitch skeletalmuscle troponin I, Human fast twitch skeletal muscle Troponin subunit C,Human fast twitch skeletal muscle Troponin subunit I Protein, Human fasttwitch skeletal muscle Troponin subunit T, Human fast twitch skeletalmuscle troponin T, Human foetal spleen expressed chemokine, FSEC, HumanGM-CSF receptor, Human gro-alpha chemokine, Human gro-beta chemokine,Human gro-gamma chemokine, Human IL-16 protein, Human IL-1RD10 proteinsequence, Human IL-1RD9, Human IL-5 receptor alpha chain, Human IL-6receptor, Human IL-8 receptor protein hIL8RA, Human IL-8 receptorprotein hIL8RB, Human IL-9 receptor protein, Human IL-9 receptor proteinvariant #3, Human IL-9 receptor protein variant fragment, Human IL-9receptor protein variant fragment #3, Human interleukin 1 delta, Humaninterleukin 10, Human interleukin 18, Human interleukin 18 derivatives,Human interleukin-1 beta precursor, Human interleukin-1 beta precursor,Human interleukin-1 receptor accessory protein, Human interleukin-1receptor antagonist beta, Human interleukin-1 type-3 receptor, Humaninterleukin-10 (precursor), Human interleukin-11 receptor, Humaninterleukin-12 40 kD subunit, Human interleukin-12 beta-1 receptor,Human interleukin-12 beta-2 receptor, Human interleukin-12 p35 protein,Human interleukin-12 p40 protein, Human interleukin-12 receptor, Humaninterleukin-13 alpha receptor, Human interleukin-13 beta receptor, Humaninterleukin-15, Human interleukin-15 receptor from clone P1, Humaninterleukin-17 receptor, Human interleukin-18 protein (IL-18), Humaninterleukin-3, human interleukin-3 receptor, Human interleukin-3variant, Human interleukin-4 receptor, Human interleukin-5, Humaninterleukin-6, Human interleukin-7, Human interleukin-7, Humaninterleukin-8 (IL-8), Human intracellular IL-1 receptor antagonist,Human IP-10 and HIV-1 gp120 hypervariable region fusion protein, HumanIP-10 and human Muc-1 core epitope (VNT) fusion protein, human liver andactivation regulated chemokine (LARC), Human Lkn-1 Full-Length andMature protein, Human mammary associated chemokine (MACK) proteinFull-Length and Mature, Human mature chemokine Ckbeta-7, Human maturegro-alpha, Human mature gro-gamma polypeptide used to treat sepsis,Human MCP-3 and human Muc-1 core epitope (VNT) fusion protein, HumanMI10 protein, Human MI1A protein, Human monocyte chemoattractant factorhMCP-1, Human monocyte chemoattractant factor hMCP-3, Human monocytechemotactic proprotein (MCPP) sequence, Human neurotactin chemokine likedomain, Human non-ELR CXC chemokine H174, Human non-ELR CXC chemokineIP10, Human non-ELR CXC chemokine Mig, Human PAI-1 mutants, Humanprotein with IL-16 activity, Human protein with IL-16 activity, Humansecondary lymphoid chemokine (SLC), Human SISD protein, Human STCP-1,Human stromal cell-derived chemokine, SDF-1, Human T cell mixedlymphocyte reaction expressed chemokine (TMEC), Human thymus andactivation regulated cytokine (TARC), Human thymus expressed, HumanTNF-alpha, Human TNF-beta (LT-alpha), Human type CC chemokine eotaxin 3protein sequence, Human type II interleukin-1 receptor, Human wild-typeinterleukin-4 (hIL-4) protein, Human ZCHEMO-8 protein, HumanizedAnti-VEGF Antibodies, and fragments thereof, Humanized Anti-VEGFAntibodies, and fragments thereof, Hyaluronidase, ICE 10 kD subunit, ICE20 kD subunit, ICE 22 kD subunit, Iduronate-2-sulfatase, Iduronidase,IL-1 alpha, IL-1 beta, IL-1 inhibitor (IL-li), IL-1 mature, IL-10receptor, IL-11, IL-11, IL-12 p40 subunit, IL-13, IL-14, IL-15, IL-15receptor, IL-17, IL-17 receptor, receptor, IL-19, IL-li fragments,IL1-receptor antagonist, IL-21 (TIF), IL-3 containing fusion protein,IL-3 mutant proteins, IL-3 variants, IL-4, IL-4 muteins, IL-4 muteinY124G, IL-4 mutein Y124X, IL-5, IL-5 muteins, 11-5 receptor, IL-6, 11-6receptor, IL-7 receptor clone, IL-8 receptor, IL-9 mature proteinvariant (Met117 version), immunoglobulins or immunoglobulin-basedmolecules or fragment of either (e.g. a Small ModularImmunoPharmaceutical™ (“SMIP”) or dAb, Fab′ fragments, F(ab′)2, scAb,scFv or scFv fragment), including but not limited to plasminogen,Influenza Vaccine, Inhibin alpha, Inhibin beta, insulin, insulin-likegrowth factor, Integrin Mab, inter-alpha trypsin inhibitor, inter-alphatrypsin inhibitor, Interferon gamma-inducible protein (IP-10),interferons (such as interferon alpha species and sub-species,interferon beta species and sub-species, interferon gamma species andsub-species), interleukin 6, interleukin 8 (IL-8) receptor, interleukin8 receptor B, interleukin-1alpha, interleukin-2 receptor associatedprotein p43, interleukin-3, interleukin-4 muteins, interleukin-8 (IL-8)protein, interleukin-9, interleukin-9 (IL-9) mature protein (Thr117version), interleukins (such as IL10, IL11 and IL2), Japaneseencephalitis vaccine, Kalikrein Inhibitor, Keratinocyte growth factor,Kunitz domain protein (such as aprotinin, amyloid precursor protein andthose described in WO 03/066824, with or without albumin fusions), LACI,lactoferrin, Latent TGF-beta binding protein II, leptin, Liver expressedchemokine-1 (LVEC-1), Liver expressed chemokine-2 (LVEC-2), LT-alpha,LT-beta, Luteinization Hormone, Lyme Vaccine, Lymphotactin, Macrophagederived chemokine analogue MDC (n+1), Macrophage derived chemokineanalogue MDC-eyfy, Macrophage derived chemokine analogue MDC-yl,Macrophage-derived chemokine (MDC), Maspin, Protease Inhibitor 5, MCP-1receptor, MCP-1a, MCP-1b, MCP-3, MCP-4 receptor, M-CSF, Melanomainhibiting protein, Membrane-bound proteins, Met117 human interleukin 9,MIP-3 alpha, MIP-3 beta, MIP-Gamma, MIRAP, Modified Rantes, monoclonalantibody, MP52, Mutant interleukin 6 S176R, myofibrillar contractileprotein Troponin I, Natriuretic Peptide, Nerve Growth Factor-beta, NerveGrowth Factor-beta2, Neuropilin-1, Neuropilin-2, Neurotactin,Neurotrophin-3, Neurotrophin-4, Neurotrophin-4a, Neurotrophin-4b,Neurotrophin-4c, Neurotrophin-4d, Neutrophil activating peptide-2(NAP-2), NOGO-66 Receptor, NOGO-A, NOGO-B, NOGO-C, Novel beta-chemokinedesignated PTEC, N-terminal modified chemokine GroHEK/hSDF-1 alpha,N-terminal modified chemokine GroHEK/hSDF-1beta, N-terminal modifiedchemokine met-hSDF-1 alpha, N-terminal modified chemokine met-hSDF-1beta, OPGL, Osteogenic Protein-1 (OP-1), BMP-7, Osteogenic Protein-2,OX40, ACT-4, OX40L, Oxytocin (Neurophysin I), parathyroid hormone,Patched, Patched-2, PDGF-D, Pertussis toxoid, Pituitary expressedchemokine (PGEC), Placental Growth Factor, Placental Growth Factor-2,Plasminogen Activator Inhibitor-1 (PAI-1), Plasminogen ActivatorInhibitor-2 (PAI-2), Platelet derived growth factor, Platelet derivedgrowth factor Bv-sis, Platelet derived growth factor precursor A,Platelet derived growth factor precursor B, Platelet Mab,platelet-derived endothelial cell growth factor (PD-ECGF),Platelet-Derived Growth Factor A chain, Platelet-Derived Growth Factor Bchain, polypeptide used to treat sepsis, Preproapolipoprotein “milano”variant, Preproapolipoprotein “paris” variant, pre-thrombin, Primate CCchemokine “ILINCK”, Primate CXC chemokine “IBICK”, proinsulin,Prolactin, Prolactin2, prosaptide, Protease inhibitor peptides, ProteinC, Protein S, pro-thrombin, prourokinase, RANTES, RANTES 8-68, RANTES9-68, RANTES peptide, RANTES receptor, Recombinant interleukin-16,Resistin, restrictocin, Retroviral protease inhibitors, ricin, RotavirusVaccine, RSV Mab, saporin, sarcin, Secreted and Transmembranepolypeptides, serum cholinesterase, serum protein (such as a bloodclotting factor), Soluble BMP Receptor Kinase Protein-3, Soluble VEGFReceptor, Stem Cell Inhibitory Factor, Straphylococcus Vaccine, StromalDerived Factor-1 alpha, Stromal Derived Factor-1 beta, Substance P(tachykinin), T1249 peptide, T20 peptide, T4 Endonuclease, TACI, Tarc,TGF-beta 1, TGF-beta 2, Thr117 human interleukin 9, thrombin,thrombopoietin, thrombopoietin derivative 1, thrombopoietin derivative2, thrombopoietin derivative 3, thrombopoietin derivative 4,thrombopoietin derivative 5, thrombopoietin derivative 6, thrombopoietinderivative 7, Thymus expressed chemokine (TECK), Thyroid stimulatingHormone, tick anticoagulant peptide, Tim-1 protein, TNF-alpha precursor,TNF-R, TNF-RII, TNF p75 Receptor, Death Receptor, tissue plasminogenactivator (tPA), transferrin, transforming growth factor beta, Troponinpeptides, Truncated monocyte chemotactic protein 2 (6-76), TruncatedRANTES protein (3-68), tumour necrosis factor, Urate Oxidase, urokinase,Vasopressin (Neurophysin II), VEGF R-3, flt-4, VEGF Receptor, KDR,flk-1, VEGF-110, VEGF-121, VEGF-138, VEGF-145, VEGF-162, VEGF-165,VEGF-182, VEGF-189, VEGF-206, VEGF-D, VEGF-E, VEGF-X, von Willebrand'sfactor, Wild type monocyte chemotactic protein 2, or ZTGF-beta 9; (ii)chemotherapy drugs comprising 13-cis-Retinoic Acid, 2-CdA,2-Chlorodeoxyadenosine, 5-Azacitidine, 5-Fluorouracil, 5-FU,6-Mercaptopurine, 6-MP, 6-TG, 6-Thioguanine, Abraxane, Accutane®,Actinomycin-D, Adriamycin®, Adrucil®, Agrylin®, Ala-Cort®, Aldesleukin,Alemtuzumab, ALIMTA, Alitretinoin, Alkaban-AQ®, Alkeran®,All-transretinoic Acid, Alpha Interferon, Altretamine, Amethopterin,Amifostine, Aminoglutethimide, Anagrelide, Anandron®, Anastrozole,Arabinosylcytosine, Ara-C, Aranesp®, Aredia®, Arimidex®, Aromasin®,Arranon®, Arsenic Trioxide, Asparaginase, ATRA, Avastin®, Azacitidine,BCG, BCNU, Bevacizumab, Bexarotene, BEXXAR®, Bicalutamide, BiCNU,Blenoxane®, Bleomycin, Bortezomib, Busulfan, Busulfex®, C225, CalciumLeucovorin, Campath®, Camptosar®, Camptothecin-11, Capecitabine, Carac™,Carboplatin, Carmustine, Carmustine Wafer, Casodex®, CC-5013, CCNU,CDDP, CeeNU, Cerubidine®, Cetuximab, Chlorambucil, Cisplatin, CitrovorumFactor, Cladribine, Cortisone, Cosmegen®, CPT-11, Cyclophosphamide,Cytadren®, Cytarabine, Cytarabine Liposomal, Cytosar-U®, Cytoxan®,Dacarbazine, Dacogen, Dactinomycin, Darbepoetin Alfa, Dasatinib,Daunomycin, Daunorubicin, Daunorubicin Hydrochloride, DaunorubicinLiposomal, DaunoXome®, Decadron, Decitabine, Delta-Cortef®, Deltasone®,Denileukin diftitox, DepoCyt™, Dexamethasone, Dexamethasone acetate,Dexamethasone Sodium Phosphate, Dexasone, Dexrazoxane, DHAD, DIC,Diodex, Docetaxel, Doxil®, Doxorubicin, Doxorubicin liposomal, Droxia™,DTIC, DTICDome®, Duralone®, Efudex®, Eligard™, Ellence™, Eloxatin™,Elspar®, Emcyt®, Epirubicin, Epoetin alfa, Erbitux™, Erlotinib, ErwiniaL-asparaginase, Estramustine, Ethyol, Etopophos®, Etoposide, EtoposidePhosphate, Eulexin®, Evista®, Exemestane, Fareston®, Faslodex®, Femara®,Filgrastim, Floxuridine, Fludara®, Fludarabine, Fluoroplex®,Fluorouracil, Fluoxymesterone, Flutamide, Folinic Acid, FUDR®,Fulvestrant, G-CSF, Gefitinib, Gemcitabine, Gemtuzumab ozogamicin,Gemzar®, Gleevec™, Gliadel® Wafer, GM-CSF, Goserelin, Granulocyte-ColonyStimulating Factor, Granulocyte Macrophage Colony Stimulating Factor,Halotestin®, Herceptin®, Hexadrol, Hexalen®, Hexamethylmelamine, HMM,Hycamtin®, Hydrea®, Hydrocort Acetate®, Hydrocortisone, HydrocortisoneSodium Phosphate, Hydrocortisone Sodium Succinate, HydrocortonePhosphate, Hydroxyurea, Ibritumomab, Ibritumomab Tiuxetan, Idamycin®,Idarubicin, Ifex®, IFN-alpha, Ifosfamide, IL-11, IL-2, Imatinibmesylate, Imidazole Carboxamide, Interferon alfa, Interferon Alfa-2b(PEG Conjugate), interleukin-2, interleukin-11, Intron A® (interferonalfa-2b), Iressa®, Irinotecan, Isotretinoin, Kidrolase®, Lanacort®,Lapatinib, L-asparaginase, LCR, Lenalidomide, Letrozole, Leucovorin,Leukeran, Leukine™, Leuprolide, Leurocristine, Leustatin™, LiposomalAra-C, Liquid Pred®, Lomustine, L-PAM, L-Sarcolysin, Lupron®, LupronDepot®, Matulane®, Maxidex, Mechlorethamine, MechlorethamineHydrochloride, Medralone®, Medrol®, Megace®, Megestrol, MegestrolAcetate, Melphalan, Mercaptopurine, Mesna, Mesnex™, Methotrexate,Methotrexate Sodium, Methylprednisolone, Meticorten®, Mitomycin,Mitomycin-C, Mitoxantrone, M-Prednisol®, MTC, MTX, Mustargen®, Mustine,Mutamycin®, Myleran®, Mylocel™, Mylotarg®, Navelbine®, Nelarabine,Neosar®, Neulasta™, Neumega®, Neupogen®, Nexavar®, Nilandron®,Nilutamide, Nipent®, Nitrogen Mustard, Novaldex®, Novantrone®,Octreotide, Octreotide acetate, Oncospar®, Oncovin®, Ontak®, Onxal™,Oprevelkin, Orapred®, Orasone®, Oxaliplatin, Paclitaxel, PaclitaxelProtein-bound, Pamidronate, Panitumumab, Panretin®, Paraplatin®,Pediapred®, PEG Interferon, Pegaspargase, Pegfilgrastim, PEG-INTRON™,PEG-L-asparaginase, PEMETREXED, Pentostatin, Phenylalanine Mustard,Platinol®, Platinol-AQ®, Prednisolone, Prednisone, Prelone®,Procarbazine, PROCRIT®, Proleukin®, Prolifeprospan 20 with CarmustineImplant, Purinethol®, Raloxifene, Revlimid®, Rheumatrex®, Rituxan®,Rituximab, RoferonA® (Interferon Alfa-2a), Rubex®, Rubidomycinhydrochloride, Sandostatin®, Sandostatin LAR®, Sargramostim,Solu-Cortef®, Solu-Medrol Sorafenib, SPRYCEL™, STI-571, Streptozocin,SU11248, Sunitinib, Sutent®, Tamoxifen, Tarceva®, Targretin®, Taxol®,Taxotere®, Temodar®, Temozolomide, Teniposide, TESPA, Thalidomide,Thalomid®, TheraCys®, Thioguanine, Thioguanine Tabloid®,Thiophosphoamide, Thioplex®, Thiotepa, TICE®, Toposar®, Topotecan,Toremifene, Tositumomab, Trastuzumab, Tretinoin, Trexall™, Trisenox®,TSPA, TYKERB®, VCR, Vectibix™, Velban®, Velcade®, VePesid®, Vesanoid®,Viadur™, Vidaza®, Vinblastine, Vinblastine Sulfate, Vincasar Pfs®,Vincristine, Vinorelbine, Vinorelbine tartrate, VLB, VM-26, Vorinostat,VP-16, Vumon®, Xeloda®, Zanosar®, Zevalin™, Zinecard®, Zoladex®,Zoledronic acid, Zolinza, or Zometa®; (iii) radiopharmaceuticalscomprising Carbon-11, Carbon-14, Chromium-51, Cobalt-57, Cobalt-58,Erbium-169, Fluorine-18, Gallium-67, Gold-198, Indium-111, Indium-113m,Iodine-123, Iodine-125, Iodine-131, Iron-59, Krypton-81m, Nitrogen-13,Oxygen-15, Phosphorous-32, Rhenium-186, Rubidium-82, Samarium-153,Selenium-75, Strontium-89, Technetium-99m, Thallium-201, Tritium,Xenon-127, or Xenon-133, Yttrium-90, and (iv) imaging agents comprisingGadolinium, magnetite, manganese, technetium, 1125, 1131, P32, TI201,Iopamidol, or PET-FDG.